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Abstract 
In this thesis I have explored different components of the pathogenesis of several 
related EBV associated cancers. In the first part of the thesis I focus on the 
microenvironment of two of these cancers, nasopharyngeal carcinoma (NPC) and 
diffuse large B cell lymphoma (DLBCL). Our group has developed a therapeutic 
vaccine against EBV which has already been shown to be safe in patients with NPC. 
Therefore, in the first results chapter (chapter 3), I present a description of the 
phenotyping of expression of the immune microenvironment including immune 
checkpoint (ICP) genes and MHC class I and class II genes in NPC tissues. I 
showed for the first time in NPC tissue samples, two types of PD-L1 expressing 
tumours: diffuse and marginal. In re-analysis of published data, I found co-
expression of immune checkpoint genes and their receptors in EBV positive NPC 
samples; information which is likely to inform the design of combination 
immunotherapy in NPC patients. I have shown in my re-analysis of EBV positive 
NPC that PD-L1 is not up-regulated by LMP-1. In chapter 4, I show the results of 
studies of the expression of collagen and collagen receptors in DLBCL in which I 
have identified the over-expression of a potentially novel immune checkpoint 
receptor, LAIR-1, on the macrophages infiltrating this tumour. In the second part of 
the thesis I switch my line of inquiry to the tumour cells of EBV-associated cancers, 
this time focussing on Hodgkin lymphoma (HL), another EBV-associated lymphoma. 
During the course of the work presented in this chapter I was able to define a role 
for aberrant sphingosine-1-phosphate (S1P) signalling in driving PI3-K activation 
mediated through up-regulation of S1PR1 and downregulation of S1PR2 receptors 
in HL. I also showed that in turn, PI3-K signalling increases the expression of 
potentially oncogenic downstream transcription factors, such as BATF3 which I have 
shown to be overexpressed in HL. These data suggest that antagonists of S1P could 
be considered for the treatment of patients with HL. 
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LAIR-1 : Leukocyte-associated Ig-like receptor-1  
LAIR-2 : Leukocyte-associated Ig-like receptor-2  
LCLs : Lymphoblastoid cell lines  
LMP-1 : Latent membrane protein -1 
LMP-2 : Latent membrane protein- 2  
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mTOR : Mechanistic target of rapamycin 
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PI3-K : PI 3-Kinase indicates phosphatidylinositol-3-kinase 
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TAMs : Tumour-associated macrophages  
TBS : Tris buffered saline  
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like domains 1  
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TNFα : Tumour necrosis factor α  
TRKA : Tropomyosin receptor kinase A 
TRKB : Tropomyosin receptor kinase B 
VTCN1 : V-set domain containing T-cell activation inhibitor 1, 
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CHAPTER ONE 
INTRODUCTION  
 2 
 
The Epstein-Barr virus (EBV) is an oncogenic herpesvirus that is associated with 
the development of a number of malignancies. Here, I discuss the general features 
of some of EBV-associated cancers that are relevant to this thesis, before 
considering the oncogenic functions of EBV and then detailing how this virus might 
contribute to the pathogenesis of each tumour type. Table 1.1 provides a list of the 
tumours associated with EBV adapted from Taylor and Steven (Taylor and Steven, 
2016). 
Table 1.1 EBV associated malignancies and their associated EBV related 
proteins 
 
Tumour type Proteins associated with EBV 
tumours 
Post-transplant lymphoproliferative 
disease 
EBNA1, 2, 3A, 3B, 3C, LP, LMP-1, 
LMP-2 
Hodgkin lymphoma EBNA1, LMP-1, LMP-2 
Diffuse large B lymphoma EBNA1, 2, 3A, 3B, 3C, LP, LMP-1, 
LMP-2 
Burkitt’s lymphoma EBNA1 
Extra-nodal T/NK lymphoma EBNA1, LMP-2 
Nasopharyngeal carcinoma EBNA1, LMP-1, LMP-2 
 
EBV indicates Epstein-Barr virus, LMP-1 indicates Latent membrane protein 1, 
LMP-2 indicates Latent membrane protein 2, EBNA-1 indicates Epstein–Barr 
nuclear antigen-1 and NK indicates Natural killer. Table 1.1 adapted from Taylor and 
Steven (Taylor and Steven, 2016).  
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1.1 The Epstein-Barr virus 
The Epstein-Barr virus (EBV) is a gamma-herpesvirus that colonises the B cell 
system of its human host, allowing it to persist asymptomatically in the majority of 
the world’s adult population. In most people primary infection goes unnoticed, 
whereas in a minority of individuals with primary infection results in infectious 
mononucleosis (IM), a benign condition that almost always resolves after several 
weeks or months. 
1.1.1 EBV is a transforming B lymphotropic virus  
 
If peripheral blood lymphocytes from asymptomatic chronic virus-carriers are 
cultured in vitro then the minor fraction of EBV-infected B cells present can grow out 
as EBV-transformed, immortalised cell lines, known as lymphoblastoid cell lines 
(LCLs), but only if T lymphocytes are first depleted or their activity inhibited with 
drugs such as cyclosporin A (Rickinson et al., 1984). Direct infection of resting B 
lymphocytes with EBV derived from producer B cell lines will also give rise to LCL. 
Publication in 1984 of the complete genome sequence of the B95.8 strain of EBV 
provided the opportunity not only to define the genes encoded by EBV, but also to 
explore how each contributes to the process of in vitro B cell transformation (Baer 
et al., 1984). The EBV genes are separated into the ‘latent’ genes, expressed in a 
phase of the virus life cycle in which there is no virus replication (known as latency), 
and the ‘lytic’ genes which are expressed during the virus replicative cycle ultimately 
leading to the assembly and release of infectious virions. The latent genes act 
collectively and in a coordinated fashion to drive in vitro B cell transformation. These 
latent genes include six nuclear antigens (EBNAs 1, 2, 3A, 3B, 3C and EBNA-LP), 
two latent membrane proteins (LMP-1 and LMP-2), the non-coding Epstein-Barr-
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encoded RNA (EBER1 and EBER2), and a number of viral miRNA (Kerr et al., 
1992, Pfeffer et al., 2004). The use of recombinant EBV technology has confirmed 
the absolute requirement for EBNA2 and LMP-1 in the in vitro transformation of B 
cells and highlighted important contributions of EBNA-LP, EBNA3A, EBNA3C and 
LMP-2A (Young et al., 2016). The form of latency observed in LCL in which all the 
latent genes are expressed is known as latency III. A summary of latent genes on 
the EBV genome are shown in Figure 1.1. 
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Figure 1.1 Latent genes of EBV genome. 
The figure shows position of latent genes in EBV. Epstein-Barr virus encoded latent 
genes including Epstein–Barr nuclear antigens (EBNAs 1, 2, 3A, 3B and 3C, and 
EBNA leader protein (EBNA-LP), latent membrane proteins (LMPs 1, 2A and 2B), 
BamHI fragment H rightward open reading frame (BHRF1) and BamHI-A fragment 
rightward reading frame (BARF1). The main genome features are highlighted: the 
origin of replication (OriP) (orange), latent gene exons (short thick green arrows); 
consistently expressed  small non-polyadenylated non-coding RNAs - EBERs 1 and 
2 (short blue arrows; splice variants of EBNA (long green and red arrows); LMP-1, 
LMP-2A and LMP-2B (black arrows) and EBNA1 are expressed in latency type II 
phase, whilst all the latent genes including EBNAs 2 and 3 are expressed in latency 
type III phase of viral infection. Figure is adapted from Young et al (Young et al., 
2016).  
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1.1.2 Asymptomatic infection of B cells 
 
Memory B cells are the major site of EBV persistence (Babcock et al., 1998). 
EBV-infected B cells initially express the latency III programme and are the in vivo 
equivalent of in vitro transformed LCL. By processes yet undefined, these EBV-
infected B cells then enter a germinal centre (GC) reaction, and express an 
alternative form of latency, known as latency II in which there is expression of 
EBNA1, LMP-1 and LMP-2, but none of the other EBNAs (Babcock et al., 2000). 
LMP-1 and LMP-2 provide surrogate CD40 and B cell receptor (BCR) signals, 
respectively, and it is their combined expression which probably mediates the 
survival of EBV-infected B cells in the GC and their subsequent differentiation 
(Gires et al., 1997, Caldwell et al., 1998). To avoid recognition by the immune 
system, EBV-infected memory B cells shut down virus gene expression (latency 
0), only occasionally switching on EBNA1 expression to promote proliferation 
(latency I) (Babcock et al., 2000). EBV-infected B cells can also differentiate into 
plasma cells which switches on the lytic cycle ultimately leading to the production 
of new virions (Laichalk and Thorley-Lawson, 2005). 
1.2 Diffuse large B cell lymphoma  
Diffuse large B cell lymphoma (DLBCL) is an aggressive tumour, resulting in death 
within 1 or 2 years if untreated.  However, this disease is potentially curable.  Around 
10% of diffuse large B cell lymphoma is EBV-positive (Swerdlow et al., 2008). 
Prevalence of EBV infection according to the subtype of DLBCL varies as follows: 
EBV is consistently positive in certain EBV-related subtypes such as EBV-positive 
mucocutaneous ulcer, EBV-positive DLBCL NOS and DLBCL associated with 
chronic inflammation, Lymphomatoid granulomatosis, and Primary effusion 
lymphoma. EBV infection represents 60-75% of plasmablastic lymphoma 
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(Swerdlow et al., 2016). Below I discuss the general characteristics of this 
heterogeneous group of diseases. 
1.2.1 Incidence of DLBCL  
 
DLBCL is the most common type of Non Hodgkin Lymphoma (NHL), accounting for 
25-30% of adult NHL in western countries and is also the most prevalent NHL in 
developing countries (Swerdlow et al., 2008). However, DLBCL represents only 
5% of paediatric NHL. Although DLBCL is an aggressive tumour, resulting in death 
within 1 or 2 years in untreated patients, it is potentially curable (Jaffe et al., 2010).  
1.2.2 Histology of DLBCL 
 
The current sub-classification of DLBCL is important because of distinct biological 
properties of the different sub-entities (Chan, 2013). However, DLBCL is usually 
characterized by a complete effacement of the nodal architecture by a diffuse 
proliferation of neoplastic large B cells.  Unlike HL, infiltration of the peri-nodal tissue 
is frequent and blood vessels are usually positive for tumour infiltration. Some cases 
are associated with prominent sclerosis, even forming bands and coarse fibres. 
Necrosis can be seen frequently and sometimes may pose diagnostic challenges if 
the entire sample is necrotic. There are many histological variants of DLBCL. World 
health organization (WHO) classification of haematolymphoid malignancies 
including the old (2008) and the new (2016) classifications of DLBCL are 
summarized in Tables 1.2 and 1.3, respectively. Some of the DLBCL variants 
included the following: 
The centroblastic (large non cleaved cell) variant is the most common subtype, 
whereby tumour cells have large rounded nuclei, snake bite nuclear chromatin, 
multiple nucleoli, with a moderate amount of eosinophilic cytoplasm (Rosai, 2011). 
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The immunoblastic variant is common in elderly men, usually in 
immunocompromised patients, and sometimes in those infected with HIV. The 
nuclei of the mitotically active neoplastic cells are sometimes atypical and are larger 
than those of reactive histiocytes, showing round, indented, or irregularly folded 
nuclei, simulating mononuclear Hodgkin cells. Sometimes this form shows some 
plasmacytoid features, with tumour cells having large eccentric nuclei, and 
peripheral basophilic cytoplasm (Rosai, 2011)  
Several other morphological variants are worth mentioning in the context of this 
thesis. They include the myxoid variant which can mimic a sarcoma (e.g. 
myxofibrosarcoma or myxoid chondrosarcoma) because of the presence of 
abundant myxoid stroma in which the round, spindle, or stellate lymphoma cells are 
suspended (Tse et al., 1991). In DLBCL with fibrillary matrix/rosettes there is an 
abundant fibrillary matrix, with or without rosette formations simulating schwannian 
origin tumours. In the spindle cell variant the lymphoma cells assume a spindle 
configuration as a result of passive entrapment in sclerotic stroma or growth in the 
form of spindle cell fascicles. This type of DLBCL may simulate morphologically 
undifferentiated pleomorphic sarcoma or other sarcomas. Although mimicking 
sarcoma, it can be morphologically identified as DLBCL through proper sampling to 
find a focus of a classic pattern of lymphoma (Tsang et al., 1992). 
Primary mediastinal B-cell lymphoma (PMLBCL)  
Although PMLBCL is a subset of DLBCL, it is a biologically distinct entity with 
features that overlap with Nodular sclerosis Hodgkin Lymphoma (NSHL). In fact this 
type of DLBCL can precede nodular sclerosis HL as well as the presentation of 
composite tumours consisting of PMBCL and NSHL. PMLBCL has a superior 
prognosis compared to other molecular subtypes of DLBCL. It usually presents as 
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a mediastinal mass with sheets of neoplastic tumour cells with clear large cells, 
sometimes with RS (Reed-Sternberg)-like cells delineated by sclerotic stroma. This 
may be a diagnostic challenge which needs to be differentiated from extra-gonadal 
germ cell tumours such as germinoma and the clear cell variant of thymoma 
(Rosenwald et al., 2003). 
Double hit lymphoma and double expressor lymphoma 
DLBCL with translocations of both cMYC and BCL2 (B-cell lymphoma 2) is called 
double hit lymphoma (DHL) and accounts for about 5% of DLBCL. This entity is 
important because it is associated with advanced stage, high international 
prognostic index (IPI) score and decreased overall survival in patients treated with 
R-CHOP. cMYC and BCL2 genes together collaborate by promoting cellular 
proliferation and survival, respectively (Green et al., 2012b).   
Double expressor lymphoma is considered a new entity recognized by the updated 
WHO classification 2016 (Table 1.3), and is defined as a lymphoma that expresses 
both BCL2 and cMYC by IHC.  This entity is more frequent than double hit lymphoma 
(around 20%). In a previous study, immunohistochemistry for cMYC and BCL2 was 
used to stratify patients and shown to be an additional predictive marker for 
aggressiveness in DLBCL (Green et al., 2012b, Smith, 2017). 
 
Transformed (secondary) DLBCL 
DLBCL may arise either de novo or as a consequence of transformation from 
indolent low grade B cell NHL, including follicular lymphoma (FL), small lymphocytic 
lymphoma (SLL), lymphoplasmacytic lymphoma (LPL), nodal marginal zone 
lymphoma (MZL), or lymphoma of the mucosa associated lymphoid tissues (MALT 
 10 
 
lymphoma). It can also less commonly arise from T cell lymphoma such as 
angioimmunoblastic T cell lymphoma (Montoto and Fitzgibbon, 2011). 
Extra-nodal DLBCL 
DLBCL can arise in extra-nodal locations, such as the gastro-intestinal tract, testis, 
CNS, skin or bone, with some specific types occurring predominantly or exclusively 
in extra-nodal sites; each having its own distinctive clinical and biological features. 
These types of lymphoma include plasmablastic lymphoma, lymphomatoid 
granulomatosis, primary effusion lymphoma, pyrothorax-associated lymphoma, 
PMLBCL, intravascular large B-cell lymphoma, T-cell/histiocyte-rich large B-cell 
lymphoma and EBV-positive DLBCL NOS (Jaffe et al., 2010). Some extra-nodal 
tumours are treated differently. This is especially the case for primary testicular 
DLBCL (PTL) and primary central nervous system (CNS) lymphoma. The former is 
usually characterized by aggressive behaviour and CNS dissemination, which 
necessitates a special treatment strategy. PTL is a highly aggressive type of DLBCL 
with poor prognosis; it is usually disseminating and commonly recurs either on the 
ipsilateral or contralateral side (Zucca et al., 2003). The standard treatment of 
localized (stage I to II) PTL is R-CHOP (Rituximab, cyclophosphamide, 
hydroxydaunocymin (doxorubicin), oncovin (vincristine), and prednisone) with CNS 
prophylaxis and contralateral testis irradiation (Vitolo et al., 2011). 
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1.2.3 DLBCL in the WHO classifications  
 
Table 1.2 WHO old classification of B cell lymphoma, 2008 
 
Diffuse large B-cell lymphoma NOS  
Common morphologic variants  
Centroblastic   
Immunoblastic  
Anaplastic and other rare morphologic variants  
Molecular subgroups  
GCB  
Activated B-cell-like (non-GCB)  
Immunohistochemical subgroups  
CD5+ DLBCL  
Primary DLBCL of the CNS  
Primary cutaneous DLBCL, leg type  
EBV+ DLBCL of the elderly  
Diffuse large B-cell lymphoma subtypes  
T-cell/histiocyte-rich large B-cell lymphoma  
Primary DLBCL of the CNS  
Primary cutaneous DLBCL, leg type  
EBV-positive DLBCL of the elderly  
Other lymphomas of large B cells  
Primary mediastinal (thymic) LBCL  
Intravascular large B-cell lymphoma  
DLBCL associated with chronic inflammation  
Lymphomatoid granulomatosis  
ALK-positive LBCL  
Plasmablastic lymphoma  
Large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease  
Primary effusion lymphoma  
Borderline cases  
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt’s 
lymphoma  
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and classical 
Hodgkin lymphoma  
 
* CNS indicates central nervous system; DLBCL indicates diffuse large B-cell lymphoma; 
EBV indicates Epstein-Barr virus; GCB indicates germinal center B cell; ALK indicates 
anaplastic lymphoma kinase. Table taken from Swerdlow (Swerdlow et al., 2008).  
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Table 1.3 WHO New classification of B cell lymphoma, 2016 
 
Diffuse large B-cell lymphoma (DLBCL) 
variants 
New modification in WHO classification 
2016 
Diffuse large B-cell lymphoma (DLBCL), NOS Immunohistochemistry algorithm for 
differentiating GCB vs ABC/non-GC type required  
may affect therapy 
Double-expressor lymphoma: Co-expression of 
cMYC and BCL2 markers is currently used for 
prognosis  
Mutational landscape better understood but 
clinical impact remains to be determined 
Germinal center B-cell type  
Activated B-cell type 
T-cell/histiocyte-rich large B-cell lymphoma 
Primary DLBCL of the central nervous system (CNS) 
Primary cutaneous DLBCL, leg type 
EBV+ DLBCL, NOS Previous name was EBV+ DLBCL of the elderly, 
now modified because can happen in younger 
patients 
Does not include EBV+ B-cell lymphomas that can 
be given a more specific diagnosis 
EBV+ mucocutaneous ulcer New category associated with iatrogenic 
immunosuppression or age-related 
immunosenescence 
DLBCL associated with chronic inflammation  
Lymphomatoid granulomatosis 
Primary mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
ALK+ large B-cell lymphoma 
Plasmablastic lymphoma 
Primary effusion lymphoma 
HHV8+ DLBCL, NOS* 
High-grade B-cell lymphoma, with cMYC and BCL2 
and/or BCL6 rearrangements 
New entity for all “double-/triple-hit” lymphomas 
other than FL or lymphoblastic lymphomas 
High-grade B-cell lymphoma, NOS* Together with the new entity for the “double-/triple-
hit” lymphomas, changes the 2008 category of B-
cell lymphoma, unclassifiable, with features 
intermediate between DLBCL and Burkitt’s 
lymphoma (BCLU). 
Includes blastoid-appearing large B-cell 
lymphomas and cases lacking cMYC and BCL2 or 
BCL6 translocations that would formerly have 
been called BCLU. 
B-cell lymphoma, unclassifiable, with features 
intermediate between DLBCL and classical Hodgkin 
lymphoma 
 
 
*New modification of 2008 Lymphoma neoplasms classification. Table taken from Swerdlow 
(Swerdlow et al., 2016). 
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1.2.4 Cell of origin (COO) Classification of DLBCL 
The latest WHO classification of lymphoid neoplasms reported in 2016 includes the 
cell of origin classification which separates DLBCL into three types: germinal center 
B cell-like (GCB), activated B-cell-like (ABC) molecular “subgroups” of DLBCL 
based on gene expression profile (GEP) as well as a group of cases that could not 
be put into either category (unclassifiable). In a landmark study microarray based 
gene expression was initially used to sub-classify DLBCL patients into GCB and 
ABC subtypes. This demonstrated prognostic stratification based on gene 
expression profiling, finding that patients with the ABC subtype had a poorer clinical 
outcome than those with the GCB subtype (Alizadeh et al., 2000, Lenz et al., 2008). 
Remission of DLBCL patients was observed to be approximately 80% in patients 
with GCB subtype, while remission was observed only in around 50% in ABC 
subtype (Pon and Marra, 2016). Despite these findings, the treatment of DLBCL 
patients still depends mainly on stage, age of the patient, and if bulky disease is 
present. Although the COO classification has implications for prognosis, according 
to the European Society of Medical Oncology (ESMO) guidelines, it has no impact 
on patient management at present (Tilly et al., 2015). DLBCL patients are treated 
with CHOP combination chemotherapy. In cases with bulky or localized tumours, 
radiotherapy is sometimes indicated (Chan, 2013). 
In addition to GCB and ABC subtypes, double-hit lymphomas (approximately 5% to 
10% of patients) and double-expressor lymphomas, which overexpress cMYC and 
BCL2 protein, are described as aggressive DLBCLs also associated with a poor 
prognosis.  
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Mutations specific to the ABC subtype involve genes associated with BCR signalling 
or upstream of nuclear factor- κappa B (NF-κB), leading to constitutive activation in 
upstream genes; CD79B, CARD11 and MYD88 as a consequence. 
 In the ABC subtype of DLBCL, mutations affecting genes involved in B-cell receptor 
signalling, NF-ĸB signalling causing constitutive activation of this pathway as a 
consequence of acquired mutations in upstream genes such as those in P2RY8, 
EZH2 and FOXO1, as well as genes involved in histone modification (Morin et al., 
2011, Manso et al., 2017). Recurrent cytogenetic alterations in DLBLC include (14; 
18) translocation involving BCL2 which is found in 45% of GCB DLBCL and 
amplification of REL was detected in DLBCLs, but absent in ABC type.  On the other 
hand, chromosomal aberrations involving chromosome 3, are seen exclusively in 
the ABC subtype and observed in 25% of patients (Rosenwald et al., 2002). 
Attempts have been made to use immunohistochemistry (IHC) to sub-classify 
DLBCL into either GCB or ABC type. A summary of these algorithms is shown in 
Figure 1.2 (Gutiérrez-García et al., 2011). The Hans criteria uses three markers 
(CD10, BCL6, and MUM1), while in the Choi algorithm, five immunohistochemical 
markers (GCET1, CD10, BCL6, MUM1, and FOXP1) are employed (Choi et al., 
2009). The Tally algorithm has the strongest correlation with microarray based 
classification (Meyer et al., 2010).  
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Figure 1.2 IHC based algorithms for classification of DLBCL. Different 
algorithms using IHC markers expression for classifying DLBCL into two 
phenotypes; germinal centre and Non-germinal centre phenotype. Colomo’s 
algorithm used (MUM1, CD10, and BCL6 markers), Hans’ algorithm used (CD10, 
BCL6, and MUM1 markers), Muris’ (CD10 and MUM1 in addition to BCL2), Choi’s 
algorithm used (GCET1, MUM1, CD10, FOXP1, and BCL6 markers), while Tally 
algorithm used (CD10, GCET1, MUM1, FOXP1, and LMO2 markers). Cut off for 
every marker positivity shown for every algorithm. Colomo’s algorithm unlike other 
algorithms identified in its classification unclassified category in addition to the other 
two phenotypes. Figure taken from Gutiérrez-García et al (Gutiérrez-García et al., 
2011). 
 
 
 
 16 
 
1.2.5 Immuno-phenotyping 
 
Apart from those markers used in the COO described above, the following IHC 
markers are also helpful in the diagnosis of DLBCL; CD19, CD20, CD22, CD79A, 
CD45, PAX-5, Vimentin and Ki-67.  Ki-67 is a gene which encodes a nuclear non-
histone protein expressed in all phases of the cell cycle but not in quiescent cells. 
In general, there is a good correlation between Ki-67 staining and mitotic count 
(Rosai, 2011). In a large series reported by He et al, patients with high Ki-67 scores 
had shorter failure-free survival (He et al., 2014). DLBCL is generally negative for 
smooth muscle actin (SMA), but it is expressed in the spindle cell variant, which may 
be misdiagnosed as intra-nodal soft tissue sarcoma. Terminal deoxynucleotidyl 
transferase (TdT) and cytokeratin (CK) are negative; however CK sometimes is 
positive in anaplastic variant of DLBCL, which may lead to the misdiagnosis of 
metastatic carcinoma or anaplastic carcinoma. However, its positivity for CD30 and 
anaplastic lymphoma kinase (ALK) is usually helpful in the diagnosis.  ALK is 
expressed in ALK-positive DLBCL either in the cytoplasm or in the both the nucleus 
and cytoplasm depending upon the chromosomal translocation involved (Rosai, 
2011). CD43 is a type I transmembrane glycoprotein expressed in different types of 
hematopoietic cells. DLBCL expresses CD43 in around 25% of cases; these cases 
respond poorly to therapy (Ma et al., 2015).  
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1.2.6 Prognostic factors in DLBCL 
 
The International Prognostic Index (IPI) is considered the most useful measure of 
prognosis for DLBCL patients. The risk factors used to calculate the IPI are: 
■ Age >60 years; 
■ High stage (III-IV); 
■ Elevated serum lactate dehydrogenase; 
■ ECOG performance status of 2 – 4; 
■>1 Extra-nodal site  
 
Table 1.4 International Prognostic Index (IPI) and Revised International 
Prognostic Index (R-IPI) with their associated risk and survival outcome  
 
Risk group 
Number of 
prognostic factors 
4 years PFS (%) 
survival 
4 years OS (%) 
IPI 
Low 
Low/Intermediate 
High/ Intermediate 
High 
  
0-1 
2 
3 
4,5 
  
- 
- 
0 
27.8 
  
- 
- 
23.9 
55.6 
Revised IPI 
Low 
Intermediate 
High 
  
0 
1,2 
3,4,5 
  
- 
- 
16.9 
  
- 
- 
33.3 
 
*OS indicates overall survival, PFS indicates progression free survival. Table taken Wang 
et al (Wang et al., 2015). 
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1.3 Hodgkin lymphoma  
HL is a common lymphoma in the Western world, with an annual incidence of 
approximately 3/100,000.   
1.3.1 Histology of HL 
 
HL is divided into two major types; classical HL (cHL) and nodular lymphocyte 
predominant (NLPHL) forms (Swerdlow et al., 2008). cHL is further divided into four 
histological subtypes: NSCHL, lymphocyte-rich classical Hodgkin lymphoma 
(LRCHL), mixed-cellularity classical Hodgkin lymphoma (MCCHL), and lymphocyte-
depletion classical Hodgkin lymphoma (LDCHL) (Mani and Jaffe, 2009). EBV 
infection varies in different types of HL, EBV infection is more common in certain 
histology subtypes of HL (more likely in MCCHL and LDCHL than in other subtypes 
of classic HL) (Massini et al., 2009). However, recent studies revealed rare cases 
of non-classic type of HL; NLPHL appeared to be EBV positive, without history of 
immunosuppression in those patients (Wang et al., 2014).     
In all HL cases, the affected lymph nodes show disruption of the tissue architecture 
containing malignant cells which are in the minority and are surrounded by non-
neoplastic cells including T- and B-lymphocytes, as well as extracellular matrix, 
including collagen. Cross-talk between the tumour cells and the tumour 
microenvironment is crucial for the growth and survival, as well as the immune 
escape of the tumour cells (Aldinucci et al., 2010). The tumour cells of NLPHL are 
known as lymphocytic and histiocytic (L&H) cells. The tumour cells of cHL are the 
more typical Hodgkin/Reed-Sternberg (HRS) cells (Küppers, 2009). L&H cells 
express B-cell markers, including CD20 and CD19. In contrast, HRS cells of cHL 
have lost the B cell phenotype. 
1.3.2 Origin of HRS cells of cHL 
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The cells from which HRS cells are derived were a subject of some debate for many 
years; early studies suggested HRS cells might be derived from macrophages, 
dendritic cells or granulocytes. However, Ralf Küppers ’ group showed that HRS 
cells have clonally rearranged immunoglobulin genes, and so it is now accepted that 
HRS cells derive from mature B lymphocytes (Küppers et al., 1994). What is more, 
this study showed that the variable region sequences of the immunoglobulin genes 
in HRS cells were subject to somatic hypermutation. This provided conclusive 
evidence that HRS cells are derived from cells that have been through a GC reaction 
(Küppers et al., 1994, Kanzler et al., 1996, Vockerodt et al., 2008, Marafioti et 
al., 2000). In around quarter of cHL, the rearranged immunoglobulin sequences 
harbour ‘crippling’ mutations that encode a non-functional surface immunoglobulin 
B cell receptor (BCR) (Kanzler et al., 1996). Because signalling through the BCR is 
important for the survival of germinal centre B cells, we can assume that HRS cells 
of cHL originate from pre-apoptotic cells that were rescued by a transforming event 
(either viral, cellular or both) (Figure 1.3) adapted from Kapatai and Murray (Kapatai 
and Murray, 2007). 
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Figure 1.3: Origin of the Hodgkin/Reed‐Sternberg (HRS) cell in relation to the 
germinal centre. A naïve B cells exposed to antigen enter the B-cell follicles, 
proliferate rapidly and establish germinal centres in form of secondary follicles. Here 
the B cells undergo somatic hypermutation of the immunoglobulin variable (IgV) 
region genes within the germinal centre. Only those cells acquiring a BCR with an 
increased affinity for antigen will survive to exit the GC. B cells with unfavourable 
BCR mutations will be eliminated by Fas-mediated apoptosis. Those carrying B‐cell 
receptor (BCR) with high affinity for antigen will escape apoptosis and survive, then 
leave the germinal centre and undergo class switching then differentiate into 
memory B cells or plasma cells. GC B cells carrying non‐functional BCR should 
undergo apoptosis, but may be rescued by Epstein‐Barr virus and/or still unknown 
genetic alterations. Such cells may be the progenitors of HRS cells, Figure taken 
from Kapatai and Murray (Kapatai and Murray, 2007). 
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The lack of expression of a functional BCR is a feature of cHL, which can occur as 
a result of ‘crippling’ immunoglobulin mutations. However, the expression of 
immunoglobulin genes can also be downregulated by epigenetic silencing of 
transcription factors which include BOB-1/POU2AF1, OCT2/POU2F2 and Spi-
1/PU.1 (Re et al., 2001, Jundt et al., 2002b, Torlakovic et al., 2001, Stein et al., 
2001), as well as the immunoglobulin promoter region itself (Doerr et al., 2005, 
Ushmorov et al., 2004). Furthermore, mutations in the octamer region of the 
immunoglobulin promoter can prevent transcription factor binding (Theil et al., 
2001). In addition, a number of other components of the BCR, or of its downstream 
signalling pathway are either absent or expressed at low levels in HRS cells 
(Schwering et al., 2003b). 
1.3.3 Suppression of the B cell phenotype in HRS cells 
As discussed above HRS cells show a global downregulation of B-cell lineage 
genes. This has been shown to be due to loss of transcription factor networks that 
regulate B cell development; including PAX5, early B-cell factor 1 (EBF1) and 
TCF3/E2A (Nutt and Kee, 2007, Bohle et al., 2013). EBF1 has been shown to 
cooperate with TCF3 and PAX5 which leads to the expression of many B-cell genes. 
EBF1 is a B-cell commitment factor, and its loss also results in the abnormal over-
expression of inhibitor of DNA binding 2 (ID2), which inhibits TCF3 to further 
suppress B-cell lineage gene expression (Küppers et al., 2003, Renné et al., 
2006). ID2 amplification occurs in around a half of all HL cases, and results in ID2 
over-expression (Renné et al., 2006). HRS cells also aberrantly express ABF1, 
which further inhibits TCF3 activity (Mathas et al., 2006).  
The loss of B cell identity also appears to be due in part to the aberrant expression 
of genes that are characteristic of other haematopoietic lineage cells such as T-
cells, NK-cells (Natural killer) and myeloid cells (Hertel et al., 2002, Ushmorov et 
al., 2004, Schwering et al., 2003a, Küppers et al., 2003, Tiacci et al., 2012, Steidl 
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et al., 2012). Notch signalling in HRS cells occurs as a result of contact with cells 
within the tumour microenvironment, including other HRS cells that express the 
Notch ligand Jagged-1 (Jundt et al., 2002a, Jundt et al., 2008, Smith et al., 2005, 
Köchert et al., 2011). Aberrant Notch signalling can lead to aberrant expression of 
T cell-specific genes, as well as suppression of B cell-specific genes, including PAX-
5 (Jundt et al., 2008). 
1.3.4 Deregulated cellular signalling in classical HL 
 
HRS cells show deregulated activation of multiple cell signalling pathways as shown 
in Figure 1.4 adapted from Murray and Bell (Murray and Bell, 2015). 
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Figure 1.4: Deregulated cell signalling pathways in HRS cells HRS cells 
constitutively activate canonical and non-canonical NF-κB pathways. Multiple 
receptors including CD30, CD40 and RANKL activate the canonical pathway 
through the IKK complex resulting in the degradation of the NF-κB inhibitors IκBα 
and IκBε, followed by the translocation of active NF-κB complexes to the nucleus 
where they activate target genes together with other genes as BCL3 and IRF5. c-
Rel overexpression can occur in subset of cases resulting in activation of NF-κB. 
TNFAIP3, negative regulator of NF-κB pathway, mediated through inhibiting the IKK 
complex. In EBV positive HL, LMP-1 can promote activation of both canonical and 
non-canonical NF-κB pathways. Another pathway mediated through cytokines 
produced either by RS cells or cells in the microenvironment, can stimulate cytokine 
receptors resulting in activation of JAK/STAT signalling pathway. Mutated SOCS1 
gene; suppressor of cytokine signalling 1 and the protein tyrosine phosphatase 
(PTPN1/PTP1B) genes can also promote activation of the JAK/STAT pathway. 
Several tyrosine kinase receptors such as PDGFA, TRKA, TRKAB and CCR5 are 
deregulated in HL, resulting in activation of transcription factors. PI3K/Akt signalling 
pathway is deregulated in HL in constitutive manner resulting in phosphorylation of 
the downstream oncogenic target Akt and P110, with subsequent effect of cell 
growth mediated through mTOR1/2. P110 which is important in B and T cell 
development can activate downstream signalling of G-protein coupled receptors. 
BCR indicates B-cell receptor; PI3-Kinase indicates phosphatidylinositol-3-kinase. 
Increased signalling indicated in green stars; functional loss by mutations indicated 
in red signs. Figure modified from Murray and Bell (Murray and Bell, 2015).  
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HRS cells show constitutive activation of NF-κB transcription factors (Bargou et al., 
1996). NF-κB activity is essential for HRS cell survival, because inhibition of this 
pathway leads to apoptosis in HL cell lines after growth factor withdrawal and also 
results in reduced tumour formation in severe combined immune deficiency (SCID) 
mice (Bargou et al., 1997, Izban et al., 2001). HRS cells express different TNF 
receptors, including CD30, CD40, TACI, BCMA and RANK all of which are able to 
trigger NF-κB signalling (Carbone et al., 1995, Fiumara et al., 2001, Horie et al., 
2002, Chiu et al., 2007). The tumour microenvironment expresses ligands of these 
receptors and thus can lead to their enhanced activation (Carbone et al., 1995, 
Pinto et al., 1997). NF-κB signalling is also activated by genomic changes in HRS 
cells including amplification of the c-REL NF-κB subunit (Joos et al., 2003, Martı́n-
Subero et al., 2002, Barth et al., 2003). Furthermore, approximately 20% of cHL 
cases also harbour inactivating mutations in the IκB inhibitor proteins, IκB alpha or 
IκB epsilon (Cabannes et al., 1999, Emmerich et al., 1999, Jungnickel et al., 
2000, Emmerich et al., 2003, Lake et al., 2009). In other cases, HRS cells 
overexpress the co-activator of NF-κB, BCL3 (Martin-Subero et al., 2006, Mathas 
et al., 2005). Finally, recurrent mutations have been reported in the TNFAIP3/A20 
gene, a negative regulator of NF-κB (Schmitz et al., 2009, Reichel et al., 2015).  
HRS cells are also characterised by aberrant JAK/STAT signalling, which promotes 
their proliferation and survival. HRS cells secrete many cytokines, including IL-7, IL-
9 and IL-13 (Kapp et al., 1999, Skinnider et al., 2001, Cattaruzza et al., 2009) all 
of which can activate JAK/STAT signalling, the net effect of which is to increase the 
phosphorylation and activation of the transcription factors STAT3, STAT4 and 
STAT6 (Kube et al., 2001, Hinz et al., 2002, Skinnider et al., 2002). Many of these 
cytokines are also secreted by other cells within the tumour microenvironment 
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(Aldinucci et al., 2002). JAK/STAT signalling is also further activated by genomic 
changes which include JAK2 amplification as well as inactivating mutations of the 
negative regulators, SOCS1 and PTPN1/PTPB1 (Joos et al., 2000, Weniger et al., 
2006, Gunawardana et al., 2014). Some receptor tyrosine kinases (RTKs), such as 
PDGFRA, TRKA, TRKB and TIE1 show over activity in HRS cells which can also 
lead to activation of JAK/STAT signalling (Renné et al., 2005, Renné et al., 2007).  
The PI3-K/Akt pathway is also constitutively activated in HL-derived cell lines and in 
HRS cells from primary tumour tissues (Georgakis et al., 2006, Dutton et al., 
2005). Importantly, the PI3-K/Akt pathway contributes to the survival of HL cell lines 
in vitro. However, the mechanisms responsible for this effect are not known.  
1.4 Nasopharyngeal carcinoma  
Nasopharyngeal carcinoma (NPC) is a tumour of the epithelial lining of the 
nasopharynx that is particularly prevalent in South East Asia. This form of NPC is 
consistently associated with EBV infection and accounts for the majority of cases in 
so called ‘endemic’ regions. It is often described as a lymphoepithelioma because 
of the prominent lymphocytic infiltration. 
Histopathological features of NPC 
The association of EBV with different histologic variants of NPC has been classified 
as follows: The majority of undifferentiated NPC are consistently positive for EBV, 
with the undifferentiated carcinoma constituting the most common subtype (Barnes, 
2005, Thompson, 2006). 
The WHO classification has divided NPC histopathology into two main subtypes, 
according to the extent of its differentiation. These include keratinizing squamous-
cell carcinoma and non-keratinizing carcinoma. Non-keratinizing carcinoma is 
further subdivided into non-keratinizing differentiated carcinoma (NKDC) and non-
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keratinizing undifferentiated carcinoma (NKUC) (Shanmugaratnam, 1978). Non-
keratinizing undifferentiated carcinoma is the most common type and is consistently 
EBV positive; EBV-positive carcinomas represent almost 97% of endemic NPC 
cases. This subtype has characteristic morphologic features, with tumours 
displaying a pronounced lymphoid infiltration. The keratinizing forms are rare, 
representing approximately 1% of the endemic forms (Lun et al., 2013). Histological 
variants of NPC differ in their association with EBV. The majority of undifferentiated 
NPC is consistently positive for EBV, while the keratinizing type is weakly associated 
with EBV. Although the undifferentiated variant is high grade, it is highly responsive 
to radiotherapy and five-year survival rates can reach 65%, unlike the more 
differentiated keratinized form, which has more dismal prognosis, in the form of 
radio-resistance and survival rates between 20-40% (Barnes, 2005, Thompson, 
2006). 
Pathogenesis of NPC 
The pathogenesis of NPC is complex and involves a persistent EBV infection of 
progenitor cells exposed to environmental carcinogens in salted fish and cigarette 
smoke and alcohol. A scheme for the pathogenesis of NPC is presented in Figure 
1.5 taken from (Young et al., 2016). 
Endemic NPC is linked to multiple factors, which include viral infection, genetic 
factors and dietary or habitual factors (Lo et al., 2004). EBV infects epithelial cells 
lining the upper respiratory tract, mainly in the oropharynx and possibly the salivary 
gland (Young and Dawson, 2014). NPC tumours were found to harbour 
monoclonal EBV genomes, indicating that EBV infection occurred before the 
expansion of the final malignant clone (Raab-Traub and Flynn, 1986). 
Furthermore, normal nasopharyngeal epithelium from high-risk patients is EBV 
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negative, indicating that EBV infection is not an early event in tumorigenesis. The 
non-polyadenylated EBER RNAs, which are abundantly expressed in latently 
infected cells, were identified in high-grade lesions including severe dysplasia and 
carcinoma in-situ, yet negative in low-grade lesions and normal nasopharyngeal 
epithelium. NPC pathogenesis is characterized by multiple genetic alterations. 
Studies of normal epithelium and the low-grade dysplastic lesions from high risk 
patients, revealed the presence of genetic alterations such as 3p and 9q deletions 
in absence of the EBV infection (Chan et al., 2000, Pathmanathan et al., 1995a). 
As described in Li et al (Li et al., 2017) and Young et al (Young et al., 2016), this 
suggest that cytogenetic changes in the epithelium are required before EBV 
infection can be established. 
Chromosomal deletion of chromosome 3p and 9p are the most frequent aberration 
in NPC which result in inactivation of tumour suppressor genes (TSGs). TSGs such 
as RASSF1, RARβ2 and p16, p15, p14, DAP-kinase located at chromosome 3p and 
9q respectively, were associated with hypermethylation changes and are shown to 
be important in NPC pathogenesis (Lo et al., 2012, Lung et al., 2012). Cell 
susceptibility to latent EBV infection is thought to acquire initial genetic alterations 
in nasopharyngeal epithelium such as Cyclin D1 overexpression, due to in part to 
gene amplification. Such genetic changes are thought to predispose cells to the 
establishment and stabilization of EBV infection, resulting in viral persistence (Chan 
et al., 2000). Once infection occurs, it is thought that EBV-encoded latent genes 
and micro RNAs sustain the growth and survival of neoplastic cells by activating a 
plethora of cell signalling pathways and by superimposing genetic and epigenetic 
changes (Young and Dawson, 2014). 
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Most cases of NPC present at a late stage and survival is poor; current treatments 
for advanced disease are limited to concurrent chemo-radiotherapy and are 
associated with significant morbidity and poor quality of life (Hui et al., 2013). 
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Figure 1.5 Timeline for cancer pathogenesis from molecular and 
cytogenetic perspective 
Tumorigenesis in NPC occur as result of multiple molecular alterations, such as 
mutations, chromosome deletions, promotor hypermethylation of specific genes, 
LOH of 3p and 9p chromosomes and EBV infection.  
Changes like LOH, cyclin D1 (CCND1) overexpression and CDKN2A, 
RASSF1A, RARB2 and DAPK1 inactivation are seen in early stages of 
tumorigenesis. These changes are believed to promote susceptibility to EBV 
infection and promote expression of EBV latent genes. Therefore, EBV can only 
be detected in high-grade pre-invasive stages of tumorigenesis, but not in low 
grade dysplastic lesions. 
Figure adapted from Young et al (Young et al., 2016).  
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1.5 Contribution of EBV to B cell Lymphoma (DLBCL and HL) and NPC  
1.5.1 EBV-associated B cell lymphomas 
 
The development of EBV-positive B cell lymphomas might be considered to be in 
essence a rare accident of EBV’s ability to colonise the B cell system. Most EBV-
associated B cell lymphomas display somatic hypermutation and therefore 
originated in cells that have experienced a GC reaction. In some cases one might 
expect that the differentiation status could in turn dictate the pattern of virus latency 
found in each tumour. HRS cells in HL express a latency II pattern identical to that 
found in the GC B cells of asymptomatic carriers and may be suggestive of a GC 
origin (Deacon et al., 1993). On the other hand, EBV-positive BL cells have a 
morphology and gene expression profile that is similar to GC B cells and so express 
a virus latency programme which resembles more closely a memory B cell (Rowe 
et al., 2014). 
1.5.2 Contribution of EBV latent genes to the pathogenesis of lymphomas 
 
In the following sections I focus on the contribution of individual virus genes to the 
pathogenesis of B cell lymphomas. By virtue of the overwhelming larger literature 
on cHL, I focus my discussion on this disease, but much of what is discussed almost 
certainly also applies to DLBCL, at least the ABC type, which shares many features 
in common with cHL 
Epstein-Barr virus nuclear antigen-1  
Epstein-Barr virus nuclear antigen-1 (EBNA-1) is necessary for the maintenance of 
EBV infection as it acts as a viral replication factor and tethers the viral genome to 
the chromosomes of daughter cells during cell division (Smith and Sugden, 2013). 
It is expressed in all forms of virus latency, with the exception of Latency 0. In 
addition to its genome maintenance function, EBNA1 is also a transcription factor 
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that regulates both viral and cellular gene expression (Frappier, 2012a, Frappier, 
2012b), as well as inhibiting TGFβ signalling, at least in part through increasing the 
turnover of SMAD2 and down-regulating the TGFβ target gene, PTPRK (Wood et 
al., 2007, Flavell et al., 2008), promoting growth and survival of cHL cells. EBNA1 
increases expression of the T cell chemokine CCL20 which may dampen the 
immune response to HRS cells by recruiting regulatory T cells to the tumour 
microenvironment (Baumforth et al., 2008).  
Latent membrane protein-1  
LMP-1 is a member of the tumour necrosis factor receptor (TNFR) superfamily and 
functions as a constitutively active homologue of the cellular CD40 receptor (Lam 
and Sugden, 2003). LMP-1 can activate multiple cell signalling pathways that are 
known to be aberrantly activated in cHL and DLBCL. These include the NF-κB, 
JAK/STAT, AP-1 and phospatidylinositol-3 kinase (PI3-K)/AKT pathways (Bargou 
et al., 1997, Dutton et al., 2005, Heath et al., 2012).  
The importance of LMP-1 in cHL pathogenesis is further emphasised by the finding 
that LMP-1 expression in primary GC B cells, the presumed progenitors of cHL, 
induces many of the changes characteristic of HRS cells. These changes include 
the down-regulation of B cell transcription factors and BCR signalling components 
required to maintain B cell identity, and the upregulation of survival genes such as 
BCL2 and BFL-1 that protect B cells from apoptosis (Henderson et al., 1991, 
Vockerodt et al., 2008). LMP-1 also induces the expression of FLICE-inhibitory 
protein (Cellular FLICE-inhibitory protein c-FLIP), a negative regulator of Fas 
induced apoptosis (Cahir-McFarland et al., 2004), suggesting that one of its major 
pathogenic roles could be to rescue pre-apoptotic GC B cells from cell death (Figure 
1.6). LMP-1 can also regulate cellular gene expression by modifying the H3K27me3 
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histone mark through poly (ADP-ribose) polymerase 1 (PARP1) activation (Martin 
et al., 2016). LMP-1 can also affect gene transcription and subsequent B-cell 
lymphomagensis through the activation of cellular miRNAs, for example by 
regulating miR-10b, miR-29b, miR-146a, and miR-155 (Motsch et al., 2007). LMP-
1 might also contribute to the characteristic morphological features of HRS cells. For 
example, induced expression of LMP1 down-regulates expression of the shelterin 
proteins, TRF1, TRF2 and POT1 leading to the formation of multinucleated HRS-
like cells (Lajoie et al., 2015). 
Latent membrane protein-2  
Latent membrane protein-2 (LMP-2) exists as two isoforms, LMP-2A and LMP-2B, 
which share 8 common coding exons but have different 5′ exons. While the 5′ exon 
of LMP-2B is non-coding, the unique N-terminus of LMP-2A includes an ITAM motif, 
which resembles the signalling domain of the BCR. Indeed, in transgenic mice LMP-
2A has been shown to function as a BCR mimic, allowing B cell development in the 
absence of normal signalling through the BCR (Caldwell et al., 1998, Merchant et 
al., 2001). In doing so LMP-2A engages signalling pathways important for B cell 
survival, including the RAS/PI3-K/AKT pathway which is implicated in HRS cell 
survival (Fukuda and Longnecker, 2007). Global gene expression studies show 
that LMP-2A can suppress expression of numerous B cell transcription factors, 
including EBF1 and E2A, recapitulating  many of the gene expression changes seen 
in HRS cells (Portis et al., 2003, Portis and Longnecker, 2004, Vockerodt et al., 
2013). LMP-2A also activates the Notch pathway, which might contribute to the loss 
of B cell identity in HRS cells (Anderson and Longnecker, 2009). However, it 
should be noted that many of the adaptor molecules necessary for both BCR and 
LMP-2A signalling are absent in HRS cells, and therefore it remains unclear whether 
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LMP-2A acts as a BCR surrogate in the context of cHL. One possible explanation 
for this paradox is that LMP-2A provides essential survival signals in the HRS 
progenitor cells, which retain the downstream BCR signalling molecules, but 
subsequent transformation events followed by downregulation of B cell specific 
genes replace some of these critical LMP-2A functions. However, given that EBV-
positive cases of cHL are consistently LMP-2A positive, it is likely that LMP-2A also 
has BCR-independent functions that are important for maintenance of the HRS 
phenotype. 
Whereas LMP-2A has been shown to induce autoimmunity in transgenic mice 
(Chang et al., 2012), LMP-1 expression in the B cells of transgenic mice can lead 
to lymphoma development (Kulwichit et al., 1998, Zhang et al., 2012). However, 
the combined expression of LMP-1 and LMP-2A in transgenic mice resulted in no 
significant B cell abnormalities (Vrazo et al., 2012), suggesting that LMP-2A might 
have tumour suppressor functions. Recently it was shown that LMP-1 was 
dispensable for EBV-induced lymphoma formation in cord blood-humanized mice 
and that deletion of LMP-2A delayed the onset of lymphoma in this model (Ma et 
al., 2017). Plasma cell differentiation was inhibited even in the absence of LMP-1 
and LMP-2 suggesting that this was important for EBV-induced lymphomagenesis. 
The apparent contradictory findings from these animal models underscore the need 
to develop better in vivo models of EBV-associated lymphomagenesis. 
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1.5.3 Suppression of the EBV lytic cycle as a potential pathogenic event in 
EBV-positive cHL 
 
Productive EBV infection is associated with the temporal expression of immediate 
early, early and late viral genes leading ultimately to the production of new virus 
particles. The switch to virus replication from latency is mediated by two distinct 
mechanisms. The first occurs via plasma cell differentiation, the second through the 
activation of the BCR. Given that the full replicative cycle of EBV leads to cell death, 
suppression of both routes to virus replication is probably necessary for 
transformation. 
Plasma cell differentiation is dependent on the temporal expression of transcription 
factors which co-ordinately induce the transcription of genes required for terminal 
B-cell differentiation while switching off the germinal centre B-cell program. B 
lymphocyte induced maturation protein 1 (BLIMP1), which is required for plasma 
cell differentiation and which can activate the EBV immediate early genes BZLF1 
and BRLF1, thus providing a mechanistic link between plasma cell differentiation 
and EBV reactivation (Reusch et al., 2015). LMP-1 has been shown to suppress 
plasma cell differentiation by inhibiting BLIMP1α expression. EBV can also induce 
expression of the dominant negative BLIMP1 isoform, BLIMP1β (Vrzalikova et al., 
2011, Vrzalikova et al., 2012). Thus, disruption of the normal functions of BLIMP1α 
is likely to be important for the pathogenesis of cHL, preventing not only the terminal 
differentiation of the tumour cell progenitors, but also virus replication. It should be 
noted that in virus-negative B cell lymphomas, BLIMP1 can be inactivated by other 
mechanisms, for example by mutation (Pasqualucci et al., 2006, Mandelbaum et 
al., 2010).The second route to EBV replication occurs via BCR activation. As 
described earlier EBV-positive HRS cells frequently have non-functional 
immunoglobulin genes and lack expression of critical downstream molecules of the 
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BCR signalling pathway. The loss of a functional BCR is likely to be an important 
event in cHL development because it could also prevent entry into the replicative 
cycle. Almost all cases of cHL bearing destructive immunoglobulin gene mutations 
are EBV-positive (Bräuninger et al., 2006). These data suggest that progenitor 
cells carrying such mutations can only survive if infected with EBV. Further support 
for this contention is provided by the observation that EBV can immortalise BCR-
negative GC B cells in vitro (Mancao et al., 2005, Chaganti et al., 2005, Bechtel 
et al., 2005). Importantly, while LMP-2A can still induce lytic cycle entry in the 
absence of a functional BCR, it cannot do so when these downstream BCR 
components are missing (Vockerodt et al., 2013). Thus, the loss of BCR, as well 
as of BCR signalling components could prevent both BCR- and LMP-2A-induced 
virus replication. Figure 1.6 summarises the GC model of EBV infection and its role 
in the pathogenesis of B cell associated EBV lymphomas.  
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Figure 1.6 EBV infection model in normal lymphoid B cells and its 
pathogenesis in B cell lymphoma. Top panel shows EBV asymptomatic infection 
in B cells begins with acquisition of the virus in naïve cells, followed by its 
proliferation in GC B cells, proceeding establishment of latency III.  LMP-1 and LMP-
2 latent genes, provide survival benefits in the GC B cells as they function as CD40 
receptor and BCR signalling respectively. Infected cells can exit GC as memory cells 
harbouring the virus, then differentiate to plasma cells with silenced infection, as 
shown in the black solid arrow.  EBV infected plasma cells, can arise directly from 
GC infected B-cells as well (highlighted with the dash arrow). Another direct infection 
model shown in the middle panel through direct acquisition of memory cells to the 
EBV infection, followed by establishment of latency type III. Lower panel of different 
types of EBV related B cell lymphomas such as post-transplant lymphoproliferative 
disease (PTLD), diffuse large B cell lymphoma (DLBCL), Hodgkin lymphoma (HL) 
and Burkitt lymphoma (BL) showed different types of latency, with unsettled exact 
cell of origin as highlighted by the black dotted lines. Figure taken from Young et al 
(Young et al., 2016).  
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1.5.4 EBV and DLBCL; additional remarks 
 
EBV is reported to be more commonly associated with DLBCL in patients who have 
evidence of immune impairment. For example, EBV-positive DLBCL constitute 
approximately 30-50% of the later onset lymphomas that arise in patients after 
transplant and as a consequence of iatrogenic immune suppression. Most EBV-
positive DLBCL express either a type II, or more frequently, a type III form of latency. 
As well as potential roles for LMP-1 and LMP-2 described above for cHL, many 
DLBCL express EBNA-2 and the EBNA-3 proteins. There is evidence that these 
proteins could contribute to DLBCL pathogenesis, for example, EBNA-3A and 
EBNA-3C are potential oncogenes, which together can repress expression of pro-
apoptotic and senescence-inducing genes (Anderton et al., 2008, Skalska et al., 
2010, Maruo et al., 2011). In contrast, EBNA3B is probably a tumour suppressor 
gene in DLBCL (White et al., 2012).  
It was also reported that EBV-positive DLBCL can occur in older patients without a 
prior history of immune suppression. This initially led to the designation by WHO, of 
a new provisional diagnostic entity, referred to as ‘EBV-positive diffuse large B cell 
lymphoma of the elderly (Oyama et al., 2003, Oyama et al., 2007). However, EBV-
positive DLBCL was also described in younger patients and in children without any 
immunodeficiency (Cohen et al., 2013, Cohen et al., 2017). This prompted a 
revision of the classification in 2016 where EBV-positive DLBCL is now referred to 
as ‘EBV-positive DLBCL NOS’. 
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1.5.5 EBV association and contribution of EBV genes in NPC 
 
In NPC tumour cells EBV has been reported to display a restricted pattern of virus 
latency with the expression of EBNA1, LMP-1 and LMP-2A (latency II). Notably, 
LMP-1 is not expressed in all NPC, and in some positive cases expression is 
heterogeneous being apparently restricted to a subset of tumour cells (Khabir et 
al., 2005). LMP-1 has been shown to inhibit epithelial cell differentiation (Dawson 
et al., 1990). In the context of NPC, LMP-1 can increase tumour cell proliferation 
and survival via its ability to activate the NF-ĸB and PI3-K/Akt pathways, as well as 
regulate growth factor receptors such as EGFR and c-MET (Dawson et al., 2012). 
LMP-1 can also promote angiogenesis through its ability to increase the expression 
of hypoxia-inducible factor 1 (HIF) and vascular endothelial growth factor (Dawson 
et al., 2012). The metastatic potential of NPC cells is increased as a result of LMP-
1-induced epithelial-mesenchymal transition. Through activation of its downstream 
signalling pathways, LMP-1 can also induce the expression of matrix 
metalloproteinases (Zhao et al., 2012). 
In contrast to LMP-1, LMP2-A is constitutively expressed in NPC where it has been 
shown to promote proliferation of NPC cells, induce epithelial-mesenchymal 
transition, as well as invasion, and migration. LMP-2A can activate these cellular 
phenotypes through its ability to stimulate intracellular signalling pathways, notably 
via Notch, PI3-K/Akt, and Wnt (Vicari and Trinchieri, 2004). 
1.5.5.1 Genetic factors in NPC development 
Although EBV is probably an early event, pre-existing genetic abnormalities, for 
example loss of chromosomal material from 3p and 9p are thought to occur before 
EBV infection and may allow the virus survive in its latent form rather than induce 
virus replication which is the normal outcome of virus infection of untransformed 
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epithelial cells (Chan et al., 2000, Chan et al., 2002, Frappier, 2012c). In keeping 
with this EBV infection is not detectable in normal nasopharyngeal epithelium, but 
has been detected in in situ cancers (Pathmanathan et al., 1995a, Pathmanathan 
et al., 1995b).  
NPC cells display evidence of activating mutations and amplification of components 
of the PI3-K signalling and receptor tyrosine kinase pathways (Chou et al., 2009, 
Chung et al., 2013, Lin et al., 2014). Recent global genomic studies have also 
identified recurrent alterations in genes involved in chromatin remodelling including 
ARID1A, KMT2D/3 and  BAP1 (Lin et al., 2014). 
Genomic landscape of NPC  
Whole exome and deep sequencing of 128 cases of NPC revealed the presence of 
9 frequently mutated genes involved in chromatin remodelling, ERK-MAPK/PI3-K 
signalling and autophagy (Lin et al., 2014). In a more recent study of more than a 
100 micro-dissected primary, recurrent and metastatic NPC samples, obtained from 
Asian and the USA, whole exome sequencing (WES) revealed the presence of 
novel molecular mutations believed to be important in the oncogenesis of NPC (Li 
et al., 2017). The study identified higher rates of somatic mutation in EBV-positive 
tumours than was previously thought (Li et al., 2017), and contrasted with EBV-
negative head and neck squamous cell carcinoma (SCC), where the spectrum of 
somatic mutations were found to be far fewer in number (Network, 2015). Somatic 
mutation in negative regulators of the NF-ĸB pathway was identified as a prominent 
feature of EBV-positive NPC, with mutation or truncation of CYCLD, TRAF3 and NF-
ĸBIA frequently identified in NPC cases derived from Asian backgrounds (Li et al., 
2017). NF-ĸB has been shown to influence the growth and survival of NPC-derived 
cell lines in vitro, underscoring the importance of pathway dysregulation in NPC 
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pathogenesis. Somatic alterations in DNA repair and chromatin remodelling genes 
were also reported, giving rise to additional genetic signatures. In agreement with 
the earlier study of Lin et al., (Lin et al., 2014), mutations in the PI-3K and Mitogen-
activated protein kinase (MAPK) pathways were also identified, with tumours 
harbouring mutations in PTEN, PIK3CA, ERB3, BRAFL, NF1, FGFR2 and FGFR3 
(Li et al., 2017). Inactivation of the tumour suppressor gene, PTEN, can also be 
induced by LMP-1, through a mechanism involving epigenetic changes and NF-ĸB 
activation (Peng et al., 2016). LMP-1 is known to activate the canonical and non-
canonical NF-ĸB signalling pathways (Soni et al., 2007).  While LMP-1 protein 
expression in NPC is variable, in their study, Li and colleagues found that 25.7% of 
the NPC cases were LMP-1 positive. Interestingly, this study found that LMP-1 
positive tumours, unlike their LMP-1 negative counterparts, were found to lack 
somatic mutations in the NF-ĸB negative regulators, suggesting that constitutive NF-
ĸB signalling is essential for both LMP-1-dependent and LMP-1-independent NPC 
pathogenesis. Hariwiyanto and colleagues established that high levels of LMP-1 and 
LMP-2 were associated with a poorer prognosis and disease-specific survival, 
suggesting that viral-encoded latent proteins may provide additional stimuli over and 
above those induced by somatic mutation of the NF-ĸB pathway (Hariwiyanto et 
al., 2010). Molecular aberrations in NF-ĸB, in addition to LMP-1-mediated NF-ĸB 
were found to contribute to the unique inflammatory background of NPC (Li et al., 
2017). LMP-1 stimulates NF-ĸB oncogenic pathway mediated through 
phosphorylation and degradation of IκBα (Yin et al., 2001).  
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1.5.5.2  Viral and cellular factors influencing tumour immunity 
It is well established that certain EBV genes can interfere with the antigen-
processing machinery. For example, EBV proteins expressed in the lytic cycle such 
as BGLF5, BILF1 and BNLF2A are known to interfere through various mechanisms 
with major antigen presentation through major histocompatibility complex molecules 
(Zuo et al., 2009). Furthermore, BCRF1 is a functional homologue of IL-10 and can 
inhibit virus-specific immunity (Vicari and Trinchieri, 2004).  
The discovery that PD-L1 and PD1 over-expression is common in EBV-associated 
NPC indicates that these two immune evasion proteins are important in the 
tumorigenic process (Zhang et al., 2015). The up-regulation of PD-L1 and PD-L2 
was reported in NPC as well as in other EBV-associated malignancies, such as HL 
may enable the tumour cells to survive the host immune response.  
Prevalence of PD-L1 protein expression in NPC 
PD-L1 expression on NPC tumours has been reported, albeit to varying extents. 
This is attributed to the use of different antibodies and different cut-off values used 
to score tumour cell positivity. It was reported by Chen et al to be positive in 89% 
(16/18) of cases (Chen et al., 2013), by Fang et al to be 95.0% (132/139) (Fang et 
al., 2014), by Zhang et al to be 95.0% (132/139) (Zhang et al., 2015), Lee et al to 
be 25% (26/104) (Lee et al., 2016), by Zhou et al to be 97.0% (128/132)  (Zhou et 
al., 2017a), by Zhou et al to be 97.0% (96/99) (Zhou et al., 2017b), by Li et al to be 
(71%) (85/120) (Li et al., 2017), by Ooft et al to be  60% (55/92) (Ooft et al., 2017), 
by Zhu et al to be 32.53% (68/209) of NPC samples (Zhu et al., 2017) and by Zheng 
et al to be 73.3% (85/116) (Zheng et al., 2017). 
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PD-L1 and association with other EBV related malignancies 
Viruses and some tumours may utilize the PD1/PD-L1 signalling pathway to avoid 
detection by the immune system (Barber et al., 2006) (Iwai et al., 2002). 
Overexpression of PD-L1, in the context of EBV-related malignancies, has been 
reported. PD-L1 overexpression has been described in EBV associated cancers, 
which can be mediated through LMP-1 or through PD-L1 amplification (Network, 
2014). LMP-1 has also been shown to induce PD-L1 expression through a 
mechanism involving AP-1 signalling in HL (Green et al., 2012a). PD-L1 over 
expression has been reported predominantly in EBV-positive post-transplant 
lymphoproliferative disorders (Green et al., 2012a). EBV positive DLBCL (EBV 
immunodeficiency related and DLBCL of the elderly) have been reported to be 
positive in (16/16) 100% of cases examined. Interestingly, however, EBV positive 
BL were reportedly to be negative in all cases examined (Chen et al., 2013). NK/T 
cell lymphoma is an aggressive form of lymphoma, which is consistently EBV 
positive. Higher levels of PD-L1 was shown to be expressed at the protein level in 
the EBV positive NK cell line (SNK-6), compared to the EBV negative NK cell line 
(NK-92). A role for LMP-1 in PDL-1 expression was established in these NK cell 
lines, through activation of the ERK-MAPK/NF-ĸB pathways (Bi et al., 2016). 
Studies have revealed the significance of high expression of PD1 in the 
microenvironment of HL which was associated with poor outcome. In this study, 
20% of patients with PD1 density >0.5% cells had disease free survival 61% versus 
89% at both 5 and 10 years (p=0.03) (Greaves et al., 2013). T cell effector functions 
in cHL can be abrogated by the engagement of PD-L1 expressed on HRS cells with 
its receptor, PD-1, on T cells resulting in functional exhaustion of the T cells (Muenst 
et al., 2009, Yamamoto et al., 2008). Amplification of the PD-L1 and PD-L2 genes 
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at 9p24 is common in NSHL (Green et al., 2012a), while the PD-L1 gene can also 
be deregulated in a proportion of cHL cases as a result of a reciprocal translocation 
that involves MHC-II transactivator (CIITA) (Steidl et al., 2011). In HL, amplification 
of PD-L1/PD-L2 is associated with an approximately 90% response rate to 
Nivolumab. (Ansell et al., 2015). LMP-1 has also been reported to induce PD-L1 
expression (Green et al., 2012a). The importance of this pathway in the 
microenvironment of cHL is exemplified by studies which show that many patients 
with relapsed or refractory cHL respond to PD1 blockade therapy (Ansell et al., 
2015) Moreover, recent study have shown PD-L1 expression in HRS highly 
expressed in cHL (90% in lymphocyte rich HL, 65% in the nodular sclerosis subtype, 
67% in the lymphocyte-depleted subtype and 81% in the mixed cellularity subtype), 
rather than NLPHL (54%). PD-L1 was associated with poor survival rates in EBV 
negative HL (Menter et al., 2016).   
PD-L1 and HL 
Studies have revealed the significance of high expression of PD1 in the 
microenvironment of HL which was associated with poor outcome. In this study, 
20% of patients with PD1 density >0.5% cells had disease free survival 61% versus 
89% at both 5 and 10 years (p=0.03) (Greaves et al., 2013). T cell effector functions 
in cHL can be abrogated by the engagement of PD-L1 expressed on HRS cells with 
its receptor, PD-1, on T cells resulting in functional exhaustion of the T cells (Muenst 
et al., 2009, Yamamoto et al., 2008) Amplification of the PD-L1 and PD-L2 genes 
at 9p24 is common in nodular sclerosis cHL (Green et al., 2012a), while the PD-L1 
gene can also be deregulated in a proportion of cHL cases as a result of a reciprocal 
translocation that involves CIITA (Steidl et al., 2011). In HL, amplification of PD-
L1/PD-L2 is associated with an approximately 90% response rate to Nivolumab. 
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(Ansell et al., 2015). LMP-1 has also been reported to induce PD-L1 expression 
(Green et al., 2012a). The importance of this pathway in the microenvironment of 
cHL is exemplified by studies which show that many patients with relapsed or 
refractory cHL respond to PD1 blockade therapy (Ansell et al., 2015). Moreover, 
recent study have shown PD-L1 expression in HRS highly expressed in cHL (90% 
in lymphocyte rich HL, 65% in the nodular sclerosis subtype, 67% in the lymphocyte-
depleted subtype and 81% in the mixed cellularity subtype), rather than Nodular 
lymphocyte predominance HL (54%). PD-L1 was associated with poor survival rates 
in EBV negative HL (Menter et al., 2016).   
The significance of immune checkpoints in these tumours is discussed in section 
1.6. 
1.5 Tumour microenvironment  
A major theme of this thesis is the tumour microenvironment. In this respect, I have 
focussed on the microenvironment of DLBCL and NPC. I have focussed mainly on 
the potential contribution of collagen and collagen receptors in DLBCL and the PD-
L1 immune checkpoint in NPC. 
General introduction of DLBCL Microenvironment 
The tumour microenvironment of DLBCL is composed of immune cells, stromal 
cells, blood vessels and extracellular matrix, which appears to be an important 
prognostic factor in DLBCL patients (Scott et al., 2016). High density infiltration of 
tumour associated macrophages (TAMs), specifically M2 macrophages is predictive 
of poor outcome in several types of cancers (Condeelis and Pollard, 2006, Qian 
and Pollard, 2010). Macrophage of M2 phenotype numbers are also strongly 
associated with inferior survival in DLBCL, which is associated with progression of 
tumour, this was described to be mediated through remodelling of the extracellular 
matrix (Shen et al., 2016). CD163-expressing macrophages in the 
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microenvironment of DLBCL was associated with Stage IV and disease progression 
(Shen et al., 2016). The potential tumour-promoting functions of TAMs may also be 
explained by their ability to induce angiogenesis mediated by the secretion of 
soluble pro-angiogenic factors, including vascular endothelial growth factor (VEGF) 
(Mantovani et al., 2004). Reports have shown that tumour cells secrete cytokines 
such as chemokine ligand 2 (CCL2) which induce polarization of monocytes to M2 
tumour promoting macrophage phenotype upon co-culturing of bone marrow 
stromal cells with lymphoma cells (Guilloton et al., 2012). Other report indicate that 
increased density of M2 macrophages (defined as CD68+CD163+ cells), but not M1 
macrophages are associated with a poor outcome in R-CHOP treated DLBCL 
patients (Wada et al., 2012) (Marchesi et al., 2015). Another study showed that a 
high density of CD163-positive M2 macrophages was a poor prognostic factor in 
DLBCL (Shen et al., 2016). These findings suggest that the ratio of CD163-positive 
M2 TAMs correlates positively with disease progression and prognosis in DLBCL. 
A study that used semi-automated quantitative analysis revealed significance of IHC 
CD3 and FOXP3 counts as good predictive markers in treated DLBCL patients 
(Coutinho et al., 2015). The immune microenvironment of DLBCL is characterized 
by infiltration of mixtures of innate response and adaptive immune cells, including 
macrophages, APC and NK, dendritic cells and reactive lymphocytes (Cohen et al., 
2017). Exhausted T cells, as demonstrated by PD1 positive TILs were reported in 
DLBCL microenvironment.  Chronic antigenic stimulation such as that induced by 
viral infections results in exhaustion of T cells, with inefficient production of antiviral 
cytokines (Wherry and Ahmed, 2004). Exhausted T cells can result in lymphoma 
development (Bryan and Gordon, 2015). PD1 positive cells were shown to be 
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predominant in EBV positive DLBCL, and associated with decreased cytokine 
secretion in in vitro studies (Quan et al., 2015). 
EBV positive and negative DLBCL are not different in terms of the frequency of T-
regs, however, CD8 positive cytotoxic lymphocytes and granzyme expression were 
predominant in the virus associated DLBCL (Cohen et al., 2017). Lenz et al profiled 
gene expression in whole DLBCL samples to identify gene expression signatures 
that correlated with differences in survival following treatment with R-CHOP and 
showed that the DLBCL microenvironment is an important indicator of outcome. 
Thus, the two stromal signatures when combined into a single stromal score 
predicted the survival of DLBCL patients. Importantly, the stromal score was present 
across both molecular subtypes of GCB and ABC, suggesting that similar tumour 
microenvironment features can be acquired during the pathogenesis of both of the 
major forms of DLBCL. High values of the stromal scores were associated with 
inferior outcomes. Genes defining the stromal-1 signature were enriched for those 
encoding extracellular matrix components, including collagens and modifiers of 
collagen synthesis. Also enriched in the stromal-1 signature was a “monocyte” 
profile, comprising genes that are more highly expressed in CD14+ blood 
monocytes than in B cells, T cells, or natural killer cells. Recruitment of stromal cells 
to the tumour microenvironment is recognised to play an important role in tumour 
progression mediated through changes in the endothelial transcription profile of 
DLBCL. The stromal-2 signature is reported to be enriched for genes associated 
with angiogenesis reflected by increased tumour blood-vessel density which 
predicts poor outcome in DLBCL patients (Lenz et al., 2008). 
Reports showed that increased density of M2 macrophages (defined as 
CD68+CD163+ cells), but not M1 macrophages are associated with a poor outcome 
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in R-CHOP treated DLBCL patients (Wada et al., 2012) (Marchesi et al., 2015). 
Another study showed that a high density of CD163-positive M2 macrophages was 
a poor prognostic factor in DLBCL (Shen et al., 2016). These findings suggest that 
the ratio of CD163-positive M2 TAMs correlates positively with disease progression 
and prognosis in DLBCL. Chemo-resistant patients showed more CD68 and 
tryptase expression, and this was associated with increased microvessel density. 
CD3 positive T cells in this study showed decreased density with bulky disease, 
which contributed to the progression and inferior outcome (Gaudio et al., 2017). 
Microarray studies have shown a distinct cluster related to the microenvironment of 
DLBCL, named host inflammatory response subtype. Although this signature was 
associated with prominent host response in the form of T cells and dendritic cells 
infiltration, however R-CHOP patients in this cluster showed inferior outcome, which 
indicated an ineffective immune response by inhibited immune cells. This signature 
was rich in inflammatory related genes, such as components of TCR genes, genes 
related to NF-ĸb and IFNγ/STAT1 signalling pathways (Monti et al., 2005, 
Abramson and Shipp, 2005). Another study examined CD3, PD1 and PD-L1 
expression in the microenvironment of DLBCL, and revealed that CD3 T cells were 
the most frequently identified cell type in the infiltrate, followed by PD-L1 and PD1-
positive cells. PD-L1 expression was described to be present more often in the ABC 
type of DLBCL. PD1 positive T cells in CD3 rich DLBCL, was associated with poor 
outcome.  There is also emerging evidence that the microenvironment can modulate 
EBV gene functions. Thus, LMP-1 induces expression of the discoidin domain 
receptor 1 (DDR-1), a potentially oncogenic receptor tyrosine kinase. However, 
DDR-1 is normally only active in the presence of its ligand, collagen, which is a major 
constituent of the cHL microenvironment. Notably, ligation of DDR-1 by collagen 
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promotes the survival of lymphoma cells in vitro (Cader et al., 2013). These 
observations suggest that some of LMP-1’s oncogenic effects may be dependent 
on the tumour microenvironment.  
1.6.1 Collagen and collagen receptors 
 
Collagen is a key constituent of the extracellular matrix (ECM) of tumour 
microenvironments where it may contribute to cancer development and progression. 
Cross talk between ECM proteins and neoplastic cells has been shown to be 
important for tumour proliferation, survival and dissemination.  
Structure of collagen 
Collagen is composed of a triple helical structure, which is formed of repeats of 
proline, hydroxyl amino acids and glycine (Pro-Hyp-Gly). The three polypeptide 
chains forming the triple helix collagen, are either similar or different in their repeats, 
frequently comprised of proline or hydroxyproline amino acid residues in X- and Y-
position respectively (Engel and Bächinger, 2005). Hydroxylation of proline occurs 
due to posttranslational enzymatic action where conversion of the proline at Y 
position occurs into hydroxyproline. Peptide bonds attaching the amino acids chains 
are located at the interior side of the triple helical structure of the collagen, conferring 
resistance to enzymatic action by proteases, however it can be degraded by 
collagenases enzyme or can be denatured (Hay, 2013). Glycine is located at very 
third position in the repeating amino acid sequence and is responsible for the folding 
of the triple helix. The hydroxylation of the proline residues is responsible for the 
structural stability of collagen and location of hydroxyproline at the Y position adds 
to this stability. The collagen structure is strengthened by the hydrogen bonds 
between the backbone of glycine and proline. Formation of collagen fibres starts 
with cleavage of pro-collagen at the N and C-terminal pro-peptide into tropocollagen 
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which is formed of three different α chains, followed by microfibril assembly with 
formation of collagen fibrogenesis, followed by formation of cross links. Collagen 
can be formed of either continuous fibres or can be interrupted with non-collagenous 
structures. Straight poly-proline helix per turn is formed of three residues with the 
glycine facing each other from the inner side (Shoulders and Raines, 2009). 
1.6.1.1 Collagen in haematolymphoid neoplasms 
Early studies of follicular lymphoma (FL) reported collagen deposition, varying from 
fine to thick fibres, particularly in high grade cases. In fact, the follicular pattern 
becomes more obvious with bands of collagen encompassing tumour follicles (Jaffe 
et al., 2010). Collagen deposition is more common in certain anatomic locations 
such as retroperitoneum, however it can also occur in other locations such as 
mediastinal, cervical or other regions (Rosai, 2011). The presence of collagen in 
inter-follicular regions can be used as an additional helpful feature in differentiating 
reactive follicular hyperplastic or the most challenging diffuse lymphoid hyperplastic 
conditions, from FL. The presence of collagen may also be of clinical significance 
as it was proposed that FL with and without sclerosis are clinically distinct, with 
findings that the former may be more indolent (McCurley et al., 1986). In FL, it was 
proposed that the collagen producing cells were fibroblasts or myofibroblasts 
(McCurley et al., 1986).  In other mature B cell neoplasms such as multiple 
myeloma (MM), 9% of cases were categorized as fibrotic myeloma with extensive 
collagen deposition. MM with marrow fibrosis is also usually associated with more 
plasma cell infiltrate and short survival.   
As mentioned earlier sclerosis is sometimes seen in other B cell lymphoma such as 
DLBCL, especially in rare variants of DLBCL like spindle cell and myxoid subtypes, 
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as well as PMLBCL and grey zone lymphoma which is rare subtypes of DLBCL 
(Rosai, 2011).  
1.6.2 Collagen receptors 
 
There are at least 9 collagen receptor genes; two of these are relevant to this thesis. 
They are the DDR-1 and LAIR-1. 
1.6.2.1 Discoidin domain receptor-1  
DDR-1 and DDR-2 are unique among receptor tyrosine kinases in being activated 
by interaction with the extracellular matrix. Both DDR-1 and DDR-2 are 
phosphorylated upon binding collagen. DDR-1 was shown to protect lymphoma cells 
from chemotherapy induced cell death. The EBV latency gene, LMP-1 was shown 
to upregulate DDR-1 in normal GC B isolated cells. Auto-phosphorylation of DDR-1 
induces the activation of downstream signalling pathways, including PI3-K/Akt and 
NF-ĸB which are important in the pathogenesis of many cancers and lymphomas, 
including HL (Cader et al., 2013).  
DDR-1 and DDR-2 have emerged as an important subgroup of potentially oncogenic 
collagen receptors (Borza and Pozzi, 2014) (Rammal et al., 2016, Valiathan et 
al., 2012, Villoutreix and Miteva, 2016). The DDRs are receptor tyrosine kinases 
which have a catalytic kinase domain with a distinct extracellular Discoidin (DS) 
homology domain (Johnson et al., 1993, Alves et al., 1995). Both receptors are 
activated upon binding to collagen. DDR-1 is activated by various types of collagen 
including type I, IV, V, VI, and VIII, whereas DDR-2 is only activated by fibrillar 
collagens, in particular collagens type I, III, and type X (Vogel et al., 1997, 
Leitinger, 2003, Shrivastava et al., 1997). 
DDR-1 expression has already been shown to be an important inducer of several 
signalling pathways including JAK-STAT, NF-κB and PI3-K (L’HÔTE et al., 2002, 
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Das et al., 2006). DDR-1 also interacts with Notch 1 and induces pro-survival 
pathways; collagen also increases activated Notch 1 expression (Kim et al., 2011). 
1.5.2.2 Leukocyte-associated Ig-like receptor-1   
Leukocyte-associated Ig-like receptor (LAIR-1) is a type I transmembrane 
glycoprotein which is a member of the Ig superfamily. It is expressed on the majority 
of human PBMCs, including NK cells, T cells, B cells, monocytes, and dendritic cells. 
Cross-linking of LAIR-1 on human NK cells induces a potent inhibitory signal that is 
capable of decreasing target cell lysis by both resting and activated NK cells in vitro. 
It also acts as an inhibitory receptor on effector T cells (Meyaard, 2008) . LAIR-1 is 
a known collagen receptor. In vitro experiments showed that collagens such as 
transmembrane collagen XVII, collagen I and III are functional ligands of LAIR-1. 
These studies showed that LAIR-1 cross linking with collagens I and II can induce 
suppression of the immune response. Tumours expressing different types of 
collagens such as collagens I, III, V, VI, XIII, XVII, XVIII, and XXIII were reported to 
be prognostic markers of tumour aggressiveness (Parikka et al., 2003, Banyard et 
al., 2003, Väisänen et al., 2005). LAIR-1 may induce immune evasion mediated 
through tumour cells expressing collagens which interact with LAIR-1 on immune 
cells (Lebbink et al., 2006). It is proposed that LAIR-1 signalling is regulated via its 
expression because LAIR-1 levels are generally higher on less differentiated or 
naive cells, and lower on more activated or differentiated immune cells (Meyaard, 
2008). LAIR-1 was recently described as a potineal target in acute myeloid 
leukaemia (AML), where inhibition of LAIR-1 expressed on surface of AML tumour 
cells induced cell death. LAIR-1 mediated the action of the apoptosis through the 
activation of the downstream signalling cAMP response element-binding protein 
(CREB) pathway through recruitment of SHP phosphatase. LAIR-1 can function 
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through activation of SHP-1/CAMK1 pathway by phosphorylating downstream 
transcriptional target gene of LAIR1; CREB and maintain development and growth 
of AML in in vitro experiments. In addition, an in vivo study showed that LAIR-1 
engrafted tumour cells sustained the growth of AML through stem cell activation 
(Kang et al., 2015).  
1.5.3 PD-L1 immune checkpoint 
 
Immune checkpoints refer to the myriads of pathways involved in inhibitory functions 
of the immune system that are essential for self-tolerance and modulating the 
duration of immune responses in tissues, thus protecting them from self-destruction. 
Recently, these immune-checkpoint pathways have been shown to be important for 
tumour evasion (Pardoll, 2012). One important checkpoint is that mediated by the 
engagement of PD-L1 expressed on tumour cells with its receptor, PD1, on T cells 
resulting in functional exhaustion of the T cells (Yamamoto et al., 2008). 
PD1 is also be expressed on other immune cells, including B cells, monocytes, 
dendritic cells and  NK cells, where it mediates its inhibitory effects on other immune 
functions (Pardoll, 2012). 
Mechanisms of PD1/PD-L1 signalling on immune evasion  
PD1 PD-L1 pathway inhibits T cell response through the interaction between PD1 
and PD-L1, leading to inhibition of TCR which is responsible for influx of calcium, 
which will be associated with several signalling pathway involved essential for T cell 
differentiation.  Mechanism of T cell inhibition starts with ligation of PD-L1 to PD1 
localized on the surface of T cells, followed by phosphorylation of PD1 when SHP1/2 
are recruited. This leads to the de-phosphorylation of lymphocyte-specific protein 
tyrosine kinase (Lck); which is responsible for phosphorylation of intracellular chains 
in T cells. As a result of Lck dephosphorylation, inactivation of cytoplasmic tyrosine 
 53 
 
kinase; Zap-70 results in inhibition of PI3-K/Akt/mTOR and Ras/MAPK/Erk 
pathways, leading to downregulation of the metabolic activity of T cells. This change 
in the T cell metabolic reprograming influences T cell differentiation, leading to 
inhibition of differentiation of effector and memory T cells, while enhancing the 
differentiation of T regulatory cells and exhausted T cells (Zhao et al., 2014, Hersey 
and Gowrishankar, 2015). 
 Although PD1 is expressed on various immune cells, its up-regulation on the 
surface of T cells, is a sign of exhaustion after persistent antigenic stimulation (Zou 
and Chen, 2008).  
PD1 can be upregulated by various stimuli, such as IFNs (Massari et al., 2015). 
Inhibition of T cell function and decrease in their number can happen through the 
high level of expression of PD1 in the microenvironment (Thompson, 2006, Wang 
et al., 2014, Blank et al., 2006).    
PD1 PD-L1 interaction can lead to increased levels of other immune checkpoint 
molecules such as IDO, which will result in further exhaustion of T cells and 
enhanced T-reg functions (Schlößer et al., 2014).  PD1 PD-L1 axis activation in the 
tumour microenvironment is not only associated with inhibition of effector T 
lymphocytes but is also associated with increased T-reg induction and function, thus 
enhancing the immunosuppressive function of T-regs. This can be enhanced by 
expression of PD1 on the surface of T-regs, resulting in differentiation to T-regs 
which express FOXP3, and which eventually will supress Th1 responses (Momtaz 
and Postow, 2014). 
Immune checkpoint inhibitors have been shown to be effective in immunogenic 
tumours, such as melanoma, renal cell carcinoma, bladder cancer, non-small cell 
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lung carcinoma, and HL (Medina and Adams, 2016). FDA approved inhibitors 
include pembrolizumab and Nivolumab (Topalian et al., 2015). 
Although PDL-1 expression is important for selecting patients for treatment with PD1 
or PDL-1 inhibitors not all PDL-1 positive tumours respond to these inhibitors 
(Pardoll, 2012). This indicates that more work is required to study the expression 
of this and other checkpoints in tumours and to relate this to outcome. 
Other immune checkpoints molecules 
In addition to the PD-L1/PD1 axis, several other immune checkpoint pathways have 
been identified in NPC. Indoleamine 2, 3-dioxygenase (IDO1), an 
immunosuppressive enzyme, was reportedly expressed in approximately 28% of 
NPC cases and shown to inhibit cytolytic T cell function in NPC cell lines. IDO1 
negatively influences lymphocyte function in tumours by modulating tryptophan 
metabolism in both antigen presenting cells and tumour cells, thereby enhancing 
tumour growth (Liu et al., 2009). Other immune-checkpoint molecules such as 
hepatitis A virus cellular receptor 2, also known as T cell Immunoglobulin and Mucin 
domain-3 (TIM3), and Lymphocyte Activation Gene-3 (LAG3) have been shown to 
be overexpressed in cancers and virus-related pathologies (Ott and Hodi, 2012). 
TIM3 is broadly expressed on immune cells and is implicated in various diseases 
such as colitis, HIV and HCV-associated diseases.  TIM3 and its ligand, Galectin-9, 
are expressed on NPC tumour cells, and increased expression is associated with 
tumour recurrence in NPC. Galectin-9 overexpression is associated with an 
increase in tumour-associated TIM3 positive lymphocytes and an increase in 
FOXP3 positive T cells in a subset of recurrent NPC patients. Expression of 
Galectin-9 on primary NPC tumours is associated with resistance to killing by 
cytotoxic CD8 T lymphocytes, which are inhibited by the effect of Galectin/TIM3 
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pathway and the recruitment of additional T-regs in NPC (Chen et al., 2017). LAG3, 
expressed on T lymphocytes, can inactivate T cells by arresting the cell cycle at S-
phase. LAG3 can induce an immunosuppressive microenvironment by enhancing 
T-reg suppressive functions (Thaventhiran et al., 2013). CTLA-4 is an inhibitory 
receptor expressed on T lymphocytes which, upon binding PD-L1, down-regulates 
pathways involved in T cell activation (Curran et al., 2010, Bour-Jordan et al., 
2011, Flies et al., 2011).  In addition to PD1, other immune inhibitory receptors such 
as B- and T-lymphocyte attenuator (BTLA) and LAIR-1 are members of the same 
family of ITIM -immunoreceptor tyrosine-based inhibition motif co-inhibitory 
receptors. When activated, recruitment of the SHP-1 and SHP-2 phosphatases 
results in inhibitory signals to downregulate T cell activation (Thaventhiran et al., 
2013). Additional PD1 ligand is PD-L2 although its precise role in modulating 
immune responses is still not verified, and its expression is more restricted 
compared to PD-L1, thus making it a less obvious target in cancer immunotherapy. 
PD-L1 is constitutively expressed by a wide variety of immune cells and non-
immune cells and most normal tissue cells seem to be able to up-regulate PD-L1 in 
the presence of strong inflammatory signals. Compared to PD-L1, constitutive basal 
expression of PD-L2 is low. PD-L2 expression was initially thought to be limited to 
antigen-presenting cells such as macrophages and dendritic cells (DCs).  In recent 
years however, several studies have shown that PD-L2 expression can be induced 
broadly on other immune cells and non-immune cells depending on 
microenvironmental stimuli (Rozali et al., 2012). PD-L1 and PD-L2 are different in 
their molecular mechanisms of interaction with PD1. Like PD-L1, PD-L2 can induce 
signalling downstream in T cell, thus modulating T-cell function, but the exact 
molecular pathway is yet to be elucidated. PD-L2 expression, like PD-L1 expression 
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may be predictive of response to Pembrolizumab (anti-PD1) immunotherapy (Rozali 
et al., 2012). 
1.6.4 Tumour microenvironment of NPC 
The tumour microenvironment comprises tumour cells and non-tumour cells such 
as fibroblasts, tumour-associated macrophages, eosinophils and lymphocytes 
(Schreiber et al., 2011). T cells are present within the microenvironment of EBV 
positive NPC (Li et al., 2017); however, EBV specific T cells are inhibited in the 
tumour microenvironment. Immunosuppressive T-regs are known to be increased 
in the peripheral circulation of NPC patients (Lau et al., 2007). Flow cytometric 
analysis of primary NPC samples, have shown that 11% of T cells exhibited T-reg 
phenotype (CD4 positive CD25 high FOXP3 positive) (Lau et al., 2007). Another 
study has shown increased recruitment of FOXP3 positive CD4 T cells in the tumour 
compartment rather than the stroma as demonstrated by double labelling (Yip et 
al., 2009). Different phenotypes of TILs have shown different impact on the 
outcome. The density of CD8 positive TILs showed positive association with lymph 
node spread while the density of FOXP3 positive TILs have impact on the tumour 
stage (Zhang et al., 2010). The density of FOXP3 positive TILs was associated with 
better overall survival and progression free survival, in all patients and in all patients 
with late stage disease. A low density of CD8 positive TILs or a high ratio of FOXP3 
positive TILs to CD8 positive TILs was correlated with better progression free 
survival in early stage patients (Yip et al., 2009). It is noteworthy that increased 
levels of FOXP3 positive T-regs were reported to be important prognostic infiltrate 
in the tumour compartment, associated with inferior survival in many cancers 
(Shang et al., 2015). The immunoscore seems to be a better prognostic factor than 
staging in early-stage colorectal cancer (Pages et al., 2009). Immunoscore was 
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performed based on the evaluation of subpopulations of T cells, especially CD8+ T 
cells (Ascierto et al., 2013). Immunoscore is a predictive factor as infiltrating CD8+ 
T lymphocytes are a marker of a pre-existing immunity that can be released from 
immunosuppression by a PD1/PD-L1 blockade. In melanoma patients treated with 
anti-PD1 antibody, recruitment of CD8+ T cells was higher at the invasive tumor 
margin and in the tumor stroma in the pre-treatment samples of responders 
compared to non-responders (Tumeh et al., 2014). 
 A recent report compared EBV positive NPC with EBV negative NPC, and identified 
a distinct microenvironment of EBV positive NPC, characterised by more 
recruitment of T cells, while CD8-psoitive lymphocytes expressing PD-L1 in virus 
positive cases showed improved overall survival and disease free survival (Ooft et 
al., 2017). Hypoxia (hypoxia inducible factor-1α) and anaemia in NPC patients have 
been shown to be associated with up-regulation of PD-L1 on immune cells (Zhou 
et al., 2017a). Tumour associated macrophages are important in tumour 
progression; a study compared the phenotypes of macrophages phenotype in EBV 
positive and negative NPC, and revealed that EBV positive tumours showed more 
infiltration of macrophages stained with pan macrophage marker; CD68 and 
increased FOXP3 T-regs. However macrophages of the M2 phenotype as labelled 
by CD163 and CD206 were more frequent in EBV negative NPC which reflects 
distinct viral induced recruitment of the microenvironment populations (Ooft et al., 
2017). 
1.6.5 MHC class I and II 
In addition to immune checkpoints, loss of MHC class I and II can contribute to 
immune escape. Reduced levels or loss of MHC class I or its accessory proteins is 
common in NPC Thus, beta-2 microglobulin was shown to be decreased or lost in 
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48.64% of NPC samples (Kouvidou et al., 1995), this protein play an important role 
in the assembly of MHC class I, which suggests that with loss of beta-2 
microglobulin, will be associated MHC class I loss. In another reports of NPC, it was 
revealed that 63% of samples have a normal level of expression of MHC class I, 
while this was reduced in 22% of cases and markedly down-regulated in 15% of 
cases (Yao et al., 2000). MHC class I downregulation can be of two different types, 
reversible if it is induced by epigenetic events or genes affecting the regulation of 
MHC class I or irreversible if it is caused by genetic or chromosomal abnormalities 
(Garrido et al., 2017). Reversible type have been suggested to benefit from PD1 
blockade therapy. Genome wide expression profiling of micro-dissected NPC 
tumour cells revealed that downregulation of MHC class I genes was associated 
with expression of EBV genes (Sengupta et al., 2006). Association between 
specific variants of MHC class I and the risk of NPC development have been 
reported in various populations (Li et al., 2009). Although MHC-I expression is 
frequently altered in NPC, reports show that MHC class II is often expressed by 
NPC tumour cells (Busson et al., 1988). MHC class II expression in NPC was 
reported to be high in the tumour cells (Yao et al., 2000). Not all NPC cases express 
MHC class II, however lower levels were observed in 37% of samples analysed; 
some of these cases also had decreased MHC class I expression. Downregulation 
of MHC class I on the surface of tumour cells results in immune escape by avoiding 
being recognized and eliminated by CTLs (Šmahel, 2017). MHC class I gene 
showed common and significant genetic aberrations in Asian background NPC and 
these mutational status in MHC class I were associated with poor outcome (Li et 
al., 2017).  
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MHC class II expression was shown to be up-regulated in Barrett's oesophagus, a 
pre-neoplastic process. In addition gain of MHC class II, but loss of MHC class I was 
observed in the same tumours (Rajendra et al., 2006). MHC class II antigens are 
not normally positive in most epithelial cells but expressed in several pathological 
conditions, such as in inflammation, autoimmune and malignant transformation. 
This gain in MHC class II expression associated with pre-neoplastic changes has 
been described before associated with loss in MHC class I (Rajendra et al., 2006). 
MHC class II was observed to be overexpressed in cervical intraepithelial neoplasia, 
another dysplastic condition (Cromme et al., 1993). CIITA gene have been 
described in the literature to fuse to PD-L1 can result in PD-L1 gene amplification 
and overexpression in lymphomas (Steidl et al., 2011). A recent study showed 
positive association between transcriptional levels of MHC class I locus in malignant 
melanoma patients and their positive response to PD1 inhibitors. Three predictive 
markers (PD-L1, granzyme A (GZMA), and MHC class I) distinguished the 
responders from non-responders to PD1 inhibitors. Tumour cells expressing MHC 
class II expression can be recognized and efficiently rejected by direct cytotoxic 
action of CD4+ T cells in melanoma patients, this anti-tumour immune response 
mediated by CD4 positive cells was shown to be promoted by PD1 blockade (Yan 
et al., 2016). 
MHC class I expressing tumours have good response to PD1 inhibitors, mediated 
through the pro-tumour activity of IFN-γ, expressed by immune cells, specifically 
PD-L1 expressing tumour. However combined tumour immunotherapy targeting 
PD1/PD-L1 axis and IFN-α and IFN-β is still in its early research (Šmahel, 2017). 
Reports revealed that PD1 blockade in HL reached 87%, while subset of HL patients 
were known to have downregulated MHC class I, thus speculating that PD1 
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blockade can be beneficial in HL cases with downregulated MHC-I, which is 
suggested to be independent from the action of cytotoxic CD8 cells (Roemer et al., 
2016). Immune cells other than CD8 cytotoxic cells, for example, macrophages, 
have been proposed to induce cytotoxic anti-tumour effects, (Thoreau et al., 2015). 
This effect can be mediated through polarization of M2 to M1 macrophages, which 
could be cytotoxic even in presence of MHC class I downregulation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 61 
 
1.6 Sphingolipids  
As well as being constitutive parts of the cell membranes of all eukaryotic cells, 
sphingolipids also have signalling functions. It is these functions which I summarise 
below, focussing particularly on sphingosine-1-phosphate (S1P). This bioactive lipid 
has been demonstrated to regulate key cellular processes such as migration, 
proliferation and survival.  
1.7.1 S1P synthesis and degradation  
S1P levels are tightly regulated by enzymes that control its synthesis and removal. 
S1P can be produced by the activity of sphingomyelinase which generates ceramide 
(Zhang et al., 1991, Cuvillier et al., 1996). Ceramide in turn is converted into 
sphingosine by ceramidase. S1P is then produced by the phosphorylation of 
sphingosine mediated by one of two sphingosine kinases (SPHK1 and SPHK2). 
Removal of S1P can occur by two distinct pathways. The first is by the de-
phosphorylation of S1P to sphingosine which is catalysed by one of two S1P 
phosphatases (SGPP1 and SGPP2). In the second pathway, S1P is degraded by 
S1P lyase (SGPL1).  S1P is transported out of cells by several members of the 
adenosine triphosphate (ATP)-binding cassette multi-drug resistant transporter 
family, including ABCC1 and ABCA1 as well by the transporter protein SPNS2 
(Mitra et al., 2006, Sato et al., 2007, Hisano et al., 1999). Extracellular S1P can 
then act upon up to five different G-protein-coupled receptors (GPCRs). This is 
known as “inside-out” signalling (Figure 1.7). 
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Figure 1.7 S1P signalling pathway  
S1P synthesis begins with hydrolysis of sphingomyelin by sphingomyelinase at the 
plasma membrane. This results in production of ceramide, which is metabolized by 
ceramidase to produce sphingosine. Consequently, sphingosine is phosphorylated 
by Sphingosine Kinases 1 and 2 (SPKH1 and 2) and is exported out of the cell by 
either SPNS2 or ATP-binding cassette (ABC) transporters. The balance between 
intracellular concentration of S1P is controlled by its synthesis and degradation: S1P 
can be converted to sphingosine by phosphatases SGPP1/2 or irreversibly 
degraded to hexadecenal and phosphoethanolamine by S1P-lyase. Figure adapted 
from Nema et al (Nema et al., 2016).  
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1.7.2 The sphingolipid rheostat  
 
S1P has been shown to increase the growth and survival of many different cell types 
(Spiegel and Milstien, 2003). By contrast, its precursors, ceramide and 
sphingosine, induce apoptosis and inhibit proliferation (Zhang et al., 1991, Cuvillier 
et al., 1996). This has led to the concept of the sphingolipid rheostat whereby the 
balance between S1P on the one hand, and ceramide and sphingosine, on the 
other, determines cell fate (Cuvillier et al., 1996).  
1.7.3 S1P signalling through its receptors  
 
Five S1P receptors (S1PR) are known to exist: These are referred to as S1PR1 
(EDG1), S1PR2 (EDG5), S1PR3 (EDG3), S1PR4 (EDG6) and S1PR5 (EDG). 
Signalling by S1PR mediates both the paracrine and autocrine effects of S1P 
(Alvarez et al., 2010). The S1P receptors couple to different G proteins (Figure 1.8). 
S1PR1, S1PR2 and S1PR3 are ubiquitously expressed, whereas S1PR4 and 
S1PR5 have restricted expression; immune cells and brain (Brinkmann, 2007, 
Chun et al., 2010). The biological response to S1P is governed by the differential 
expression of these S1P receptors.  
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Figure 1.8 S1P receptors family signalling pathways. There are five cell surface 
S1P receptors (S1PR1-5); each coupling to a different repertoire of G proteins. 
S1PR1 stimulation results in activation of a range of downstream signalling 
pathways including the PI3-K, PLC, PI3-K β pathways. S1PR1 activation leads to 
phosphorylation of AKT with subsequent Rac pathway activation. Activated S1PR1, 
S1PR3, and S1PR5 can inhibit adenylate cyclase (AC) mediated through Gi, on the 
contrary, S1PR4 stimulation results in AC activation as well as Cdc42. S1PR2 and 
S1PR3 inhibits Rac via activation of Rho kinase, that is mediated through binding to 
G12/13. S1PR1, S1PR2, S1PR3, and S1PR4 can activate ERK and PLC pathways 
mediated through binding to Gi. In contrast to other S1PR receptors, S1PR5 inhibits 
ERK activation and activates JNK pathway. Taken from (Sanchez and Hla, 2004). 
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S1PR1  
S1PR1 was discovered in 1990 (Hla and Maciag, 1990) and has been found to be 
expressed on many cell types including endothelial cells (Chun, 2013). In the 
immune system, S1PR1 is expressed on T and B cells, macrophages, dendritic cells 
and NK cells (Goetzl et al., 2004) (Chun, 2013). S1PR1 exclusively couples to Gi 
protein which leads to the activation of ERK and PI3-K/Akt signalling, promoting cell 
survival and proliferation. S1PR1 signalling also leads to the activation of Rac, a 
Rho family small GTPase which drives cell migration.  
S1PR2  
S1PR2 couples to Gi, Gq and G12/13 (Windh et al., 1999, Okamoto et al., 2000, 
Takuwa, 2002). In contrast to S1PR1, signalling through S1PR2 inhibits Rac and 
downstream cell migration (Estrada et al., 2008) (Takuwa et al., 2002). 
Furthermore, S1PR2 mediated Rho activation results in the inhibition of Akt 
signalling, thereby reducing cell survival and inhibiting cell proliferation (Sanchez et 
al., 2005, Schüppel et al., 2008).   
S1PR3  
S1PR3 couples to several different G proteins which results in the activation of 
phospholipase C (PLC) and Ca2+ via Gq and ERK, PI3-K and Rac. The activation 
of these signalling pathways is context dependent but leads mainly to increased cell 
survival, proliferation and migration (Windh et al., 1999, Okamoto et al., 1999).  
S1PR4  
S1PR4 couples with Gi and G12/13 to activate ERK, PLC and Rho as well as Ca2+ 
mobilisation, cytoskeleton rearrangement and cell migration (Ishii et al., 2004). 
S1PR4 expression is largely restricted to lymphoid tissues although its function is 
poorly described.  
S1PR5  
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S1PR5 can couple with Gi and G12/13 and is highly expressed in the brain. It has 
been suggested to have potential functions in the maturation of oligodendrocytes 
(Terai et al., 2003).  
1.7.4 Over-expression of SPHK1 and cancer  
 
The overexpression of SPHK1 transforms NIH3T3 fibroblasts and enhances tumour 
formation in mice (Xia et al., 2000). SPHK1 has been shown to be over-expressed 
in many cancer types. Furthermore, this over-expression has been shown to 
correlate with increased tumour grade and reduced patient survival (Ruckhäberle 
et al., 2008, Pchejetski et al., 2005, Sobue et al., 2008a, Sobue et al., 2008b, 
Vadas et al., 2008).  
SPHK1 has been shown to have important anti-apoptotic effects, for example it can 
protect against death induced by the withdrawal of serum or the addition of TNFα 
(Cuvillier et al., 2010). This is likely to be due to SPHK1 increasing the levels of the 
anti-apoptotic proteins, BCL2 and MCL1, whilst at the same time S1P can also 
increase the expression of pro-apoptotic proteins, BAD BAX (Sauer et al., 2005, Li 
et al., 2008) (Avery et al., 2008). 
The reduced expression of SPHK1 also leads to reduced cell proliferation and can 
trigger apoptosis in cancer cells arising from the prostate, pancreas, brain and 
breast (Akao et al., 2006, Pchejetski et al., 2005) (Guillermet-Guibert et al., 2009, 
Baran et al., 2007, Kapitonov et al., 2009, Taha et al., 2006).  
SPHK1 is also implicated in the development of resistance to cancer therapies 
(Pchejetski et al., 2005, Baran et al., 2007). This is in part because it is well 
established that many cancer treatments (as renal cell carcinoma) which rely on the 
generation of ceramide (Ogretmen and Hannun, 2001). For example, in a mouse 
model of prostate cancer, tumours overexpressing SPHK1 were larger and more 
 67 
 
resistant to docetaxel and this was associated with reduced ceramide production 
(Pchejetski et al., 2005). 
1.7.5 Induction of aberrant cell signalling by S1P in cancer cells 
 
Aberrant expression of S1P in B cell lymphomas 
One report has shown that SPHK1 is over-expressed in NHL, and was associated 
with higher clinical grade in 44 tumour samples (Bayerl et al., 2008). 
Another study has shown that p53 knockout mice developed thymic lymphoma, 
associated with increased levels of SPHK1/S1P while ceramide was decreased. 
Notably, loss of the SPHK1 gene in this model completely abolished the 
development of thymic lymphomas and improved the survival rates by 30% 
(Heffernan-Stroud et al., 2012). A number of lines of evidence suggest that 
aberrant S1P signalling could contribute to the pathogenesis of B cell lymphomas. 
For example, SPHK1 is over-expressed in NHL and its inhibition can prevent 
ceramide catabolism and potentiate cell death in a mantle cell lymphoma line (Webb 
et al., 2015). S1PR1 is also over-expressed in HL and promotes migration the 
migration of HL cell lines in vitro (Kluk et al., 2013). Conversely, S1PR2 is an 
inhibitory receptor, is mutated in patients with DLBCL. 
S1P is a crucial element for the constitutive activation of STAT3 in tumour cells. For 
example, in one study it was shown that STAT3 could induce the expression of 
S1PR1 which was elevated in STAT3 positive tumours. In turn the increased S1PR1 
expression further activated STAT3 and upregulated IL6 (Lee et al., 2010). In the 
ABC form of DLBCL, STAT3 is highly active and is regulated by S1PR1 (Liu et al., 
2012). 
There is a positive feedback loop between S1PR1 and STAT3, highlighting a crucial 
role for S1P in the constitutive activation of S1P in tumour cells.  Furthermore, in 
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ABC subtype DLBCL, STAT3 has been found to be highly active and this is due, at 
least in part, to S1PR1 (Liu et al., 2012). 
Aberrant expression of S1P in EBV associated malignancy-NPC 
S1P signalling is implicated in the pathogenesis of NPC. EBV infection, or 
ectopically expressed EBV-encoded latent genes (EBNA1, LMP-1, and LMP2-A) 
resulted in increased expression of SPKH1. Stimulation of the NPC cell lines by 
exogenous S1P enhanced the migratory activity of the tumour cells and was 
mediated through activation of AKT. This migratory activity was inhibited by 
knockdown of one of the S1P receptors; S1PR3, which was associated with 
decreased levels of AKT. This feature was clarified by using LY294002; a PI3-K 
inhibitor which resulted in reduced migration of tumour cells in the presence of S1P. 
Moreover, S1PR3 receptor was the only S1P receptor which showed differential 
expression in micro-dissected NPC versus normal nasopharyngeal epithelium (Lee 
et al., 2017a). 
1.7.6 Contribution of SPHK1-S1P signalling to altered cell migration in 
cancer 
 
The differential expression of S1PR1 and S1PR2 is important for regulating 
migratory responses. S1PR2, which usually inhibits cell migration and is highly 
expressed by GC B cells where it plays a critical role in GC B cell positioning and 
confinement of B cells to the GC; in S1PR2-deficient mice this is disrupted leading 
to large poorly defined GC (Cattoretti et al., 2009, Green and Cyster, 2012). In 
contrast, lymphocyte egress is regulated by S1PR1 (Cyster, 2005). This is well 
demonstrated by the use of FTY720, a functional S1PR1 antagonist which leads to 
lymphopenia in several animal models and in humans, as a result of lymphocyte 
egress (Chiba et al., 1998, Yagi et al., 2000, Mandala et al., 2002). 
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Changes in S1P receptor expression or function could also contribute to cancer 
development. For example, the S1PR2 –deficient mice described above are prone 
to develop tumours that resemble DLBCL (Cattoretti et al., 2009). Furthermore, 
S1PR2 is mutated in around one quarter of patients with DLBCL (Cattoretti et al., 
2009).  
1.7.7 Therapeutic targeting of S1P or its receptors 
There are a variety of therapies against S1P or its receptors that might eventually 
find application in cancer patients. Below I briefly summarise some of these.  
The anti-S1P monoclonal antibody, Sphingomab, sequesters S1P thus preventing 
its interaction with S1PR (O'Brien et al., 2009). Sphingomab has been shown to 
reduce tumour progression in murine xenograft models mainly through inhibition of 
angiogenesis (Visentin et al., 2006). The humanised form of Sphingomab, known 
as Sonepcizumab has been used in a Phase I clinical trial in cancer patients 
(ClinicalTrials.gov Identifier: NCT00661414).  
S1P receptor antagonists include FTY720 (fingolimod) an analogue of sphingosine 
(Sanchez et al., 2003). FTY720 once phosphorylated inside cells binds to S1PR1, 
3, 4 and 5. FTY720 results in the internalisation and degradation of S1PR1 
(Matloubian et al., 2004).  
SPHK1 inhibitors act not only to reduce S1P production but also to increase 
ceramide and sphingosine levels. They include delipidated human serum (DHS) and 
N,N-Dimethylsphingosine (DMS) both of which can reduce the growth of gastric and 
lung cancers in mice (Endo et al., 1991, Okoshi et al., 1991). Non-lipid SPHK1 
inhibitors (compounds SPHK1 I-V) are non-competitive inhibitors of the Adenosine 
triphosphate (ATP) binding site and are effective at nanomolar potencies (French et 
al., 2003).  
 70 
 
*Note: Some text within this chapter is taken from our recent book chapter in the series: 
(Hudnall and Küppers, 2018) 
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1.8 Aims of the Study 
The overarching aim of this study was to explore different components of the 
pathogenesis of three EBV-related cancers  
General Aims:  
Aim 1) to explore the immune microenvironment of NPC and the potential for tumour 
cells to be recognized by T cells. 
Aim 2) to investigate expression of collagen and collagen receptors in DLBCL 
Aim 3) to define the role of aberrant sphingosine-1-phosphate signalling in HL 
Specific Aims 
Aims of Chapter 3 
1) To confirm PD-L1 is overexpressed in NPC 
2) To study potential relationship of PD-L1 and LMP-1 expression in NPC  
3) To explore immune checkpoint co-expression in NPC, and their potential 
relationship with LMP-1 expression 
4) To investigate the different patterns of PD-L1 expression (marginal or 
diffuse) which may reflect the underlying molecular mechanism (Inducible 
or constitutive) of PD-L1 expression in NPC 
5) To investigate the frequency and distribution of TILS (CD3) positive cells 
in relation to PD-L1 and PD1 in NPC 
6) To explore the subcellular patterns of PD-L1 protein expression in NPC 
7) To explore the prevalence of PD-L1 expression in tumour cells versus 
immune cells in NPC 
8) To investigate correlation of PD-L1 and PD1 expression in the tumour and 
the microenvironment in NPC 
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9) To study the frequency and the spatial distribution of lymphocyte immune 
infiltrate using lymphocyte subpopulation panel in NPC  
10) To study immune visibility by evaluating MHC class I and II in NPC by IHC 
assay 
Aims of Chapter 4 
1) To explore the expression of collagens and collagen receptors in GC B cells and 
DLBCL, through the re-analysis of published datasets 
2) To investigate the expression of LAIR-1 and DDR-1 collagen ligands in GC B 
cells and DLBCL using immunohistochemistry 
3) To identify cells in the microenvironment expressing LAIR-1 in DLBCL  
4) To investigate in vitro the effect of collagen ligation on LAIR-1 expression in 
macrophages 
Aims of Chapter 5 
1) To study the expression of S1P receptors focusing mainly on S1PR1 and S1PR2 
in normal lymphoid tissue and HL 
2) To study the effect of S1P and its receptors on the P13-K pathway using P-AKT 
signalling as a read out in HL cell lines 
3) To identify the transcriptional targets of P13-K signalling pathway in HL and study 
expression of BATF3 in normal lymphoid tissue and HL  
4) To investigate the co-expression of BATF3 and S1PR1 in normal lymphoid tissue 
and HL 
5) To study the effect of BATF3 on S1PR1 expression in HL cell lines 
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CHAPTER TWO 
MATERIALS AND METHODS 
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2.1 Tissue samples  
2.1.1 Nasopharyngeal carcinoma 
 
19 samples were used for MHC class I and MHC class II immunohistochemistry 
panels, 17 of these cases were available for the Immune checkpoint and T cell 
subpopulation panels. NPC samples were from UK and provided by Dr Graham 
Taylor (University of Birmingham, Institute of cancer and genomics). The samples 
were primary tumour and confirmed to be EBV positive. Clinical and pathological 
details in Appendix 1. 
2.1.2 DLBCL samples 
2.1.2.1 Construction of tissue microarray of DLBCL 
 
I selected tumour rich areas using 28 samples H&E sections retrieved from the 
pathology department, at Queen Elizabeth Hospital, Birmingham (QEHB) based on 
a cohort of 305 DLBCL patients with full clinical annotation, diagnosed between 
1996 and 2008. I used the DLBCL tissue microarray (TMA) to examine the 
expression of C1q, S1PR1, BATF3 and S1PR2. Cores for the TMA were selected 
from viable tumour areas in triplicate from different areas. Areas displaying adipose 
tissue infiltration at the periphery of the lymph node, necrotic or haemorrhagic areas 
were excluded. Another set of TMA was selected from areas with macrophages or 
‘starry-sky’ pattern. TMA recipient blocks were constructed based on pathological 
assessment in collaboration with Dr Vikki Rand, Northern Institute for Cancer 
Research, Newcastle University. Controls were used within every set of TMA, as 
tonsil, large bowel, and renal cortex.  Clinical details of these samples are shown in 
Table 2.1 
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          Table 2.1 Clinical details of DLBCL samples 
 
Factor Numbers 
Gender M=22 
F=6 
Immunophenotype GCB=10 
ABC=18 
BCL2 Negative=5 
Positive=7 
Strong positive=3 
Not available=3 
Stage 1=6 
2=7 
3=6 
4=9 
Lactate dehydrogenase (LDH) Normal=8 
>450=12 
>1000=5 
>5000=3 
Revised International Prognostic 
Index (R-IPI) 
1=3 
2=14 
3=11 
B symptoms No=13 
Yes=15 
Overall survival (OS) Alive=14 
Deceased=14 
  
*IHC classification was done by IHC using Hans' algorithm (Hans et al., 
2004). 
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2.1.3 HL samples 
A TMA composed of 43 samples were provided by Dr. Elizabeth Soilleux, John 
Radcliffe Hospital, Oxford, UK. All samples had been reviewed in Oxford and 
confirmed as primary HL with classification into histological subtypes.  
2.2 Immunohistochemistry (IHC)  
2.2.1 Positive and negative controls 
 
As controls for all staining, FFPE tonsil blocks were obtained from QEHB, and fresh 
paediatric tonsils were obtained from Birmingham Children’s Hospital under local 
ethics committee approval (Ref No.06/Q2702/50). Part of these were fixed in 10% 
v/v formaldehyde (Sigma-Aldrich Ltd., Gillingham) and sectioned by the 
Histopathology Department at the Royal Orthopaedic Hospital, Birmingham (ROH).  
The remainder were processed in our lab for other experiments.  
2.2.2 Sectioning of tissues 
 
Before sectioning, FFPE blocks were chilled for approximately 20 minutes on ice. 
FFPE blocks were cut to 4µm in thickness. Sections were floated in a heated water 
bath at 40°C. Sections were then immediately positioned onto positively charged 
adhesive-coated slides (Vectabonded, Surgipath™). This was performed in our lab, 
by HBRC at the University of Birmingham, or by the histopathology department at 
the ROH. Slides were kept at 4°C for long term storage.  
2.2.3 Haematoxylin and eosin (H&E) protocol 
For staining, de-paraffinisation of the section was performed by placing in histoclear 
for 10 min, followed by hydration through decreasing concentrations of ethanol 
baths (100%, 90%, and 70%) and then washes with water for 2 min. Sections were 
stained in haematoxylin for 5 minutes, followed by a wash in running tap water for 2 
minutes in hot water then for 2 minutes in cold water. This was followed by staining 
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in Eosin Y for 30 seconds. Dehydration in increasing concentration of ethanol for 3 
minutes was followed by 100 % ethanol for 3 minutes. Histoclear washes, then 
followed by mounting in DPX media (Table 2.2) 
2.3 Optimisation of antibodies  
Each new antibody was tested on tissue that was identified to express that antigen 
according to the Human Protein Atlas (available online at: www.proteinatlas.org). 
The dilution provided by the company was used only as an indication of dilution 
range. The optimum concentration of each antibody was determined by testing 
different antibody dilutions on control tissue using positive and negative control 
sections. Antibodies previously validated by members of our group using HEK293 
cell lines (University of Birmingham) included: S1PR2, S1PR1, LAIR-1 and DDR-1. 
Other antibodies were validated by Dr Vrzalikova using knockdown experiments by 
western blots or immunofluorescence staining; these antibodies included those 
against BATF3.  
 2.4 IHC  
For IHC, sections of paraffin-embedded tissue biopsies were initially de-waxed 
using histoclear solutions (National Diagnostics), for 10 minutes. Rehydration was 
performed by immersing the slides in IMS for 2x5 minutes, followed by washing 
under running tap water for 5 minutes. Blocking was done with 0.3% hydrogen 
peroxide (Sigma-Aldrich Ltd., Gillingham) for 15 minutes to inactivate any 
endogenous peroxidase, followed by a further wash under running tap water for 5 
minutes. Different methods of antigen retrieval were optimised to individual 
antibodies. 
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2.4.1 Citrate Antigen Retrieval  
Citrate-Antigen retrieval method was used to expose antigens. To prepare antigen 
retrieval buffer, 1.26g of sodium citrate (VWR) and 0.25g citric acid (VWR) were 
added to 1 litre of distilled water, and the pH adjusted to between 5.9-6.1 using 0.1M 
sodium hydroxide. The citrate buffer was heated in a microwave at full power for 10 
min. The slides were immersed into the buffer and heated at medium and low power 
for 10 minutes each. Slides were then cooled for 15 minutes at 4°C then washed in 
running tap water for 5 minutes. Prior to staining, a hydrophobic barrier was drawn 
around tissue sections using a Pap pen (Sigma-Aldrich) and conditioned with Tris-
buffered saline with 0.1% Tween-20 (TBS-T) for 10 minutes. Tissue sections were 
blocked with 5X casein (Vector Labs) diluted in distilled water for 10 minutes to 
prevent non-specific background staining. The primary antibodies were added to the 
tissue and incubated at room temperature for 1 hour or 18 hours at 4°C as required 
(Tables 2.2 and Table 2.3). The slides were washed with PBST to remove the 
primary antibody. Anti-rabbit/anti-mouse secondary universal antibody (Vector 
Labs) was added to the tissue, and incubated for 30 minutes at room temperature. 
Slides were washed with PBST 3x 5 minutes each. Diaminobenzidine (DAB) (about 
100 µl per section) was added and slides incubated for 5 minutes, followed by 
rinsing in tap water for 5 minutes. The slides were counterstained by immersing in 
Mayer’s haematoxylin (Sigma-Aldrich Ltd), for 5 minutes, rinsed under running water 
and then sequentially dehydrated through 70% ethanol (Sigma-Aldrich Ltd., 
Gillingham), 100% ethanol and histoclear for 10 minutes each, before being 
mounted with a coverslip using a drop of Omnimount mounting media (National 
Diagnostics). A bright field microscope was used to visualise the slides. 
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Agitated low temperature epitope retrieval (ALTER)  
Slides were loaded in a rack and placed in a 1.5 litre glass beaker containing 100 
mls of EDTA buffer Tween-20 pH8 and 900 ml distilled water. The beaker was 
covered with foil and placed on a hotplate stirrer (Jenway) 600 rpm at 65°C for 18 
hours. The solution was then cooled by placing the beaker under running water for 
5 minutes, followed by blocking and antibody incubation as described above. 
2.4.2 Cytospins preparation for IHC/IF 
 
Cultured cells were washed in serum-free Roswell Park Memorial Institute medium 
RPMI-1640 and re-suspended at a concentration of 2x106 cells/ml in serum-free 
RPMI-1640 with 10% v/v formaldehyde (Sigma-Aldrich Ltd.).  Cells were placed on 
X-tra positive charged Adhesive glass slides (Surgipath Europe) using the Cytospin 
cytocentrifuge (Shandon, Runcorn, Cytofunnel® disposable sample chambers, and 
filter cards and Cytoclips™ (ThermoFisher). 100µl of cultured cells (i.e. 2x105 cells) 
were added to each sample chamber and centrifuged at 1000 rpm for 5 minutes. 
Cytospins were fixed in 10% neutral buffered formalin for 10 minutes, then rinsed in 
water, then left to air dry for 30 minutes and stored at -20°C. Before staining, slides 
were thawed and the endogenous peroxidase activity was blocked by immersing 
the slides for 10 minutes in 0.3% hydrogen peroxide (Sigma-Aldrich), following 
which slides were rinsed in running tap water, then subjected to  IHC or IF. Cytospins 
from HL cell lines (L591, L428, L1236 and KMH2) were used in experiments 
performed in Chapter 5. 
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2.5 A20 syngeneic xenograft mouse model of DLBCL 
A20 tumour cells were injected at 3 x 106 cells/mouse intravenously and 
subcutaneously into 6-9 week old female BALB/c mice (Charles River) (this 
experiment was performed  by Tracey Perry, University of Birmingham) 
(Home office ethical approval, project no. PPL70_8280). At day 28, mice 
were killed by cervical dislocation and the lymphomas from spleen and 
subcutaneous tissue were collected in RPMI-1640, and were analysed by 
flow cytometry (performed by Tracey Perry, University of Birmingham). A 
portion of the tumour was preserved for FACS and the rest for embedding in 
paraffin after fixing in 10% neutral buffered formalin (Surgipath, Leica 
Microsystems, Milton Keynes). After a minimum of 24 hours, the tissues were 
embedded in paraffin wax. Paraffin sectioning and H&E staining were 
performed by the services at the ROH. 
2.6 Immunofluorescence (IF) 
2.6.1 Detection of antigen by singleplex/multiplex immunofluorescence (IF) 
using Opal staining method 
 
Opal™ immunostaining, enables multi-labelling in-situ in formalin-fixed, paraffin-
embedded (FFPE) tissue or cells using fluorescent dyes and primary antibodies 
raised in different species. The initial simple multi-labelling method using the 
tyramide signal amplification (TSA) as was described before (Toth and Mezey, 
2007).The newer Opal method uses labelling by fluorophores that bind in a covalent 
bond to the antigen. After labelling with the dye, removal of the marker by heating 
process will not affect the TSA signal. This facilitates next sequential binding of 
second or third antibody to be visualized and labelled and avoiding the issue of the 
overlapping (PerkinElmer Assay development guide booklet). The Opal kit by 
PerkinElmer was used according to manufacturer’s protocol. 
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Opal Staining Protocol 
Sections were immersed in Xylene 3x10 min, and re-hydrated by immersing the 
slides in 100%, 95% and 70% ethanol for 10 minutes each, followed by a 2 minute 
wash in distilled water and 5 minute wash with TBST wash. Incubation in 0.3% 
hydrogen peroxide as above for 15 minutes was done, and then slides washed 
again in distilled water for 5 minutes. Antigen retrieval was done using Citrate buffer 
as described above (Section 2.4), then washed with distilled water and 
reconditioned by TBST. For blocking, antibody diluent background reducing reagent 
(S3022, Dako) was used. The antibody was incubated overnight for 18 hours at 4°C 
or 1 hour at room temperature (Table 2.2 and Table 2.3). To optimise primary 
antibody as recommended by PerkinElmer Opal protocol (Figure 2.1 provided from 
PerkinElmer guide booklet), staining was performed initially using conventional IHC 
at several dilutions: the same dilution as used for IHC and the antibody was diluted 
3 times and 5 times the dilution used in standard IHC, because this IF technique is 
considered to be more sensitive. After primary antibody incubation, slides were 
washed in TBST. Anti-rabbit/anti-mouse secondary universal antibody was applied 
to the sections for 30 minutes. Slides were rinsed with TBST 3x 5 minutes each.  
Signal amplification was carried out with various dyes from the Opal™ Fluorophore 
kit. Opal dyes were optimally diluted in amplification diluent (FP1135), (range 
dilution 1:50-1:200) and incubated on slides for 10 minutes. A second round of 
microwave treatment (MWT in Figure 2.1) with citrate buffer (pH 6) solution was 
performed for 15 minutes on low heat setting to strip the antigen-antibody complex.  
This allows for multiplexing of different targets on the same section. A second run 
of antibody incubations was performed as above starting from the blocking step after 
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MWT (step 4 in figure 2.1), using different fluorophores for different targets. Stripping 
was optimised by checking for co-localization of antibodies in the same section, 
where antibody was omitted. If cross-reactivity was visualized then stripping time 
was increased (30 minutes of heating in citrate buffer). Another method of avoiding 
the cross reactivity was changing in the order in which antibodies were applied. 
DAPI (ThermoFisher) at dilution of (1:1000) was added to sections and incubated 
for 5 minutes, followed by a wash in TBST for 5 minutes and slides mounted using 
Vectashield mounting media (H-1400, Vector laboratories). Cells were visualized 
using a Nikon E600 UV microscope. To account for autofluorescence, an unstained 
slide was used from the same tissue-type, prepared using the steps above but no 
antibody/ fluorophore was applied. 
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Figure 2.1 Multiplex IF protocol (Chart provided taken from PerkinElmer Assay 
development guide booklet). 
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   Table 2.2. Reagents and kits used in IHC 
 
Kit/Reagent Vendor 
Catalogue 
number 
Conditions 
Diaminobenzidine (DAB)  Vector 
laboratories  
SK-4105 1:1000 substrate 
for 5 min 
P-xylene-bis-pyridinium 
bromide (DPX) 
Invitrogen X1525 
 
Ready to use 
Casein Vector 
laboratories 
SP-5020 Diluted in 5x 
Distilled water 
Mayer’s hematoxylin  Sigma MHS128-4L 5 min  
PAP-PEN  Agilent 
Technologies 
S200230-2 
 
Ready to use 
Rb anti-Sheep IgG 
(H+L) Secondary antibod
y 
ThermoFisher 31480 1:100 for 30 
minutes 
RAT  secondary antibody Agilent 
Technologies 
P0450 1:200 TBS for 10 
min 
Sodium citrate tribasic 
dihydrate ACS reagent 
Sigma S4641-1KG 
 
Section 2.4 
DAB Agilent 
Technologies 
K346711 Apply for 5 minutes 
HRP secondary antibody Vector 
laboratories 
labs 
ImmPRESS
™ 
Universal 
Antibody Kit 
Anti-
Rabbit/Mou
se Ig (MP-
7500) 
Ready to use 
Ethylenediaminetetraacet
ic acid  (EDTA)  
REF 1C100X (Binding 
Site., 
Birmingham
, UK) 
Section 2.4 
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Tables 2.3 Markers used in IHC and IF 
 
Target 
protein 
Vendor 
Antibody 
Clone 
Dilution 
IHC 
Dilution 
IF 
Lymphoid markers 
CD4 Leica 4B12 N/A 
 
Automated Bond RX 
by (Chris Bagnall) 
CD8 Leica 4B11 N/A 
 
Automated Bond RX 
by (Chris Bagnall) 
FOXP3 Abcam Ab20034 N/A 
 
Automated Bond RX 
by (Chris Bagnall) 
CD3 Agilent 
Technologies 
IR503 ready to 
use 
(tissue) 
ready to use (tissue) 
CD3 Leica NCL-L-
CD3-565 
N/A 
(tissue) 
Performed by Dr Alex  
Dowell 
CD20 Agilent 
Technologies 
IR604 ready to 
use 
(tissue) 
ready to use (tissue) 
CD20 Leica L26 N/A Automated Bond RX 
by (Chris Bagnall) 
CD30 Agilent 
Technologies 
Ber-H2 ready to 
use (tissue) 
ready to use (tissue) 
BCL6 
(PG-
B6p) 
Agilent 
Technologies 
GA625 ready to 
use (tissue) 
ready to use (tissue) 
     
 
 
EBV related markers 
LMP-1 Gift of Professor 
Martin Rowe  
CS-1-4;  NA 1:100 (tissue) 
1:80 (cytospins) 
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                                               Collagen markers 
Collagen 4 Abcam M0785 (Clone 
CIV 22) 
N/A 1:200 
Collagen 3 Abcam ab7778 1:100  (tis
sue) 
1:600 (tissue) 
Collagen 6 LSBio LS-B696 1:200 
(tissue) 
1:600  (tissue) 
Collagen 1 Abcam ab34710 1:400 
(tissue) 
N/A 
Collagen 4 Abcam ab21294 
(M0785 Clone 
CIV 22) 
1:200  
(tissue) 
1:400 (tissue) 
 
Collagen receptors markers 
DDR-1 Cell Signaling D1G6) XP® 1:80  
(tissue) 
1:250 (tissue) 
LAIR-1 Sigma HPA011155 1:200 
(tissue) 
1:600  (tissue) 
1:400 (Cytospins) 
LAIR-2 Abcam ab183145, 
rabbit 
1:50 
(tissue) 
1:100 (tissue) 
C1Q Agilent 
Technologies 
F0254 N/A 1: 80 (tissue) 
 
 
Neo-vascularization markers 
 
CD31 Agilent 
Technologies 
IR610 1:50 
(tissue) 
1:100 (tissue) 
 
 
Immune checkpoint markers 
PD-L1 
 
 
Cell Signaling 
technology 
(E1L3N) XP 
Rabbit 
monoclonal 
antibody 
N/A 1:800 (tissue) 
(Performed by Dr 
Alex  Dowell) 
PD1 
 
Abcam N/AT105 
 
N/A 1:200 (tissue) 
(Performed by Dr 
Alex  Dowell) 
 
 
 
Macrophages/monocytes markers 
CD163 Leica NovocastraTM 
Lyophilized 
1:100 
(tissue) 
1:600 (tissue) 
MRC-1 Sigma AMAB90746 1:200 
(tissue) 
1:600 (tissue) 
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CD68 
(PG-M1) 
Agilent 
Technologies 
GA613 1:200 
(tissue) 
1:1200 (tissue) 
 
 
 
Dendritic cell (DC) markers 
CD123 
(BR4MS) 
Leica NCL-L-CD123 1:80 
(tissue) 
1:200 (tissue) 
CD23 
(DAK-
CD23) 
Agilent 
Technologies 
GA781 1:200 
(tissue) 
1:400 (tissue) 
 
 
 
Lipid related antibodies markers 
S1PR1 
(H-60) 
Santa Cruz SC-25489 1:500 
(tissue) 
1:1200 (tissue) 
1:600 (cytospins) 
S1PR2 
 
Sigma HPA014307 1:200 
(tissue) 
1:200 (tissue) 
1:80 (cytospins) 
 
 
Tag antibodies 
HA tag 
(Y-11) 
Santa Cruz sc-805 N/A 1:100 (cytospins) 
V5 tag 
(SV5-
Pk1) 
Abcam SV5-Pk1 
ab27671 
N/A 1:200 (cytospins) 
 
 
 
Miscellaneous 
C-MYC 
(Y69) 
Abcam ab23072 1:1000 
(tissue) 
1:2800 
(cytospins) 
Phospho-Akt 
(Ser473) 
Cell Signaling 9271 N/A 1:100 
(cytospins) 
MHC class I 
(Anti-HLA 
Class 1 ABC) 
[EMR8-5] 
Abcam ab70328 Automated 
Bond RX by 
(Chris 
Bagnall) 
NA 
MHC class II 
(Anti-HLA 
DR + DP + 
DQ) 
[CR3/43] 
Abcam ab17101 Automated 
Bond RX by 
(Chris 
Bagnall) 
NA 
Ki-67 Abcam ab6526 ready to 
use (tissue) 
ready to use 
(tissue) 
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BATF3 
 
R&D systems AF7437 1:1200 
(tissue) 
1:400 
(cytospins) 
1:2200 (tissue) 
1:800 
(cytospins) 
 
Table 2.4 Reagents and kits used in multi-labelling IF 
 
Kit/Reagent Vendor Catalogue number Conditions 
OPAL 7-color Kit 
 
PerkinElmer 
 
NEL797001KT Section 2.6 
Opal™ 3-Plex Kit PerkinElmer 
 
NEL791001KT Section 2.6 
Antibody Diluent, 
Background 
Reducing 
Agilent 
Technologies 
S3022 ready to use 
applied for 10 
minutes 
VECTASHIELD 
hardSet Mounting 
Medium 
Vector 
laboratories labs 
H-1400 
 
ready to use 
Antigen Retrieval 
Citra Plus Solution 
Biogenex HK081-20K 
 
10x, ready to 
use 
Anti-rabbit IgG 
(goat)HRP 
Secondary antibody 
 
PerkinElmer NEF812001EA 
 
1:200 in PBS 
10 min 
Anti-mouse IgG 
(Goat) HRP 
Secondary antibody 
PerkinElmer NEF822001EA 
 
1:200 in PBS 
10 min 
DAPI ThermoFisher D21490 1:1000 in 
PBS 10 min 
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2.6.2 Automated IHC and multiplex staining 
 
Automated IHC staining for MHC class I and II and multiplex labelling using the 
lymphocyte population panel was performed by Chris Bagnall, optimized in 
collaboration with Perkin Elmer using Leica Bond RX. IHC slides scanning was 
performed by Chris Bagnall at HBRC, University of Birmingham. Antibodies details 
used in those 2 panels are shown in Table 2.3. 
2.6.3 Digital semi-automated quantitative scoring using Vectra scanner and 
Inform software 
 
The multiplex immunofluorescence labelling was performed for the following 
reasons:  
1. Simultaneous detection of multiple tissue biomarkers; confirm single cell co-
expression for several biomarkers in one tissue section e.g. characterization of 
the functional status of immune cells e.g.exhausted dysfunctional T cells, 
expressing PD-1/PD-L1 (PD1-CD3/PD-L1-CD3 double positive cells) 
2. Retain spatial cellular distribution, that can’t be visualized by other multilabelling 
techniques such as flow cytometry. For example, identification of tumour cells 
versus microenvironment. 
3. To obtain results for more markers when tissue is precious, and not enough 
sections remaining.  
4. Allow quantitative analysis of protein levels in cell lines and tissues for defined 
phenotypes as well as cellular location (e.g nuclei, cytoplasm or membrane)  
Recent studies have shown it is possible to multilabel up to 12 biomarkers in 
lymphoid and myeloid panels, which allowed visualization of 14 different immune 
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cell populations in-situ in a formalin-fixed paraffin-embedded tissue section. This 
enabled immunological classification of patients who responded according to high 
and low myeloid densities of immune cells, which enabled prediction of the response 
to neoadjuvant GVAX A GM-CSF tumour vaccine therapy used in pancreatic ductal 
adenocarcinoma. The immunosuppressive cluster was associated with inferior 
survival (Tsujikawa et al., 2017). 
2.6.3.1 Vectra Slide Scanning System  
The Vectra imaging system provided by PerkinElmer is designed for scanning of 
tissues labelled with immunofluorescent markers. It is able to distinguish different 
fluorophores without overlap and discounts autoflourescence, facilitating the 
accurate quantification of each marker signal. Separation of all of the fluorescence 
signals within the sample is essential for quantitative measurement (PerkinElmer 
Assay development guide booklet). Vectra system version 3.0.3 software, provided 
by PerkinElmer in the HBRC, University of Birmingham was used for multispectral 
imaging. The scanning protocol was created as recommended by PerkinElmer using 
all filters available on the Olympus microscope.  The multispectral camera is able to 
capture wavelengths between 420—720 nm, therefore the following fluorophores 
were used for staining: Cyanine 3, Cyanine 3.5, Cyanine 5, Cyanine 5.5, Flourescin, 
Texas red, Opal 520, Opal 540, Opal 570, Opal 620, Opal 650, Opal 670, Opal 690 
and DAPI. Antibodies were optimized with recommended exposure time set 
between 100-150 milliseconds. The images were taken using an Olympus BX-51WI 
microscope using 10X, 20X and 40X magnifications which captured the 
multispectral images for further analysis using Inform image analysis software 
(PerkinElmer). Following whole slide scan, phenochart 1.0.4 (PerkinElmer) was 
used (Figure 2.1) for manual selection of representative areas of interest of the 
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tumour or tumour stroma or overlying epithelium. For tissue sections, at least 4 HPF 
(20x) and for cytospins, 3 HPF (20X) were used for quantification. Scanning of these 
fields using the high power protocol was applied on selected areas.  Areas of 
crushing, necrosis, and haemorrhage were avoided.  
2.6.3.2 Analysis by Inform software  
Inform Tissue Finder (Version 2.2.0, PerkinElmer) is software that allows the 
analysis of multi-labelled image within different or same cellular compartment per 
single cell with a resultant intensity of the marker in every cellular compartment. The 
software is semi-automated, whereby it needs repeated steps of training and 
algorithm development, which allows easy usage of the same protocol on different 
tissue sections for phenotyping. The algorithm constitutes steps of training for 
different tissue regions such as tumour, stroma or vessels.  This will give results of 
counts per phenotype in every anatomical location after tissue segmentation is 
performed. In addition, it allows spatial distribution for every phenotype to be 
provided. Moreover, the software is user-friendly for a pathologist to assess, who is 
used to bright-field evaluation, so the fluorescent image can be converted into 
pseudo-haematoxylin and brown staining mimicking DAB (Perkin Elmer assay 
development booklet guide). Multispectral images were acquired using Inform 
software which allowed spectral un-mixing of the image by selecting the specific 
fluorophores. 
Training included creation of a new project and a new algorithm using a spectral 
library, selecting the reference controls for every fluorophore and use of 
autofluorescence slides for every tissue or cell line. The tissue segmentation step 
was used to classify different tissue regions within sections (e.g stroma, tumour and 
background). This segmentation was performed by the manual drawing tool which 
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is available in the software and which uses different coloured annotations to 
differentiate the tumour, the stroma and background (non-cellular areas/empty 
areas). Cell segmentation was done by adjusting cytoplasmic, membranous and 
nuclear compartment sizes. Following segmentation, cell phenotyping was done 
(Figure 2.2 and Figure 2.3). It is hard or sometimes impossible to differentiate 
overlapping markers in multispectral images. The available options of spectral un-
mixing and assessment of every marker singly or coupled with any other marker 
stained, facilitated evaluation of the multiple stained proteins localized within the 
same cells. Positivity of markers were based on visual assessment of the author to 
the intensity scores. An illustration of a sample multi-labelled with PD-L1 (green), 
CD3 (red) and DAPI is shown Figure 2.4.  
Training was performed on every batch using a maximum 8-9 total multispectral 
images, because variability in tumour areas within different tumours confused the 
software, and made training more difficult.  After visual based morphological serial 
tissue classification, the software could easily differentiate tumour cells from stroma 
cells in NPC. In lymphoid malignancies (DLBCL), markers like CD20 were helpful in 
differentiating tumour cells from stromal cells/mature lymphocytes, DAPI was used 
to identify tumour cells as large nuclei, while stromal cells were either spindle or 
rounded if lymphocytes. 
2.6.3.3 Exporting the data 
 Data output of the software included a separate file, for every field, with per-cell and 
per-cellular-compartment mean intensity and total intensity values for the entire cell 
and separately for the cytoplasm, membrane and nucleus. Tissue segmentation, 
cell segmentation, and phenotyping map were also included in the exported data.  
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Figure 2.2 Multi-labelling using OPAL, Vectra system and Inform software (Chart 
provided in PerkinElmer Assay development guide booklet). 
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Figure 2.3 Steps of scanning using Vectra and image analysis using Inform software in an Opal stained section of tonsil 
(LAIR-1; green).
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Figure 2.4 Steps of training for tissue/cell segmentation and scoring using tissue, cell segmentation and cell phenotyping 
A) Tumour stained with PD-L1 (green) and CD3 (red), B) Tissue segmentation map with tumour (red) and stroma (green), C) Cell segmentation 
map with nuclear segmentation (green) and cellular segmentation (coloured), D) Phenotyping map, where PD-L1 positive phenotype is 
represented by green dots, negative cells were labelled as blue, yellow as double positive for PD-L1 and CD3, pink is CD3 single phenotype, 
(T) indicates tumour and (S) indicates stroma, 20X magnification. 
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2.6.3.4 Examples of cell phenotyping using Inform 
BATF3-S1PR1-CD30 phenotyping in HL using Inform:  
I classified tumours that were triple stained with BATF3-S1PR1-CD30.  
The following phenotypes were measured: 
1) S1PR1 single positive cells S1PR1 staining was identified in tumour cells, 
blood vessels and reactive lymphocytes.  
2) BATF3 single positive cells 
3) CD30 single positive cells.  
4) S1PR1+ve-CD30+ve cells (but negative for BATF3).  
5) BATF3+ve CD30+ve cells (but negative for S1PR1).  
6) BATF3+ve-S1PR1+ve-CD30+ve cells. 
7)  BATF3-ve-S1PR1-ve-CD30-ve cells.  
.BATF3-S1PR1-PAKT phenotyping in HL cell lines 
I classified samples which were triple stained with BATF3-S1PR1-AKT in 4 HL cell 
lines (L591, L428, L1236 and KMH2) using Inform.  
The following phenotypes were measured: 
1) S1PR1 single positive cells. 
2) BATF3 single positive cells  
3) P-AKT single positive cells. 
4) S1PR1+ve-P-AKT+ve cells (but negative for BATF3).  
5) BATF3+ve P-AKT +ve cells (but negative for S1PR1).  
6) BATF3+ve-S1PR1+ve-P-AKT+ve cells. 
7)  BATF3-ve-S1PR1-ve-P-AKT-ve cells.  
Thresholds for these markers were subjective and based on morphological 
examination of the localisation of the stain and the intensity. The following markers 
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were considered to be specific if they were localized in the following subcellular 
localizations: BATF3 (nuclear), S1PR1 (membranous), AKT (membranous), and 
CD30 (membranous).These cells were screened for protein expression of BATF3, 
S1PR1, S1PR2, and pAKT by IHC once, in all HL cell lines experiments to validate 
expression performed by Q-PCR and western blot. In vitro studies including 
transfection and stimulation experiments of chapter 5 were performed by Dr 
Vrzalikova; University of Birmingham (Vrzalikova et al., 2018). 
Immune checkpoint T-cell panel phenotyping in NPC using Inform 
NPC cases were stained with CD3/cy3, PD1/FITC, PD-L1/cy5. Whole slide 
scanning of the cases was carried out using the Vectra, 5 HPF (20X) were selected 
using phenochart 2.0.4. Areas that contained tumour and stroma areas were 
selected.   
The following phenotypes were measured: 
1) PD-L1 single positive cells.  
2) CD3 single positive cells.  
3) PD1 single positive cells  
4) PD-L1+ve-CD3+ve cells.   
5) CD3-ve-PD-L1-ve-PD1-ve cells.  
The following markers were considered to be specific if they were localized in the 
following subcellular localizations: CD3 (membranous), PD-L1 (membranous +/-
cytoplasmic) and PD1 (membranous). This scoring was done in the tumour and 
stroma compartments. After analysis, threshold used for considering PD-L1 as 
positive was equal or more than 5% as clinically used in malignant melanoma and 
others. The threshold for PD1 positivity was if >5% of TILs were positive, as 
described by Zhou et al (Zhou et al., 2017b). An example of the phenotyping map 
and various phenotypes for immune checkpoint T-cell panel is shown in Figure 2.1. 
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2.7 Semi quantitative scoring 
Semi-quantitative scoring in HL, DLBCL and NPC will is described below. 
Semi-quantitative scoring for BATF3 and S1PR1 HL 
The threshold to score S1PR1 as tumour positive was previously described by Kluk 
et al (Kluk et al., 2013), whereby a case was considered positive if S1PR1 was 
present in  ⩾25% of tumour cells.  For consistency, I applied the same cut-off when 
assessing the expression of BATF3 and all other S1P receptors (S1PR1 and 
S1PR2) markers. 
Semi-quantitative scoring of MHC class I and class II in NPC 
Whole slide scanning of the 19 NPC cases stained for MHC class I and MHC class 
II was carried out using the digital scanner, HBRC SCN400 Leica, by Chris Bagnall. 
The slides were analysed digitally with the whole section screened at low power 
(10X) and high power (60X). First the presence of overlying epithelium was 
evaluated, and if present, was evaluated for atypia. Staining was evaluated in the 
epithelium, using H-score, for MHC class I. The epithelium should be positive, so 
this was used as an internal positive control. Immunostaining was considered 
positive for MHC class I or MHC class II if it was membranous +/- cytoplasmic. For 
MHC class I and II lymphocytes were used as positive internal controls. For 
evaluating tumour downregulation, of MHC class I or MHC class II, comparison with 
the lymphocytes was used. H-score was calculated for each case using the following 
formula: [% of cells with intensity 0 x 0] + [% of cells with intensity 1 x 1] + [% of cells 
with intensity 2 x 2] + [% of cells with intensity 3 x 3] (McCarty et al., 1985). Intensity 
of markers were classified into weak (+), moderate (++) or strong (+++). Intensity 
scores were subjective and were based on comparison with the positive internal 
control intensity, for example MHC class II intensity was compared with 
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lymphocytes, which were consistently positive with strong intensity (Figure 2.5). 
Scoring by the author was revised in 8 out of 19 random cases of immuno-stained 
MHC class I and class II by second senior pathologist; Dr Abeer Shaaban (Queen 
Elizabeth hospital, University of Birmingham). Disagreement in scoring of 2 cases 
were mentioned, these were re-evaluated. 
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Figure 2.5 Illustration of different intensity of IHC MHC class II in NPC 
Tumour cells are stained to MHC Class II (white arrows), displaying weak A), moderate B) and strong C) intensity, while adjacent 
lymphocytes strong intensity of staining served a positive internal control, (red arrows). 
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2.8 Digital quantification using Image J software 
Image J software (NIH) was used to analyse 6 DLBCL samples.  Image J was used 
to count the morphologically identifiable tumour cells (by haematoxylin) in direct or 
in close contact with the collagen-positive stromal fibres of stained cells in 10 HPF 
of tumour (40X) for each case. An average was taken for analysis. Non-viable 
tumour cells were excluded. 
2.9 Statistical analysis  
Student’s t test was used to determine statistical significance in parametric data, 
using two tailed t-test. Mann–Whitney U test was used to determine statistical 
significance in non-parametric data. Comparisons of proportions of phenotypes 
quantified by H-score or using Inform were done using the Chi-squared test. When 
plotting markers for correlation, Pearson rank test was used. For correlation matrix 
analyses (performed by Dr Graham Taylor) of histopathological scoring performed 
by the author, Spearman’s rank test was used. A p-value of < 0.05 was considered 
to be statistically significant. Statistical analysis of data was performed using 
Microsoft Excel 2007 and GraphPad Prism 7 software.  
2.10 Re-analysis of published gene expression data 
The re-analysis of the raw data (published and unpublished) of microarrays and 
RNA-seq data was performed by Dr Wenbin Wei and Dr Robert Hollows at the 
University of Birmingham. Microarray data (lymphoma and NPC), were downloaded 
from the Gene Expression Omnibus website (GEO) website. Probe-level quantile 
normalization plus robust multi-array (RMA) average normalization of raw CEL files 
was performed, using the affy package in R. Differential expression analysis was 
performed using the Limma package in R. Differential expression criteria used was 
of absolute fold change 1.5 and p value<0.05 were used.  
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Dr Reuben Tooze, provided data from the meta-analysis of eleven different DLBCL 
gene expression datasets including more than 2000 cases of whole tumour primary 
DLBCL microarrays which was published  (Care et al., 2015) and the analysis was 
performed in collaboration with the University of Leeds, pathology department. 
(Care et al., 2015). The resultant p values and correlations for each gene from all 
datasets were merged by taking the median values. The author used the genes 
identified in this analysis that were either positively or negatively correlated with 
LAIR1 and examined the overlap with all known collagen genes or collagen receptor 
genes, or a published macrophage gene expression signature (Doig et al., 2013). 
The author tested the significance of the overlap using Chi square test. 
RNA-seq data from (Morin et al., 2011, Béguelin et al., 2013)  were downloaded 
from the GEO website (GSE45982, GSM1129344, GSM1129345, GSM1129346 
and GSM1129347) for DLBCL samples and GC B cells were aligned to the hg19 
human genome using Rsubread aligner (Liao et al., 2013) and assigned to 
individual genes using the feature Counts function. Read counts were then 
normalized between samples and converted to counts-per-million reads for each 
gene using the edge R package (Robinson et al., 2010). For RNA-seq analysis, 
only genes which had counts-per-million of greater than 1 in at least four samples 
were considered.  
The author performed all the enrichment analysis and statistical tests such as chi 
square in results chapter 3, 4 and 5. To investigate the biological functions of genes 
of interest from the microarray/RNA-seq analysis, 6.7 DAVID ontology tool 
(http://david.abcc.ncifcrf.gov/home.jsp) was used. For this gene lists were submitted 
using human NCBI reference identifier (Dennis et al., 2003). 
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Heat maps of NPC biomarker data were prepared by Dr Robert Hollows using the 
gplots package in R. Hierarchical clustering for the heat maps used average linkage 
between samples/markers, based on 1 – correlation as the distance measure. All 
markers including PD-L1, PD1, MHC class I, MHC class II, CD3, CD8 and FOXP3 
were scored on a scale from 0 to 100. 
2.11 Details of individual datasets 
Lymphoma data from Brune dataset (Brune et al., 2008)  
Microarray data were downloaded from GEO (GSE12453) for 11 DLBCL samples, 
5 NLPHL samples, 4 T cell rich B cell lymphoma (TCRBL) samples, 5 FL samples 
and 5 Burkitt’s lymphoma (BL). In addition, 4 HL samples were downloaded from 
GSE14829. Tumour samples were compared with normal/control; 5 samples, also 
downloaded from GSE12450. Each of B cell subsets from tonsil GC B cells 
(centrocytes and centroblasts), plasma cells and from the peripheral blood (naïve B 
cells and memory cells) were used as a control for differential expression analysis. 
I used GC B cells (centrocytes and centroblasts) control samples in the differential 
gene expression analysis. 
Lymphoma data from Morin dataset (Morin et al., 2011)  
Data were downloaded from NIH database of genotypes and phenotypes 
(dbGap;http://www.ncbi.nlm.nih.gov/gap) accession code: phs000532-v5.p2 and 
comprised of RNA-seq of total 104 DLBCL cases: 32 ABC DLBCL (3 EBV 
positive), 54 GCB and 18 others DLBCL (1 EBV positive). Control samples were 4 
tonsillar GC B cell (centroblasts and centrocytes) samples Béguelin et al, by 
(Béguelin et al., 2013), separately downloaded from the GEO  at 
http://www.ncbi.nlm.nih.gov/geo/) (accession GSE45982), they included  
GSM1129344, GSM1129345, GSM1129346 and GSM1129347. I used in the 
analysis a total of 86 cases of GCB and ABC-DLBCL and four controls.  
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Lymphoma data from Steidl dataset (Steidl et al., 2012)  
 Microarray data were downloaded from GEO (GSE39133) (Steidl et al., 2012) for 
29 micro-dissected HL and 5 micro-dissected GCB control samples, with known 
EBV status in subset of the samples. 
NPC RNA-seq data from Dong H dataset (Dong H, 2016)   
RNA-seq data of whole NPC identified by (Dong H, 2016)   were downloaded from 
GEO (GSE68799) and included 42 EBV (LMP-1) positive Chinese NPC and 4 
control samples formed of non-neoplastic nasopharyngeal tissue (1 control was 
LMP-1 positive and the remaining 3 LMP-1 controls were negative). Differentially 
expressed genes were identified using edge R with p< 0.001 and read CPM >1 in 
at least half of the samples. Data is available at NCBI website: 
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68799  
Micro-dissected NPC microarray data from Hsu dataset (Hsu et al., 2012)  
NPC microarray dataset GSE12452 included gene expression from 31 NPC and 10 
micro-dissected controls; non-neoplastic nasopharynx. Criteria used to identify 
differentially expressed genes. Fold change and p value as previously mentioned.  
Whole NPC tumour microarray data from Bose dataset (Bose et al., 2009) 
NPC microarray dataset GSE13597 included 32 NPC samples of whole tumour 
sections, with undifferentiated nasopharyngeal carcinoma histology. Genes 
differentially expressed between LMP-1 positive and LMP-1 negative NPC were 
evaluated in this array using, LMP-1 status and levels were determined using Q-
PCR, fluidigm and IHC. Controls were three samples of non-malignant 
nasopharyngeal tissue. 
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2.12 Cell culture  
2.12.1 Monocytes Isolation of monocytes from PBMCs using Miltenyl CD14+ 
magnetic beads 
Human PBMCs were isolated from leukocyte buffy coats from healthy donors. A 
total of 20 mls of whole blood were provided in each cone from one donor. Blood 
was added to serum free RPMI1640 and layered on the top of Lymphoprep (Axis-
Shield) and subjected to density gradient centrifugation 1400 RPM for 30 min. The 
buffy layer of white blood cells was then washed and suspended in sterile MACs 
buffer (Miltenyi Biotech). 
2.12.2 Cell culture counting  
 
Cell density was calculated using a Neubauer haemocytometer 
(Marienfeld,Harsewinkel). Dead cells were identified by Trypan Blue (Sigma-Aldrich 
Ltd., Gillingham) and excluded from counting. Live cells were counted using an 
Olympus CK30 inverted light microscope in four regions, and then an average of the 
total number was calculated. This number was then multiplied by 104 and the dilution 
factor of the Trypan Blue to get the number of cells per ml of culture. 
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2.12.3 CD14+ cells isolation from PBMCs  
 
Isolation of human CD14+ monocytes was performed using Miltenyi magnetic bead 
separation kit according to manufacturer’s protocol. Resulting CD14+ monocytes 
were checked for purity by flow cytometry staining using CD14-FITC (ThermoFisher) 
before proceeding to differentiation process with the assistance of Tracey Perry 
(University of Birmingham).    
2.12.4 Polarisation of monocytes into M1 and M2 subtypes 
 
Polarization of monocytes to M1 and M2 macrophages with Granulocyte-macrophage 
colony stimulating factor (G-MCSF) and Macrophage colony-stimulating factor (M-CSF) 
was performed. The buffy coat layer of leukocytes was collected and placed into a 
fresh 50 ml conical tube. CD14+ monocytes were plated in RPMI-1640+10% 
FBS+1% glutamax (Invitrogen) for M0, and with the addition of 5ng/ml of G-MCSF 
(Peprotech) for M1 or 25ng/ml of M-CSF (Peprotech) for M2. After 10 days of 
differentiation, attached cells were collected and washed with sterile PBS, then re-
suspended in density 2x106 cells/ml in complete medium.  
2.12.5 Collagen stimulation pre-differentiation 
 
Collagen type I at concentration 10 microgrammes/ml, prepared fresh in cold sterile 
PBS was used for coating plastic 6-well tissue-culture plates. 1-2 mls of diluted 
collagen solution per well was used. The plates were incubated at 4 °C for 2 hours, 
then collagen was removed by washing carefully with 2mls of PBS. Monocytes were 
cultured on 6-well plates at a density of 1 x106 /ml, together with either collagen, 
vehicle (acetic acid) or left untreated as a control. 
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2.12.6 Collagen stimulation post-differentiation 
 
Soluble collagen was added directly to cells using 100ug/ml soluble type I collagen 
(Millipore), vehicle (acetic acid) and PBS for untreated cells, for 30 minutes, 1, 2, 4, 
24, 48, and 72h. After these time points, cells were harvested, stained and analysed 
by flow cytometry for LAIR-1 and macrophage markers (Table 2.5).  
2.12.7 Preparation of Human acute monocytic leukaemia cells 
 
Human acute monocytic leukaemia (THP-1) cell line, provided by Dr Carmela De 
Santo, University of Birmingham was cultured in RPMI 1640 (Gibco, Life 
Technologies Ltd) supplemented with 10% v/v FBS (Sigma), 1 mM pyruvate (Gibco) 
and 1% penicillin-streptomycin (Sigma-Aldrich). 
2.12.8 Maintenance of monocytes/macrophages and THP1 in culture  
 
Cells were incubated at 37°C in a humidified atmosphere rich in 5% carbon dioxide 
(Galaxy R CO2 Incubator; RS Biotech). Cell viability and counting was evaluated 
with an inverted microscope. THP-1 cells were passaged to prevent overgrowth.  
2.12.9 Flow cytometry staining with flurophore-conjugated antibodies  
 
After harvesting the monocytes or macrophages, the expression of different markers 
was evaluated by staining with 3µl of each of the following antibodies: LAIR-1, 
CD163 and CD14 (Table 2.5). A minimum of 1x106 cells were used for each panel 
of antibodies. For THP-1 cells before staining, frozen cells were thawed to 37°C and 
diluted in 10 ml of cold PBS or DMEM with 10% FCS, followed by centrifugation of 
cells at 1,100 RPM for 10 minutes. The cells were washed once more and finally re-
suspended in 1ml of PBS or DMEM with 10% FCS. 
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Table 2.5 Summary of the antibodies used for FACS analysis  
Antibody Species Clone Company Fluorophore 
Catalogue 
number 
CD14 Human 61D3 ebioscience FITC 11-0149-42 
CD163 Human GH/61 ebioscience APC 17-1639-41 
LAIR-1 Human 342219 R&D PE FAB2664P 
 
2.12.10 FACS analysis 
 
In vitro polarised macrophages were stained with panel of fluorescently conjugated 
antibodies.  Cells with high side scatter and low forward scatter were excluded from 
analysis.  Gated population was then analysed for CD14 expression.  The CD14+ve 
cells were then further analysed for M1 and M2 phenotypes. M1 phenotype was 
defined CD163-ve/+ve low. M2 phenotype was defined CD163+ve. Then LAIR-1 
expression was assessed in the M1 and M2 populations. Flow cytometry analysis 
was performed under the supervision of Tracey Perry, University of Birmingham.   
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CHAPTER THREE 
CHARACTERISATION OF THE IMMUNE-MICROENVIRONMENT 
AND MHC EXPRESSION IN NASOPHARYNGEAL CARCINOMA 
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3.1 INTRODUCTION 
Nasopharyngeal carcinoma (NPC) is a tumour which arises in the lining of the 
nasopharyngeal epithelium and which is particularly prevalent in South East Asia. 
NPC is driven by a persistent Epstein-Barr virus (EBV) infection of target cells 
following exposure to environmental carcinogens in salted fish and cigarette smoke. 
Most NPC cases present at a late stage (Omar et al., 2006) and survival is poor; 
current treatments for advanced disease are limited to concurrent chemo-
radiotherapy and are associated with significant morbidity and poor quality of life 
(Busson, 2013). Therefore, innovation in the therapeutic approach is required, not 
only to improve cure rates, but also to de-intensify conventional treatments and 
reduce long-term toxicities. 
PD-L1, an immune checkpoint molecule, is expressed in 89-95% of NPC (Chen et 
al., 2013). A role for PD-L1 and its receptor, PD1 in NPC was shown by clinical trials 
with clinical responses as reduction in tumour size in a proportion of NPC patients 
receiving the humanized monoclonal antibody, pembrolizumab, which blocks PD1 
(Hsu et al., 2015). NPC patients over-expressing PD-L1 measured by IHC have 
inferior outcomes in contrast to patients with lower IHC expression scores (Zhang 
et al., 2015, Fang et al., 2014, Zhou et al., 2017b). In contrast, one report describes 
a positive correlation between PD-L1 expression by IHC and survival in patients with 
non-metastatic NPC (Lee et al., 2016). 
The molecular mechanisms which underpin the frequent expression of PD-L1 in 
NPC are unclear. One possibility is that PD-L1 overexpression occurs in response 
to inflammatory cytokines released by infiltrating anti-tumour lymphocytes (Fang et 
al., 2014). This mechanism of tumour escape from immune-cell mediated response 
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is called adaptive immune resistance, and may indicate a possible mechanism to 
target by PD1 blockade. 
Intrinsic immune resistance is an alternate scenario, whereby PD-L1 is constitutively 
expressed because of underlying dysregulated signalling pathways in the tumour 
cell or possibly by genetic mechanisms such as amplification; expression in such 
cases does not indicate the presence of an active immune response (inducible type) 
(Taube et al., 2012). However, another recent study has shown that both these 
mechanisms are not necessarily mutually exclusive, whereby PD-L1 can be 
secondarily expressed due to a superimposed Interferon-gamma (INF-γ)  effect 
overlapping an existing constitutive mechanism (Topalian et al., 2016). In order to 
develop the necessary immunotherapeutic agents for NPC patients, it is important 
to know if PDL-1 overexpression is of the constitutive or inducible type. 
Recent reports indicate that EBV-LMP-1 could also regulate PD-L1 expression. 
Thus, EBV negative NPC cell lines transfected with LMP-1 show elevated levels of 
PD-L1 expression when treated with INF-γ, however in this study IFN-γ alone was 
able to independently increase PD-L1 expression in NPC cell lines. In EBV positive 
NPC, LMP-1 up-regulates not only PI3-K, but also AP-1, STAT3 and NF-ĸB 
pathways, and this is proposed to sustain the over-expression of PD-L1 (Chen et 
al., 2013, Fang et al., 2014). In addition, NPC was reported to show decreased or 
loss of expression of MHC class I, which could contribute to tumour escape of NPC 
cells (Sengupta et al., 2006, Kouvidou et al., 1995, Yao 
 et al., 2000). Microarray analysis of micro-dissected NPC has shown that the 
downregulation of MHC class I was associated with EBV gene expression 
(Sengupta et al., 2006). Other studies show alterations at the protein level of MHC 
class I. Thus, beta-2 microglobulin (B2M) expression was reduced or absent in 
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18/37 NPC cases (Kouvidou et al., 1995). As B2M is essential for the formation of 
MHC class I molecules (Springer, 2015), this suggests impairment in antigen 
processing and presentation functions in NPC.  
Unexpectedly, MHC class II has been reported to be upregulated in NPC (Busson 
et al., 1988). MHC-DR is up-regulated in 55% of NPC cases (Li et al., 2007).and in 
some cases MHC class II may be expressed more frequently in the tumour 
compared with the tumour stroma (Yao et al., 2000). Not all NPC cases express 
MHC class II, however, with lower levels observed in 37% of samples analysed; 
some of these cases also had decreased MHC class I expression (Yao et al., 2000). 
To summarize, the presence of significant variability in the heterogeneous 
microenvironment of NPC, with its distinctive exuberant lymphocytic infiltration, 
suggests that use of targeted therapy against immunomodulatory functions might 
be beneficial. I focussed on the PDL-1/PD1 pathway in this chapter because this is 
the only checkpoint (apart from the combination with anti-CTLA4 drugs) which has 
so far been investigated clinically in NPC patients. The aim of this chapter is to 
comprehensively characterize the immune microenvironment of EBV-associated 
NPC and to study the potential role of LMP-1. In turn, this knowledge might help to 
refine therapies against immune checkpoints for patients with this disease. 
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3.2 RESULTS  
3.2.1 PD-L1 is an immune signature gene that is up-regulated in NPC tumour 
cells compared to normal nasopharyngeal epithelium 
 
In the first series of analyses I wanted to compare the global expression of immune-
related genes in NPC tumour cells with that in normal tissues. The initial premise 
being to confirm the over-expression of PD-L1 in these tumours. To do this I made 
use of the following three datasets: 
 Dataset (1) a published microarray study; GSE12452 (Hsu et al., 2012) that 
had described gene expression in micro-dissected NPC tumour cells and in 
non-neoplastic/normal nasopharyngeal epithelium and which were re-
analysed by Drs Wei and Hollows  (Hsu et al., 2012). 
 Dataset (2) a comprehensive list of immune checkpoint genes (ICP) compiled 
by Grace Mitchell in our laboratory (Appendix 2). 
 Dataset (3) a list of extended immune signature genes termed the Co-
ordinate Immune Response Cluster (CIRC) by Lal et al comprising a 61 gene 
cluster of inhibitory molecules which influences the immune infiltration (Lal et 
al., 2015) (Appendix 3).  
Figure 3.1 and Tables 3.1 and 3.2 show that there was no significant enrichment or 
depletion of ICP signature genes (Dataset 2) among those genes either up- or down-
regulated in micro-dissected NPC compared to normal nasopharyngeal epithelium. 
However, Figure 3.2 and Tables 3.3 and 3.4 show that CIRC genes (Dataset 3) were 
significantly enriched among those genes up-regulated in NPC and depleted among 
those genes down-regulated in NPC. Genes up-regulated in NPC and present in 
both ICP and CIRC signatures were TNFSF4, ICOS, PD-L1 and CTLA4.  
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Figure 3.1 PD-L1 is among the ICP genes upregulated in micro-dissected NPC 
tumour cells compared to the normal nasopharyngeal tissue 
A and B; Venn diagrams show the overlap between ICP genes and those either up- or 
down-regulated in NPC compared to normal nasopharyngeal epithelium.  
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Table 3.1: Number of genes upregulated and downregulated in micro-dissected NPC 
versus normal epithelium and present in the immune checkpoint signature 
 
Genes of the arrays 
Total 
number 
Number of genes used in the enrichment analysis 
(present on both Immune checkpoint related 
genes and NPC array=20219) 
Immune checkpoint genes 
65 62 
Upregulated genes in micro-dissected  NPC 
versus normal epithelium 2270 2270 
Downregulated genes micro-dissected  NPC 
versus normal epithelium 1140 1140 
 
 
Table 3.2: Chi-squared test of the overlap between genes differentially expressed 
in micro-dissected NPC versus normal epithelium and ICP genes 
 
Genes of the array 
Observed 
(0) 
Expected (E) 0-E 
Chi 
square 
Odds 
Ratio 
p-value 
Immune checkpoint 
genes and 
upregulated genes 
in micro-dissected  
NPC versus normal 
epithelium 
9 6.960435213 2.0392205 0.597407 1.343395 0.4396 
Immune checkpoint 
genes and genes 
downregulated in 
micro-dissected  
NPC versus normal 
epithelium 
2 3.495721846 
-
1.4957218 
0.639978 0.55703 0.4237 
 
Tables 3.1 and 3.2 summarises the results of statistical test performed for these 
analyses. 
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Figure 3.2 PD-L1 is among the CIRC genes upregulated in micro-dissected NPC 
tumour cells compared to the normal nasopharyngeal tissue 
A and B Venn diagrams show the overlap between CIRC genes and those either up- or 
down-regulated in NPC compared to normal nasopharyngeal epithelium.  
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Table 3.3: Number of genes upregulated and downregulated in micro-
dissected NPC versus normal epithelium and present in CIRC signature 
 
Genes of the arrays 
Total 
number 
Number of genes used in the 
enrichment analysis (present on 
Immune signature CIRC genes and 
NPC array=20219 ) 
Immune signature CIRC 59 55 
Upregulated genes in micro-dissected  
NPC versus normal epithelium 
2270 2270 
Downregulated genes micro-dissected  
NPC versus normal epithelium 
1140 1140 
 
Table 3.4: Chi-squared test of the overlap between genes differentially 
expressed in micro-dissected NPC versus normal epithelium and present in 
CIRC genes 
 
Genes of the arrays 
Observed 
(0) 
Expected 
(E) 
0-E 
Chi 
square 
Odds 
Ratio 
P-value 
Immune signature 
CIRC 
genes and 
upregulated genes in 
micro-dissected  
NPC versus normal 
epithelium 
14 6.174885009 7.825115 9.916367 2.708398 0.0016 
Immune signature 
CIRC 
genes and genes 
downregulated in 
micro-dissected  
NPC versus normal 
epithelium 
1 3.101043573 -2.1010436 1.423516 0.309303 0.2328 
 
Tables 3.3 and 3.4 summarises the results of statistical test performed for these 
analyses 
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3.2.2 PD-L1 expression and LMP-1 status in NPC 
Having confirmed the over-expression of several immune inhibitory molecules, 
including PD-L1 in NPC, and because it was previously reported that LMP-1 can up-
regulate PD-L1 in NPC cell lines (Fang et al., 2014), I next wanted to determine if 
the expression of these genes varied by LMP-1 status. LMP-1 status was known for 
42 tumours reported in the re-analysis of micro-dissected NPC described above; 
(GSE68799) by Dong H  (Dong H, 2016) (Dataset 5). Only two ICP genes, CD276 
and GZMB, were up-regulated in LMP-1-positive NPC versus LMP-1-negative NPC, 
and no ICP genes were down-regulated in LMP-1-positive compared with LMP1-
negative micro-dissected NPC (Figure 3.3, Tables 3.5 and 3.6). Only 5 CIRC genes, 
CCL5, CD276, CXCL9, CXCL10 and GZMB were upregulated in LMP-1-positive 
compared with LMP-1-negative micro-dissected NPC (Figure 3.4, Tables 3.7 and 
3.8). These data suggest that other factors, possibly cellular in origin, might up-
regulate PD-L1 when LMP-1 is not expressed. These data are also consistent with 
a recent study that showed that PD-L1 IHC expression scores in patient samples 
were not correlated with the EBV DNA load (Zhou et al., 2017b).  To further study 
if LMP-1 status had any impact on expression of ICP genes and CIRC genes, I took 
advantage of a further dataset; GSE13597, by Bose et al (Bose et al., 2009) (re-
analysed by Drs Wei and Hollows), referred to here as Dataset (4), a microarray 
analysis that had compared gene expression in whole NPC tissues (i.e. including 
non-tumour components) versus that in whole normal nasopharyngeal tissue (Bose 
et al., 2009). Analysis of ICP genes in Dataset 4 (Bose et al., 2009) is shown in 
Figure 3.5 and Tables 3.9 and 3.10 and revealed only the up-regulation of ICOS 
(Inducible T-Cell Costimulator) (among ICP genes) in LMP-1-positive versus LMP-
1-negative whole NPC. Analysis of the CIRC genes revealed the upregulation of 
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HLA-DPB1, ICAM1, HLA-DOB, IL7R, ICOS and HLA-DPA1 (Figure 3.6 and Tables 
3.11 and 3.12).  
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Figure 3.3  PD-L1 is not present among genes up-regulated in LMP-1-positive 
micro-dissected compared to LMP-1-negative micro-dissected NPC and ICP 
genes, Venn diagrams show the overlap between ICP genes and those genes either 
up- or down-regulated in LMP-1-positive vs LMP-1-negative micro-dissected NPC.  
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Table 3.5: Number of genes upregulated and downregulated in LMP-1 positive 
micro-dissected NPC versus LMP-1-negative micro-dissected NPC and 
present in ICP signature 
 
Genes of the arrays 
Total 
number 
Number of genes used in the 
enrichment analysis (present on 
both Immune checkpoint related 
genes and NPC array=20219) 
Immune checkpoint related 
genes 
65 62 
Upregulated genes in LMP-1 
positive versus LMP-1 negative 
micro-dissected NPC  
96 95 
Downregulated genes in LMP-1 
positive versus LMP-1 negative 
micro-dissected NPC  
643 643 
 
 
Table 3.6: Chi-squared test of the overlap between genes upregulated and 
downregulated in LMP-1 positive micro-dissected NPC versus LMP1-negative 
micro-dissected NPC and present in ICP signature 
 
Genes of the 
arrays 
Observed 
(0) 
Expected 
(E) 
0-E Chi 
square 
Odds 
Ratio 
P-value 
Immune checkpoint 
genes and genes 
upregulated in LMP-1 
positive versus LMP-
1 negative micro-
dissected NPC  
2 0.291295747 1.7087043 10.02304 7.191039 0.0015 
Immune checkpoint 
genes and genes 
downregulated in 
LMP-1 positive 
versus LMP-1 
negative micro-
dissected NPC  
0 1.971612265 -1.9716123 1.971612 0 0.1603 
 
Tables 3.5 and 3.6 summarises the results of statistical test performed for these 
analyses. 
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Figure 3.4 PD-L1 is not present among those genes up-regulated in LMP-1-positive 
micro-dissected compared to LMP1-negative micro-dissected NPC and CIRC genes. 
A and B; Venn diagrams show the overlap between CIRC genes and those genes either 
up- or down-regulated in LMP-1-positive vs LMP-1-negative micro-dissected NPC. 
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Table 3.7: Number of genes upregulated and downregulated in LMP1 positive 
micro-dissected NPC versus LMP-1-negative micro-dissected NPC and present 
in CIRC signature 
 
Genes of the arrays 
Total 
number 
Number of genes used in the enrichment 
analysis (present on both Immune 
checkpoint related genes and NPC 
array=20219) 
Immune signature CIRC 59 55 
Upregulated genes in LMP-1 positive 
versus LMP1 negative micro-dissected 
NPC  
96 95 
Downregulated genes in LMP-1 positive 
versus LMP-1 negative micro-dissected 
NPC  
643 643 
 
Table 3.8: Chi-squared test of the overlap between genes upregulated and 
downregulated in LMP-1 positive micro-dissected NPC versus LMP-1-negative 
micro-dissected NPC and present in CIRC signature 
 
Genes of the arrays Observed (0) Expected (E) 0-E Chi square Odds 
Ratio 
P-value 
CIRC signature 
genes and genes 
upregulated in LMP-1 
positive versus LMP-
1 negative micro-
dissected NPC  
5 0.258407517 4.7415925 87.004819 22.3 <0.0001 
CIRC signature 
genes and genes 
downregulated in 
LMP-1 positive 
versus LMP-1 
negative micro-
dissected NPC  
0 1.74901088 -1.7490109 1.74901088 0 0.186 
 
Tables 3.7 and 3.8 summarises the results of statistical test performed for these 
analyses 
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Figure 3.5 PD-L1 is not present among those genes up-regulated in LMP-1-positive 
compared to LMP-1-negative whole tumour NPC and ICP genes. A and B; Venn 
diagrams show the overlap between ICP genes and those genes either up- or down-
regulated in LMP1-positive versus LMP1-negative whole tumour NPC. 
 
 
Up LMP-1 positive whole NPC  Down LMP1-positive whole NPC  ICP genes ICP genes 
Overlap-genes upregulated in LMP-1 
positive versus LMP1-negative NPC and ICP  
B A 
ICOS 
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Table 3.9: Number of genes upregulated and downregulated in LMP-1 positive 
whole tumour NPC versus LMP-1-negative whole tumour NPC and present in ICP 
signature 
 
Genes of the arrays 
Total 
number 
Number of genes used in the 
enrichment analysis (present on both 
Immune checkpoint related genes and 
NPC array=12823 
Immune checkpoint related genes 65 1 
Upregulated genes in LMP-1 positive 
versus LMP-1 negative whole NPC  
402 224 
Downregulated genes in LMP-1 positive 
versus LMP-1 negative whole tumour NPC  
57 36 
 
Table 3.10: Chi-squared test of the overlap between genes upregulated and 
downregulated in LMP-1 positive whole tumour NPC versus LMP-1-negative 
whole tumour NPC and present in ICP signature 
 
Genes of the arrays Observed (0) Expected (E) 0-E Chi 
square 
Odds 
Ratio 
P-value 
Immune checkpoint 
genes and genes 
upregulated in LMP-1 
positive versus LMP-1 
negative whole NPC  
1 0.017468611 0.9825314 55.263 NA <0.0001 
Immune checkpoint 
genes and genes 
downregulated in LMP-
1 positive versus LMP-1 
negative whole NPC  
0 0.002807455 -0.0028075 0.002807 0 0.9577 
 
Tables 3.9 and 3.10 summarises the results of statistical test performed for these 
analyses. 
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Figure 3.6 PD-L1 is not present among those genes up-regulated in LMP-1-positive 
compared to LMP1-negative whole tumour NPC and CIRC genes  
A and B; Venn diagrams show the overlap between Immune signature CIRC genes and 
those genes either up- or down-regulated in LMP-1-positive versus LMP-1-negative 
whole tumour NPC.  
 
 
  
Overlap-genes upregulated in LMP-1 positive versus LMP1-negative 
NPC and CIRC genes 
HLA-DPB1 
ICAM1 
HLA-DOB 
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Table 3.11: Number of genes upregulated and downregulated in LMP1 positive 
whole NPC versus LMP-1-negative whole NPC and present in Immune signature 
CIRC signature 
 
Genes of the arrays 
Total 
number 
Number of genes used in the enrichment 
analysis (present on both and Immune 
signature CIRC NPC array=12823) 
Immune signature CIRC 59 6 
Upregulated genes in LMP1 positive 
versus LMP1 negative whole NPC  
402 224 
Downregulated genes in LMP1 positive 
versus LMP1 negative whole NPC  
57 36 
 
Table 3.12: Chi-squared test of the overlap between genes upregulated and 
downregulated in LMP-1 positive NPC versus LMP-1-negative whole NPC and 
present in Immune signature CIRC signature 
 
Genes of the arrays Observed (0) Expected (E) 0-E Chi square Odds 
Ratio 
P-value 
Immune signature 
CIRC 
and genes upregulated 
in LMP-1 positive 
versus LMP-1 negative 
whole NPC  
6 224 5.9555486 797.9181356 NA <.0001 
Immune signature 
CIRC 
and genes 
downregulated in LMP-
1 positive versus LMP-
1 whole NPC  
0 36 
-
0.0168447 
0.016845 0 0.8967 
 
Tables 3.11 and 3.12 summarises the results of statistical test performed for these 
analyses. 
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3.2.3 Co-expression of PD-L1 with other immune checkpoints in NPC 
 
The co-expression of immune checkpoints has not been investigated in NPC. Such 
knowledge is likely to be important for future trials which will probably employ 
checkpoint inhibitors in combination. Therefore, I used Dataset (5); GSE68799 by 
Dong H et al (Dong H et al, 2016) which constituted of RNA-seq data of NPC, re-
analyzed from EBV Chinese 42 NPC samples, to perform an evaluation of the 
correlation between PD-L1 expression and that of other relevant checkpoint 
molecules, especially important here were PD1 and PD-L1, but I also included B 
and T lymphocyte associated (BTLA), hepatitis A virus cellular receptor 
2 (HAVCR2), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), adenosine 
A2a receptor  (ADORA2A), V-set domain containing T-cell activation inhibitor 
1  (VTCN1), indoleamine 2,3-dioxygenase 1 (IDO1) and lymphocyte activating 
3  (LAG-3). I observed that PD-L1 is positively correlated with the following immune 
checkpoint genes in order of decreasing R value: PD-L2, hepatitis A virus cellular 
receptor 2 (HAVCR2), LAG3, ADORA2A, CTLA4, IDO1, BTLA followed by PD1. 
PD1 is positively correlated with the following immune checkpoint genes in order of 
decreasing R value: ADORA2A, BTLA, LAG3, CTLA4, HAVCR2, PD-L2, PD-L1, 
VTCN1 followed by IDO1 (Figure 3.7 and Table 3.13).  
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Figure 3.7 Correlation between the expression of immune checkpoint genes 
in primary EBV positive NPC  
PD-L1 expression is positive correlated with PD-L2, HAVCR2, LAG3, ADORA2A, 
CTLA4, IDO1, BTLA followed by PD1. The plots are based on the 42 tumour 
Chinese NPC samples. BTLA indicates B and T lymphocyte associated, HAVCR2 
indicates hepatitis A virus cellular receptor 2, CTLA-4 indicates cytotoxic T-
lymphocyte associated protein 4, ADORA2A indicates adenosine A2a receptor, 
VTCN1  indicates V-set domain containing T-cell activation inhibitor 1, IDO1 
indicates indoleamine 2,3-dioxygenase 1 and LAG-3 indicates lymphocyte 
activating 3.  
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Table 3.13 Correlation coefficients for the co-expression analysis of Immune 
checkpoints in NPC   
 
Immune 
checkpoint 
genes 
VTCN1 LMP-1 IDO1 ADORA2A PDCD1 LAG3 HAVCR2 PD-L1 PD-L2 BTLA CTLA4 
VTCN1 1.000 -0.177 -0.068 -0.329 0.067 
-
0.258 
-0.305 -0.403 -0.256 0.111 0.073 
LMP-1 -0.177 1.000 0.072 0.152 -0.127 0.005 0.213 0.276 0.296 -0.075 0.073 
IDO1 -0.068 0.072 1.000 0.170 0.056 0.272 0.327 0.343 0.367 0.175 -0.025 
ADORA2A -0.329 0.152 0.170 1.000 0.631 0.487 0.369 0.411 0.370 0.341 0.189 
PD1 0.067 -0.127 0.056 0.631 1.000 0.543 0.415 0.179 0.308 0.627 0.433 
LAG3 -0.258 0.005 0.272 0.487 0.543 1.000 0.662 0.492 0.536 0.367 0.321 
HAVCR2 -0.305 0.213 0.327 0.369 0.415 0.662 1.000 0.608 0.808 0.401 0.535 
PD-L1 -0.403 0.276 0.343 0.411 0.179 0.492 0.608 1.000 0.811 0.232 0.379 
PD-L2 -0.256 0.296 0.367 0.370 0.308 0.536 0.808 0.811 1.000 0.430 0.561 
BTLA 0.111 -0.075 0.175 0.341 0.627 0.367 0.401 0.232 0.430 1.000 0.526 
CTLA4 0.073 0.073 -0.025 0.189 0.433 0.321 0.535 0.379 0.561 0.526 1.000 
 
Tables 3.13 summarises the results of statistical test performed for these analyses. 
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3.2.4 Protein expression of PD-L1 in primary NPC 
 
Before embarking on an analysis of the protein expression of PD-L1 and PD1 in 
primary NPC, I first optimised conditions for immunohistochemistry of these markers 
and the T cell marker CD3 (Figure 3.8). PD-L1 staining in tonsil was positive in the 
superficial layers of the squamous epithelium lining the crypt. PD1 was positive in a 
membranous pattern in scattered activated lymphocytes within the GC, a few 
lymphocytes within the mantle zone, and on other non-lymphoid populations in the 
interfollicular region where it was localized in the cytoplasm as well as the 
membrane. CD3 was positive in the reactive T cells. Multiplex IF for CD3, PD-L1 
and PD1 was also optimized (hereafter referred to as the ‘immune checkpoint-T cell 
panel; Figure 3.9). 
Next, I investigated the expression of PD-L1 in NPC samples. PD-L1 was positive 
in tumour cells in 16/17 (94.11%) NPC samples when using a cut off ≥ 5% of PD-L1 
positive cells as published by Heeren et al (Heeren et al., 2016) and Fang et al 
(Fang et al., 2014). An example of PD-L1 staining in tumour cells illustrating that 
the tumour is positive for PD-L1 at the periphery is shown in Figure 3.10 A. I also 
performed a semi-automated analysis of PD-L1 expression using Inform software. I 
found that the two methods of scoring were significantly positively correlated 
(r=0.6418 and p< 0.00001; Figure 3.10 B and Table 3.14). 
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Figure 3.8 IHC of tonsil used as a positive control for the immune checkpoint-T cell panel, A) PD-L1 is expressed by the tonsil crypt 
squamous epithelium at the black arrows (40X). B) PD1 is expressed by many reactive lymphocytes in the germinal centre (GC), few in mantle 
zone at black arrows (40X). C) CD3 is positive in the follicular and mantle zone T cells (40X) at black arrows. (E) indicates epithelium, (GC) 
indicates germinal centre, (MZ) indicates mantle zone.
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Figure 3.9 Example of optimized multiplex IF for the Immune checkpoint-T cell panel 
A) PD-L1 (green) is positive in tonsillar squamous epithelium (arrow head) and present in the GC, B) PD-L1 (green) is present in 
the GC cells (white arrow head) and T cells in mantle zone (red arrow head), C) PD1 (yellow) is expressed by the reactive 
lymphocytes in GC, D) CD3 (red) is expressed by the reactive T cells, E) DAPI staining the nuclei (blue) F) overlay of the four 
multispectral images, (20X), (GC) indicates germinal centre, (MZ) indicates mantle zone, (E) indicates epithelium.
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Figure 3.10 Expression of PD-L1 in NPC 
A) Representative example of NPC that has PD-L1 (green) expression mainly on the periphery in a membranous pattern, 20X
A 
PD-L1 
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B) Positive correlation between PD-L1 scored using either semi-automated Inform 
scoring or semi-quantitative scoring of percentage of tumour cells. 
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3.2.5 Expression of PD-L1 protein in overlying epithelium and NPC 
To confirm the over-expression of PD-L1 in NPC and to describe the expression of 
PD-L1 in the non-neoplastic epithelium of NPC biopsies (the latter is not yet 
reported), I analysed PD-L1 expression in the non-neoplastic epithelium which was 
present in 7/17 NPC biopsies. One of these samples contained normal looking 
epithelium, while the remaining 6 cases had atypical changes, but it was not 
possible to grade them based on immunofluorescence stained slides.  PD-L1 was 
expressed in non-neoplastic or pre-invasive epithelium in 2/7 samples. Comparison 
of H-scores for tumour versus the non-neoplastic epithelium, showed a significant 
increase in PD-L1 expression in the tumour (Figure 3.11, Table 3.14; p=0.0001). 
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Figure 3.11 Expression of PD-L1 in non-neoplastic tissue in NPC biopsies 
A) Shown are representative cases of the staining of PD-L1 in non-neoplastic epithelium from NPC biopsies, image was converted to bright-
field to allow evaluation of the dysplasia. Left panel, the overlying epithelium was negative for PD-L1 (black arrows). Scattered reactive CD3 
(brown) positive T cells are seen in the tumour stroma. Right panel, PD-L1 was seen positive in parts of the epithelium (black arrows). 
PD-L1 CD3 
Positive Negative 
A 
PD-L1 CD3 
E 
E 
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B) Graphical representation shows significantly higher H-scores for PD-L1 
expression in tumour compared to non-neoplastic epithelium (p=0.0001), H-score 
indicates histoscore. 
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Table 3.14 PD-L1 expression in NPC and non-neoplastic epithelium 
Case 
number 
Overlying 
epithelium 
Epithelium 
status 
PD-L1 
status 
overlying 
epithelium 
PD-L1 
status 
tumour 
epithelium 
H-score 
overlying 
epithelium 
H-score 
Tumour 
epithelium 
1 Absent  - - Positive - 90 
2 Present  Atypical Negative Positive 0 220 
 4 Present Atypical Positive Positive 100 150 
7 Absent - - Positive - 50 
 8 Present  Atypical Negative Negative 0 4 
 9 Absent - - Positive - 210 
10 Present  Atypical Positive Positive 40 100 
11 Absent - - Positive - 140 
12 Present  Atypical Negative Positive 0 15 
14 Absent - - Positive - 230 
15 Present  Normal Negative Positive 0 100 
16 Present  Atypical Negative Positive 0 15 
17 Absent - - Positive - 20 
18 Absent - - Positive - 25 
20 Absent - - Positive - 70 
21 Absent - - Positive - 35 
22 Absent - - Positive - 20 
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3.2.6 Patterns of PD-L1 expression in NPC  
 
The pattern of PD-L1 expression has not been described in NPC, i.e. whether it is 
inducible or constitutive. This is important because the expression of these distinct 
patterns may have prognostic implications. For example, better disease free survival 
and disease specific survival has been reported for patients with the marginal type 
rather than the diffuse type of PD-L1 expression in cervical SCC (Heeren et al., 
2016). In this study, the scoring system for PD-L1 was as reported by Heeren et al 
which defined the diffuse pattern as one which may reflect a constitutive mechanism 
of intrinsic tumour resistance related to molecular alterations and showing the 
presence of PD-L1 positive tumour cells in the whole tumour (Heeren et al., 2016). 
The marginal expression of PD-L1 is likely to represent the inducible type, where 
cytokines released by effector T cells induce PD-L1 expression, I found that 8/16 
NPC tumours were of diffuse type.  An example of diffuse expression is shown in 
Figure 3.12. I found that 8/16 cases were of the marginal type. Figure 3.13 shows 
that the marginal type existed as two variants, either focal when PDL-1 was present 
in peripheral foci, and circumferential when PD-L1 expression was found through 
the whole outer portion of the tumour cluster. Figure 3.14 shows IF images 
converted to bright-field for better visualisation of these different patterns. Figure 
3.15 shows that tumours with a diffuse pattern of expression have, as expected, 
significantly higher levels of PD-L1 protein expression than marginal type tumours 
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Figure 3.12 Example of diffuse pattern of PD-L1 expression in NPC PD-L1 (green) is diffusely positive in the tumour cells, amongst the 
tumour groups, with strong intensity. Numerous CD3 positive T cells (red) in close/direct relation to PD-L1 positive tumour cells, 20X (T) 
indicates tumour, (S) indicates stroma. 
T 
S 
T 
T 
PD-L1-CD3 
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Figure 3.13 Examples of the marginal pattern of PD-L1 expression in NPC  
A) and B) Tumour cells are PD-L1 (green) positive only at the periphery (red arrows), circumferentially. Numerous CD3 positive T 
cells (red) (white arrows) are in close/direct relation to PD-L1 positive tumour cells, 20X. (T) indicates tumour, (S) indicates stroma
T 
PD-L1 CD3 
S 
B 
T 
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Figure 3.14 Multiplex IF converted to bright-field image, showing variants of marginal pattern of expression of PD-L1 in tumour cells  
Both examples are merged images and show groups of tumour cells positive for PD-L1 (green) at the tumour-stroma interphase in focal (left 
panel), and circumferential (right panel) patterns. Many PD-L1 positive tumour cells in green (red arrows) at the tumour-stroma interface, were in 
direct contact with scattered CD3 positive T cells in brown at the white arrows, in a clustered non uniform pattern (20X). (T) indicates tumour, (s) 
indicates stroma.  
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Figure 3.15 Significantly higher PD-L1 expression in diffuse type NPC, H-
scores for PD-L1   expression in diffuse versus marginal type NPC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 146 
 
3.2.7 The frequency and distribution of T cells in PD-L1 expressing NPC 
Although the frequency of CD3 positive cells was reported to be not significantly 
different between PD-L1-positive and PD-L1-negative head and neck SCC (Kim et 
al., 2016), the relationship between PD-L1 expression types and the frequency and 
distribution of CD3 positive cells has rarely been explored in NPC. Therefore, I 
studied the distribution of CD3-expressing cells in relation to PD-L1 expression in 
tumour cells in the series of 17 NPC cases that were co-stained by IF. I found that 
in all marginal type cases, T cells were in contact with tumour cells at the tumour-
stroma interface, with a high density of T cells in 7/8 cases; most cases also showed 
a non-uniform distribution of T cells with focal clustering of a high density of CD3 
positive T cells (Figure 3.16 A-C; Table 3.15). Next, I examined the distribution of 
CD3 positive cells in samples with diffuse expression of PD-L1. The density of CD3 
positive T lymphocytes in the diffuse/constitutive type was variable among cases 
but uniform, with no clustering in any case (Figure 3.16 D).  
Next, I wanted to examine if CD3 expression was correlated with PD-L1 expression 
in NPC. To do this I initially took advantage of the re-analysis of Dataset 5 described 
above (Dong H., 2016). Figure 3.17 A shows a strong positive correlation between 
CD3 and PD-L1 mRNA expression in NPC (r=0.97; p=<0.0001). I also correlated H-
scores for PD-L1 with CD3 counts in both the intra-tumour and stromal 
compartments. Surprisingly, I found no significant correlation between PD-L1 
expression and CD3 counts in either the intra-tumour or the stroma (Figure 3.17 B). 
Furthermore, I observed no significant difference in the frequency of intra- tumour 
or stromal CD3 density with PD-L1 scores using Inform and H-scores as shown in 
Figure 3.17 C and stromal CD3 positive cells between NPC tumours displaying 
either the marginal or diffuse patterns of PD-L1 expression. 
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Figure 3.16 Multiplex IF and graphical representation of CD3 distribution and correlative analysis of CD3 with PD-L1 in constitutive and marginal 
type of PD-L1 expression NPC A) Diffuse type of PD-L1 positive NPC stained with CD3 (red), and PD-L1 (green). PD-L1 is observed diffusely in the tumour 
cells. Tumour sample is uniformly highly populated with CD3 in both the tumour and stromal compartments (white arrows). B) Example of diffuse type which 
displayed low levels of CD3 (red) positive cells in both tumour and stroma compartments (white arrows), C) An example of marginal type, with non-uniform 
aggregation of CD3 (red) at the white arrow around the peripheral PD-L1 (green) positivity in the tumour at the red arrow. 
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PD-L1-CD3 
High TILs uniform 
 (non uniform at interface) 
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Table 3.15 Topographic description of CD3 in relation to marginal type of PD-L1 
positive tumours 
 
Case 
number 
CD3 at contact of PD-
L1 +ve tumour cells 
CD3 density at the PD-L1 
positive tumour interface 
with the stroma 
CD3 distribution at the 
PD-L1 positive tumour 
interface with the 
stroma 
2 Present High uniform  
7 Present Low uniform  
10 Present High Non-uniform  
12 Present high  uniform  
16 Present low uniform  
17 Present high Non uniform  
18 Present  high  Non uniform  
22 Present  high Non uniform  
 
Table 3.17 summarises the topographic distribution of CD3 in relation of PD-L1 tumour 
positive cells. 
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Figure 3.17 Correlation between CD3 and PD-L1 expression in NPC 
A) Graphs show a strong positive correlation between CD3 and PD-L1 mRNA 
expression in NPC (r= 0.97; p<0.0001), B) Graph shows that the frequency of CD3-
positive cells was not significantly different between NPC displaying either a diffuse or 
marginal pattern of PD-L1 expression, p=0.74.  
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C) Graphs show that the frequency of CD3-positive cells in the intra-tumour compartment is 
not correlated with PD-L1 scores.  
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3.2.8 Subcellular localization of PD-L1 in NPC  
A different sub-cellular localization of PD-L1 staining i.e. cytoplasmic, or 
membranous (either complete or incomplete) has been reported in different solid 
and hematological tumours using the FDA-approved PD-L1 antibody 
(Scognamiglio et al., 2016). However, a detailed description of the sub-cellular 
localization of PD-L1 has been rarely reported in NPC. PD-L1 expression was 
described by Zheng et al in NPC, with the most commonly cytoplasm-mainly 
tumors represents 65.9% of patients, while mixed cytoplasmic and membranous 
pattern of PD-L1 positivity were described in 24.7% of patients. Membrane mainly 
tumour were the least frequent representing 9.4% (Zheng et al., 2017). High 
expression of cytomembranous pattern was associated with inferior outcome in 
loco-regional advanced NPC (Zheng et al., 2017). I found that all PD-L1 positive 
tumours showed incomplete membranous staining, complete membranous in 
12/16 cases, and cytoplasmic in 11/16 cases. In total 14/16 NPC showed mixed 
patterns of PD-L1 localization (Table 3.16). Incomplete was observed as partial 
membrane staining and complete as circumferential membrane staining. An 
illustration of these different patterns in a diffuse type of PD-L1- expressing tumour 
is shown in Figure 3.18.
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Figure 3.18 show different patterns of the sub-cellular localization of PD-L1 expression in NPC. An example of diffuse type of 
PD-L1 (green) expression in NPC, with membranous complete (white arrow), membranous incomplete (white broken arrow) in 
addition to cytoplasmic staining (head white arrow head), (20X).  
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Table 3.16 indicates presence of either membranous (complete or incomplete), 
cytoplasmic or mixed staining.  
 
Case 
number 
Membranous 
Cytoplasmic 
Mixed 
(Either membranous complete,  
membranous incomplete +/- 
cytoplasmic) 
Complete Incomplete 
1  + + + + 
2  + + - + 
 4  + + + + 
7  + + + + 
 8  - - - - 
 9  + + + + 
10  - + + + 
11  + + + + 
12  + + - + 
14  + + + + 
15  + + + + 
16  - + - - 
17  - + - - 
18  + + -  + 
20  + + + + 
21  + + + + 
22 - + + + 
Total 12 16 11 14 
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3.2.9 Classification of PD-L1 expression into tumour predominant and 
immune predominant types 
I next classified the NPC samples into immune predominant or tumour 
predominant, based on the cell phenotype in which PD-L1 is most highly 
expressed. Tumour predominant was defined as PD-L1 expressing cells are 
observed more in the tumour cells than the immune cells (TILs or others), while 
immune predominant was defined as PD-L1 expressing cells are dominantly 
immune cells (TILs or other) more than the positivity observed in the tumour cells. 
This was based on a recent study of head and neck SCC that classified PD-L1 
phenotypes into immune predominant or tumour predominant. This is important 
because in these tumours the immune predominant form confers a better survival 
independently of other clinical parameters, including HPV status and stage 
(Heeren et al., 2016). I found that 14/16 cases were of tumour predominant type, 
and only 2 were of immune phenotype type (Table 3.17). Examples of both types 
are shown in Figure 3.19. 
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Figure 3.19 Classification of PD-L1 expression into tumour predominant and immune predominant subtypes, Top panel, Tumour 
predominant type: PD-L1 expression (green) is predominantly present in the tumour (broken white arrows) and in few CD3 T cells expressing 
PD-L1 (white arrows). Bottom panel, Immune predominant type: PD-L1 is expressed mainly by immune cells, such as CD3 cells (white arrows) 
and in few tumour cells (broken white arrows) 20X. 
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Table 3.17 summarizes PD-L1 expression patterns in NPC 
Case 
number 
Tumour 
predominant 
(TP) versus 
immune 
predominant (IP) 
PD-L1 positive intra-tumour assessment 
PD-L1 positive 
stroma 
assessment 
PD-L1 expression by 
tumour 
PD-L1 +ve  CD3 T 
cells 
PD-L1 +ve  
CD3 T cells 
1 TP Diffuse Present  (low) Present (low) 
2 TP Marginal (circumferential) Present (low) Present (low) 
 4 TP Diffuse Absent  Present (low) 
7 TP Diffuse Present (low) Present (low) 
 8 Negative Negative Negative Negative 
 9 TP Diffuse Present (low) Present (low) 
10 TP Marginal  (focal)  Present (low) Present (low) 
11 TP Diffuse Present (high) Present (low) 
12 IP Marginal (focal)  Present (low) Present (high) 
14 TP Diffuse Present (low) Present (low) 
15 TP Diffuse Present (low) Present (low) 
16 TP Marginal (focal)  Present (low) Present (low) 
17 IP Marginal (focal) Present (low) Present (low) 
18 TP Marginal (circumferential) Present (low) Present (high) 
20 TP Diffuse Present (low) Present (low) 
21 TP Marginal (focal)  Present (low) Present (high) 
22 TP Marginal (focal)  Present (low) Absent 
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3.2.10 T cells expressing PD1 are in direct contact with PD-L1 positive NPC 
tumour cells 
PD-L1 was only expressed on immune cells, and not on tumour cells. PD1-positive 
T cells were in direct contact with PD-L1 positive tumour cells (Figure 3.20 A-E). 
Next, I examined the correlation between PD1 and PD-L1 frequency in the tumour 
versus stroma. Figure 3.21 F, is an illustration of scatter plotting of all cases, for PD-
L1 versus PD1 frequency in the intra-tumour compartment and Figure 3.20 G plot 
for PD-L1 and PD1 in the stroma. I found no significant correlation between PD-L1 
and PD1 expression in the intra-tumour compartment (r= 0.1494 and p=0.592), 
while I found a significant correlation using Pearson correlation between PD1 and 
PD-L1 expression in the stroma (r= 0.74 and p=0.000683). PD1 correlates with the 
PD-L1 expression in the stroma but not in tumour. This can be explained by higher 
level of expression of PD-L1 (tumour) more than PD1 (tumour), mean of scores were 
27.98% and 13.6%, respectively. This can be explained by the presence of half of 
the samples were PD-L1 expressing -diffuse type. In addition, PD-L1 was present 
more in the tumour (27.98%) not the stroma (9.69%), respectively, this is matching 
with tumour predominant and immune predominant classification seen in figure 
3.19. 
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Figure 3.20 Multiplex co-staining for PDL-1-PD1-CD3 expression in NPC A-B) PD1 (yellow) is expressed in CD3-positive cells (red) at white 
arrows, C) show that these cells are in direct contact with PD-L1 (green) positive tumour cells (broken white arrows),  D) DAPI staining the nuclei 
(blue), E) Merged of all channels (20X), (T) indicates tumour, (S) indicates stroma.  
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F-G) Plot show a significant positive correlation between the frequency of PD-L1 and PD1 positive cells in the stroma but 
not in the tumour compartment. 
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3.2.11 T cell expression of PD-L1 in NPC  
14/17 cases showed PD-L1 expression on CD3-positive T cells. PD-L1 expressing 
T cells were predominantly in the intra-tumour compartment as opposed to the 
stroma (mean PDL-1 positive/all CD3+=17.64 versus 6.6, respectively; p=0.01; 
Figure 3.21 and Figure 3.22). There was no significant difference in the frequency 
(percentage of positive cells) of PD-L1 expression in T cells between diffuse and 
marginal type NPC. 
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Figure 3.21 Expression of PD-L1 in CD3 positive cells in NPC Four panels, showing tumour and stromal compartments showing scattered T 
cells highlighted with CD3 (red) are seen expressing PD-L1 at the white arrow, 20X. (T) indicates tumour, (S) indicates stroma. 
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Figure 3.22 Significant enrichment of CD3 expressing PD-L1 as represented by 
CD3-PD-L1 double phenotype, in intra-tumour and stroma 
A) The graph shows the proportion of CD3 expressing PD-L1 with significant difference 
between PD-L1 double positive CD3 distributed in tumour or stroma,  (p= 0.01), B) 
however, there were no significant difference between CD3 expressing PD-L1 in marginal 
and diffuse types.   
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In summary the data on PD-L1 expression in NPC shows that it: 
 is higher in NPC compared to normal epithelium 
 is not correlated with LMP-1 expression in primary NPC 
 is correlated with the expression of other immune checkpoints, particularly 
PD-L2 
 is correlated with PD1 expression in the stroma 
 can be either diffuse or marginal 
 can be expressed on T cells particularly in the intra-tumour compartment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 166 
 
3.3 RESULTS PART TWO:  Frequency of cells expressing FOXP3, CD4, CD8 
and CD20 in NPC 
In the following section, I focus my description of the microenvironment of NPC on 
an analysis of the phenotype of T cells, and the presence of B cells.  
3.3.1 Optimizing a lymphocyte subpopulation panel in tonsil 
 
First, I tested the staining for the following markers: CD8, FOXP3 and CD20 
(hereafter referred to as the ‘lymphocyte subpopulation panel’). CD20 stains the 
GCB cells and the mantle zone B cells, while for T cell subsets, CD8 was positive 
in numerous extra-follicular T cells and FOXP3 was shown to be positive in the 
nuclei of T lymphocytes in the GC and in the inter-follicular regions (Figure 3.23). 
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Figure 3.23 Multiplex IF for the ‘lymphocyte subpopulation panel’ 
CD8 (yellow) stains mainly within the T cell zone (white arrows), FOXP3 (pink) is expressed by scattered  lymphocytes, inside and 
many of the  cells outside the GC (white arrows), CD20 (magenta) is expressed in GC and mantle zone naïve B cells (white arrows), 
left lower panel DAPI staining the nuclei (blue), (20X). (GC) indicates germinal centre, (MZ) indicates mantle zone. 
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3.3.2 Frequency of T and B cells in NPC 
Next, I measured the frequency of the sub-population of cells stained with the 
‘lymphocyte subpopulation panel’ (Table 3.18). There were no significant 
differences in the frequency of cells positive for CD8, FOXP3 and CD20, in the 
tumour compared with the stroma (Figure 3.24). 
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Table 3.18 Summary of quantification of frequency of CD8, CD20 and FOXP3 positive cells 
distributed in the tumour and stroma using the lymphocyte multiplex panel 
Case ID 
% of CD8 +ve cells % of FOXP3 +ve cells % of CD20 +ve cells 
Tumour Stroma Tumour Stroma Tumour Stroma 
1 4.1 4.9 2.1 1 4 3.3 
2 11 18.1 2.8 3.4 13.7 21.2 
4 33.4 25.5 31 10.4 1.1 9.5 
7 2.7 3.3 1.3 1.5 6.6 15.9 
8 7.3 2.5 7 4.2 1.8 7.1 
9 15.4 27 7.5 11.2 3.9 19.8 
10 43.6 22.5 16.5 4 5.4 3.3 
11 9.8 9.4 4.3 13.4 7.7 3 
12 11 10.8 73.9 44.1 3 9.4 
14 21 10.4 8.2 2 1.9 2 
15 3.9 2.7 0.1 0.4 31.3 25.2 
16 4.6 2.8 2.4 1.2 1.1 1.4 
17 4.3 7.5 0.9 0.9 4.1 0.5 
18 5.2 14.7 4.5 4.8 4.9 3.4 
20 13.6 8.8 10.6 7.8 24.5 14.3 
21 16.8 11 1.9 2.8 8.4 9.3 
22 17.2 46.6 9.5 19.2 1.7 1.5 
Median 10.4 9.9 5.8 4.1 4.5 8.2 
SD 11 11.1 17.4 10.4 9.1 7.6 
SD indicates standard deviation, +ve indicates positive. 
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Figure 3.24 Frequency of CD8, FOXP3 and CD20-positive cells in stroma and 
tumour of NPC  
There were no significant differences in the frequency of cells positive for CD8, FOXP3 
and CD20, in the tumour compared with the stroma.  
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3.3.3 FOXP3 is present in the majority of CD3-positive and CD4-positive but 
rare in CD8 positive T cells in NPC 
I co-stained a subset (8 cases) of NPC tumours for CD4, CD3, CD8 and FOXP3. I 
found that most FOXP3 expressing cells were CD3 and CD4-positive, whereas only 
a minority were CD8-positive (Figure 3.25). 
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Figure 3.25 Phenotypic analyses of FOXP3 positive cells in NPC 
FOXP3 is present in the majority of CD3/CD4-positive T cells but rare in CD8 positive T cells in NPC. A) FOXP3 (pink) is in the nuclei 
of scattered CD3 positive T cells (cyan) at the white arrows head. Occasional FOXP3 positive cells are negative for CD3 at the red 
arrow. B) FOXP3 (pink) is positive in the nuclei of scattered CD4 (green)-positive cells (white arrows head). C) FOXP3 (pink) is 
positive in the nuclei of immune cells (red arrow), and occasional nuclei of CD8 positive T cells (yellow) at the white arrow (20X), (T) 
indicates tumour, (S) indicates stroma. 
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3.4 RESULTS PART THREE: MHC class I and MHC class II expression in 
NPC 
In the final section, I describe the results of IHC for MHC class I and class II 
expression in NPC. 
3.4.1 MHC class I protein expression in NPC 
 
MHC class I expression was measured by H-score in tumour and adjacent 
epithelium. Immune cells were used as a positive internal control. MHC class I was 
negative in 1/19 NPC. In 18/18 cases tumour cells were heterogeneously positive. 
12/18 patients had a tumour MHC class I H-score lower than the median of the 
normal epithelium (Figure 3.26 and Table 3.19). MHC class I expression patterns 
in tumour were as follows: MHC class I was strongly expressed in tumour cells in a 
diffuse pattern (constitutively high) Figure 3.27 A, while other tumours showed 
decreased expression of MHC class I with some groups of tumour cells positively 
stained, while others were negative (beneath the positive covering epithelium) 
(Figure 3.27 B).
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Figure 3.26 MHC class I IHC H-scores in NPC tumour cells compared with the 
covering epithelium  
MHC class I was negative in 1/19 NPC. In 18/18 cases tumour cells were 
heterogeneously positive for MHC class I but in 12/18 cases expression was lower 
than the median of that in covering epithelium (Table 3.19)
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Table 3.19 Results of MHC class I IHC expression in tumour and covering 
epithelium  
 
Case 
number 
Tumour H-
score 
MHC class I status 
of stromal cells 
Covering epithelium H-
score 
1 
140 Positive 160 
2 
260 Positive 120 
4 
130 Positive 160 
6 
270 Positive 270 
7 
85 Positive 270 
8 
190 Positive 270 
9 
170 Positive 180 
10 
80 Positive NA 
11 
170 Positive 160 
12 
210 Positive 270 
14 
270 Positive 120 
15 
140 Positive 270 
16 
130 Positive NA 
17 
250 Positive 270 
18 
220 Positive NA 
20 
0 Positive 270 
21 
240 Positive 270 
22 
240 Positive 270 
Median 
180  270 
Mean 
177.5  218.6 
SD 
75.5  63.5 
SD indicates standard deviation, +ve indicates positive, NA indicates non available. 
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Figure 3.27 MHC class I expression in NPC  
A) MHC class I is strongly positive in tumour cells (black arrows), 20X, B) Tumour cells are focally positive for MHC class I (black arrows), 
with some tumour clusters negative. Covering epithelium is strongly positive (red arrow), 20X, (T) indicates tumour, (S) indicates stroma. 
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3.4.2 MHC class II protein expression in NPC 
MHC class II was absent in 1/19 cases. 18/19 cases were positive but 
heterogeneously. 10/18 patients had a tumour MHC class II H-score lower than the 
median of the covering epithelium (Figure 3.28 and Table 3.23). I found that thirteen 
NPC patients had MHC class II positive stromal cells. Two patients had scattered 
MHC class II positive TILs. Two patients had few MHC class II positive TILs. These 
stromal cells may include tumour-associated macrophages and TILs, but to 
distinguish and confirm this will require extra-stains. (Figures 3.29-3.31).  
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Figure 3.28 MHC class II H-scores in the NPC tumour cells and the covering 
epithelium  
MHC class II was absent in 1/19 cases, which was strongly stained for MHC class 
I. 18/19 cases were positive for MHC class II but heterogeneously. 10/18 patients 
had a tumour MHC class II H-score lower than the median of the covering 
epithelium.  
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Table 3.20 Results of MHC class II IHC expression in tumour and covering 
epithelium  
 
Case 
number 
Tumour H-
score 
MHC II status of 
stromal cells 
Covering 
epithelium H-score 
1 
270 Positive 270 
2 
260 Positive 270 
4 
210 Positive 100 
6 
80 Positive 100 
7 
120 Positive NA 
8 
160 Positive 270 
9 
270 Positive 270 
10 
40 Positive 120 
11 
240 Positive NA 
12 
80 Positive 80 
14 
270 Positive NA 
15 
120 Positive NA 
16 
0 Positive NA 
17 
110 Positive NA 
18 
120 Positive 120 
20 
80 Positive NA 
21 
200 Positive NA 
22 
210 Positive NA 
Median 
10.4  195 
Mean 
157.8  187 
SD 
86  88.2 
 
SD indicates standard deviation, +ve indicates positive, NA indicates non available.
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Figure 3.29 MHC class II expression in NPC A) MHC class II was strongly positive in stromal cells (red arrows), but negative in the tumour 
cells (white arrows) 20X, B) Tumour cells are focally positive (white arrows), while the covering  epithelium is strongly positive (red arrows), 20X, 
C) Tumour cells showing heterogeneous pattern, some tumour cells are weakly positive while others are moderately stained (white arrows) 20X, 
D) MHC class II diffuse strong positive in tumour cells (white arrows) 20X, (T) indicates tumour, (S) indicates stroma. 
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Figure 3.30 MHC class II expression in TILs of NPCA) MHC class II negative case (white arrows), with sparse TILs that are positive for 
MHC class II (red arrows), 20X B) 20X, Tumour is diffusely positive (white arrows) with scattered positive TILs within the tumour (red 
arrows) TILs indicates Tumour infiltrating lymphocytes.  
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Figure 3.31 MHC class II expression in overlying epithelium  
A) MHC class II was positive partially in the dysplastic epithelium (red arrows), while the adjacent normal looking epithelium was 
negative (black arrows) 20X B) Another example showing covering epithelium positive in the upper two thirds of the epithelium (red 
arrows), negative is labelled at the white arrows. The underlying stromal cells are also positive (white arrows), D) 20X. 
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3.4.3 MHC class I and class II expression in NPC 
 
Next, I explored if MHC class I and MHC class II were co-expressed or 
downregulated in the same sections. I identified three patterns: A) Tumours with 
high H-scores for both markers, B) tumours with high H-scores for MHC class I but 
lower MHC class II scores or C) vice versa. Low and high MHC class I and II scores 
were defined based on the value of the median of the H-score, in the case of MHC 
class I the median was 170, while for MHC class II, the median was 160. (Figure 
3.32 and table 3.21.  
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Figure 3.32 MHC class I and MHC class II IHC expression H-scores by 
tumour cells 
H-scores of MHC class I and MHC class II expression for each patient are shown. 
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Table 3.21 An illustration of MHC class I and class II scores in matched NPC 
cases  
 
MHC-I and-II score classification 
Number of 
cases 
Tumours with low both MHC class I and-II 5 
Tumours with high H-scores for both markers 6 
Tumours with high H-scores for MHC class I but lower MHC 
class II scores 
3 
Tumour with absent MHC class I and low MHC class II 1 
Tumour with absent MHC class I and low MHC class II 1 
Tumours with high H-scores for MHC class II but lower 
MHC class I scores 
2 
Total number of cases 18 
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3.4.4 Correlation of NPC IHC data 
Finally, I was interested to explore the possible correlation between all of the 
markers I had stained on a whole cohort basis. To do this a correlation matrix was 
created in which each marker was compared to all the others (Figure 3.33). This 
analysis revealed several interesting correlations. First, it showed a correlation 
between; MHC class I expression and PD1-positive immune cells in the tumour 
(r=0.43), MHC class I and MHC class II expression and CD3+ cells in the stroma 
(r=0.43 and 0.45 respectively); and MHC class II expression on the tumour cells and 
PD-L1 expression on the tumour cells (r=0.61). These results might have been 
expected since MHC expression would be required for the presentation of viral or 
cellular neo-epitopes to T cells. 
This analysis also revealed a correlation between CD3+ cells and CD8+ cells in the 
tumour and stroma (r=0.35 and r=0.53, respectively), as well as FOXP3+ cells in 
the tumour (r=0.35). There was also a strong correlation between CD8+ cells in the 
tumour or stroma and FOXP3+ cells in tumour or stroma (r=0.57-0.77), this 
correlation between T-reg and CD8+ cells may indicate active immune response, 
recruiting T-reg, suggesting that high numbers of CD8+ cells may be functionally 
inhibited by T-regs. T-regs infiltration was reported to be associated with 
immunosuppression and tumour development in various cancers (Szylberg et al., 
2016). Positive correlation of stromal CD3+ cells, CD8+ cells with stromal PD-L1+ 
cells and PD1+ cells may implicate the presence of anti-tumour immune response 
which may induce PD-L1 overexpression. On the contrast to the aforementioned 
findings in the stroma, intra-tumoural CD3+ cells was negatively correlated with 
PD1+ and PD-L1+ cells in the tumour. This can be interesting, because previous 
report in colorectal immunoscore showed that low tumoural CD3 density was 
associated with inferior outcome (Zhu et al., 2017). No correlation was observed 
between CD3 expression in the tumour and stromal compartments, which could be 
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explained by local inhibitory mechanisms within the tumour microenvironment which 
exclude T cells from the tumour (i.e. T cells remain preferentially localised within the 
stroma). Only weak correlation observed between PD-L1 expression within the 
tumour (T) and stromal (S) compartments, probably reflecting the different 
mechanisms controlling expression. For half of the cases (8/16) PD-L1 tumour 
expression was described as diffuse (intrinsic), which may result from tumour-
specific changes such as increased NF-ĸB signalling, AKT-mTOR pathway 
activation, loss of PTEN etc. Marginal PD-L1 expressing tumour may be up-
regulated by extrinsic mechanisms, such as induction by IFNγ or other inflammatory 
cytokines which will also act via the PI3K-Akt-mTOR pathway. A positive correlation 
was observed between stromal CD3+ cells and tumour and stromal PD-L1+ cells. 
As previously noted, PD-L1 expression may be induced by inflammatory cytokines, 
such as IFNγ, produced by T cells. The observed tumour PD-L1+ cells expression 
patterns include both marginal and diffuse; marginal is most often described as 
cytokine-induced, but diffuse (intrinsic) expression may still be increased by extrinsic 
mechanisms such as inflammatory cytokines. This is in broad agreement with the 
analysis of individual samples (Fig. 3.17 C), where a weak positive correlation was 
shown between CD3+ cells stroma and both PD-L1+ cells in the tumour and stroma. 
No or only weak correlation (positive or negative) observed between all of the 
lymphocyte subsets analysed (CD3, CD8, FOXP3, CD20) and PD1 which raises the 
question as to which cells are expressing PD1 as non T cells, such as NK cells or 
possibly macrophages or dendritic cells, as reported in other cancers that PD1 can 
be presented on non T cells, which needs to be further determined. 
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Figure 3.33 Correlation matrix of IHC protein expression levels determined by 
Inform/H-score for each marker used in this study Correlation matrix for 15 
cases of NPC using Spearman's test for each marker. Apart from MHC class I and 
MHC class II (H-scores were used), all parameters are the frequency of cells positive 
for the marker in the tumour or stroma compartment. T indicates tumour, s indicates 
stroma. 
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3.5 DISCUSSION 
In this study, I have described in detail the phenotypic characteristics of the tumour 
immune microenvironment of NPC, focussing on T cell phenotypes and especially 
on the expression of the T cell immune checkpoint mediated by PD-L1/PD1. There 
is currently much interest in using PD-L1/PD1 inhibitors against virus-associated 
cancers, such as NPC  (Hsu et al., 2015). 
Results from current clinical trials using FDA approved PD1 inhibitors have been 
reported. One trial employed Pembrolizumab in patients with recurrent metastatic 
NPC and showed an overall response rate of 25.9% (27 patients: 1 CR, 6 PR, and 
14 stable disease), in addition to other promising results in the form of reduction in 
target lesion size. In this trial, progression free survival (PFS) was reported to be 
49.7% after 6 months and 28.9% after 12 months; the median duration of response 
was 10.8 months (Hsu et al., 2017). Another phase II study using Nivolumab 
monotherapy, which has recruited 43 patients with recurrent and metastatic NPC is 
currently in progress. This study has reported an overall response rate of 19%, 
suggesting effectiveness of PD1 blockade in endemic non keratinizing NPC patients 
(NCT02339558) (Ma et al., 2017). 
I have confirmed previous studies that report the over-expression of PD-L1 in NPC. 
Perhaps somewhat surprisingly, I was not able to show that PD-L1 expression was 
significantly higher in cases that were LMP1-positive, given that LMP-1 has been 
shown to induce PD-L1 expression in cell lines. This is presumably because non-
viral mechanisms to induce PD-L1 expression are operational in cases of LMP-1-
negative NPC. In a recent study of the mutational landscape of NPC, it was shown 
that LMP-1 expression and mutations affecting negative regulators of NF-ĸB 
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expression (found in 41% of cases) are  mutually exclusive in NPC, both pathways 
can lead to PD-L1 expression (Li et al., 2017). This can point to the non LMP1-
pathway mediated through NF-ĸB and could explain why I did not observe a 
correlation between PD-L1 and LMP-1 in my study. PD-L1 has also been shown to 
be upregulated by INF-γ in malignant melanoma cell lines (Gowrishankar et al., 
2015). This was mediated through activation of NF-κB and this mechanism was 
restricted to the inducible type of PD-L1 expression, however the underlying 
mechanism of constitutive type of PD-L1 in NPC is still unresolved (Gowrishankar 
et al., 2015).  Co-expression of immune checkpoint genes (PD-L1 and IDO1) were 
reported in a transcriptome analysis performed on muscle invasive bladder cancers, 
by re-analysis of the Cancer Genome Atlas (TCGA) and these immune checkpoint 
genes were identified in an immune genes cluster associated with an aggressive 
phenotype and d with poor outcome (Ren et al., 2017). Recent data showed 
promising response to combined immune checkpoint inhibitors, of PD1 (Nivolumab) 
and CTLA4 (Ipilimumab), in late stage malignant melanoma, with response to 
treatment reaching 60% (Larkin et al., 2015). The combination of CTLA-4 and PD1 
blockade has been the most successful of all combinations currently tested, and is 
approved for the treatment of advanced melanoma (Callahan et al., 2016). PD1 
and CTLA-4 blockade in melanoma patients showed an increased rate of objective 
tumour responses as compared to blocking either checkpoint alone, supporting the 
notion that combinatorial checkpoint blockade may result in increased clinical 
benefit, with response rates of 40% across all dose levels examined (Wolchok et 
al., 2013).  One striking feature of this combination was the relatively high rate of 
complete responses or near-complete responses, however relatively high rate of 
toxicities were also observed (Callahan, 2016). Currently, there is an ongoing 
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Phase II clinical trial recruiting 35 patients with advanced stage NPC, to assess 
responses to both Ipilimumab and Nivolumab (NCT03097939) (Van Waes and 
Musbahi, 2017). 
I found in the re-analysis of RNA-seq data from LMP-1 positive NPC patients that 
there was a significant positive correlation between the expression of PD-L1 with 
other immune checkpoints (PD-L2, HAVCR2, LAG3, ADORA2A, CTLA4, IDO1, 
BTLA followed by PD1). Importantly, apart from IDO1, these immune checkpoints 
have so far not been shown in NPC and need further investigation for potential future 
combinational therapy. For example, LAG3 and PD1 were shown to be co-
expressed in TILs infiltrating murine ovarian cancer. This co-expression showed 
synergistic inhibitory action on T lymphocytes and inhibited the growth of the ovarian 
cancer, this was the observed with combined LAG3 and PD1 inhibition (Huang et 
al., 2015). In my study, I found significant positive correlation between PD1 and 
LAG3 in NPC, similar to that described in a study of colorectal cancer (Lal et al., 
2015). 
Importantly, PD-L1 was observed in both the tumour cells and the cells of the 
stroma, suggesting a contribution to this checkpoint from non-tumour cell 
populations. Regarding the distribution of PD-L1, almost half of patients had a 
diffuse pattern of PD-L1 staining in their tumours, a pattern which may reflect an 
intrinsic underlying mechanism, such as amplification as described in other tumours 
as head and neck SCC. Compared to the marginal type of PD-L1 expression, this 
constitutive/diffuse pattern was recently described to be associated with poor 
outcomes in patients with head and neck SCC (Heeren et al., 2016)  
PTEN loss was reported to induce up-regulation of PD-L1 in colorectal cancer and 
to be associated with aggressive phenotype and associated with high potentiality 
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for metastasis (Song et al., 2013). Whether mutations in PTEN in NPC impact on 
PD-L1 expression has not yet been explored. However, recent studies have shown 
that recurrent mutations involving the PI3-K pathway with involvement of mutations 
in PTEN gene, was not commonly observed in NPC (Li et al., 2017). PTEN loss 
was shown in different types of cancer such as in glioma, breast and prostate and 
can increase PD-L1 expression mediated through activation of the AKT–mTOR 
pathway (Parsa et al., 2007).  
Clearly, studies assessing the impact of the pattern of PD-L1 expression on patient 
outcomes are warranted in NPC. The description in the present study, of the 
existence of focal and circumferential forms of marginal expression is novel and will 
also require future studies, both laboratory and clinical-based, in order to determine 
the significance of this finding. 
I also observed a high density of PD1 expressing T cells in some NPC, which is in 
accordance with previous studies on NPC which showed high infiltration of PD1 
positive immune cells (Zhou et al., 2017b, Zhang et al., 2015). The co-expression 
of PD1 and PD-L1 is reported to be associated with decreased disease free survival 
in NPC patients (Zhang et al., 2015). . However, overall I observed a weak negative 
correlation between PD1 and PD-L1 in the patient cohort studied. In passing I note 
that one patient with a particularly high frequency of PD-L1-positive cells also had a 
high frequency of PD1-positive cells. 
I have also seen that NPC tumours can recruit FOXP3-expressing cells and these 
were present both within the tumour and the stroma, although more of them were 
present in the tumour areas. These results are broadly in agreement with data 
reported by Yip et al (Yip et al., 2009).  Many of these FOXP3-expressing cells were 
CD4-positive, rather than CD8-positive T cells. In addition to regulatory T cells, the 
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presence of B cells in the microenvironment could also suppress the function of CD8 
cells and also potentially convert effector T cells to T-reg (Schwartz et al., 2016). 
Moreover, B cells were reported to have good or bad prognosis in different disease 
settings (Schwartz et al., 2016). If infiltrating B-cells in the NPC microenvironment 
are suppressive then they may represent a therapeutic opportunity given the 
availability of B-cell depleting monoclonal antibodies such as Rituximab.  
Given the critical role of MHC class I in target cell recognition by cytotoxic T-cells, 
it is unsurprising that MHC class I downregulation is a common feature of many 
cancers, including NPC (Yao et al., 2000). My results are similar to previous 
reports. Thus, we observed patients with normal MHC class I levels and other 
patients with reduced MHC class I on the tumour cells. PD-L1 was reported to be 
mutually exclusive with MHC class I expression in ovarian surface epithelial 
serous tumours (Aust et al., 2017) and represents two different evasive 
mechanisms, however I reported different features in NPC tumours, MHC class I 
was down-regulated in one case, but PD-L1 expression was preserved in the 
tumour and vice versa, which suggest the simultaneous involvement of two 
different evasive mechanisms in NPC tumours, unlike ovarian serous tumours 
which display two mutually exclusive immune escape mechanisms. 
I also observed MHC class II expression on the NPC tumour cells, again a range of 
expression levels was noted across the patient cohort as has been described by 
previous work (Yao et al., 2000) . The expression of MHC class II by the tumour 
cells could render them visible to CD4+ T-cells which are increasingly being shown 
to act as direct effectors in the context of human malignancy (Perez-Diez et al., 
2007, Quezada et al., 2010). We note that the tumour of four out of seven patients 
had reduced MHC class I expression (H-score < median H-score of 180) but these 
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tumours had levels of MHC class II expression that exceeded the median MHC class 
II H-score. This result suggests that boosting an effective EBNA1- T-cell response 
(which is primarily mediated through MHC class II) could potentially be a good 
method to overcome the MHC class I down-regulation that frequently occurs in NPC.  
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CHAPTER FOUR 
 
EXPRESSION OF COLLAGENS AND COLLAGEN RECEPTORS IN 
DIFFUSE LARGE B CELL LYMPHOMA 
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4.2 INTRODUCTION 
DLBCL is a tumour derived from the malignant transformation of B cells undergoing 
clonal expansion in the GC. The pathogenesis of this tumour is complex; with a 
common histology underpinned by a unique biology that explains an observed 
difference in clinical outcome (Pasqualucci and Dalla-Favera, 2015). Gene 
expression profiling has identified two major DLBCL subgroups, referred to as the 
GCB and ABC forms, which are believed to originate from distinct stages of B cell 
differentiation (Alizadeh et al., 2000). Thus, GCB DLBCL is characterised by the 
expression of typical GC markers such as BCL6 and CD10, whereas ABC DLBCL 
expresses markers of a later stage of B cell differentiation, such as IRF4  (Meyer et 
al., 2010). These two subgroups of DLBCL are also characterised by distinct 
molecular abnormalities (Swerdlow et al., 2016). For example, GCB DLBCL may 
be defined by translocations leading to BCL2 over-expression, mutations of the 
histone methyltransferase EZH2, and deletions of PTEN, all of which are rarely 
encountered in ABC DLBCL (Testoni et al., 2015). In contrast, ABC DLBCL is 
associated with chronic active B cell receptor (BCR) signalling and NF-ĸB 
deregulation (Bohers et al., 2014). The clinical significance of this COO is evident 
in R-CHOP-treated patients, whereby ABC DLBCL has a substantially inferior 
outcome (Alizadeh et al., 2000) . In light of these clinical implications, the new WHO 
classification recognizes these DLBCL subtypes as separate diagnostic entities 
(Swerdlow et al., 2016).  
Other studies suggest that the DLBCL microenvironment is an important indicator 
of outcome. Lenz, et al. defined two stromal signatures which, when combined into 
a single stromal score, predicted the survival of DLBCL patients (Lenz et al., 2008). 
Importantly, the stromal score was present across both the GCB and ABC subtypes, 
suggesting that similar tumour microenvironment features could be acquired during 
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the pathogenesis of both of the major forms of DLBCL (Lenz et al., 2008). Genes 
defining the stromal-1 signature were enriched for those encoding extracellular 
matrix components, including collagens such as DDR-2 and collagens (e.g 
COL1A2, COL1A1 and COL5A1, COL5A2, COL6A2, COL6A3, COL8A2) , modifiers 
of collagen synthesis and genes which are initiators of fibrogensis (Lenz et al., 
2008). Also enriched in the stromal-1 signature was a “monocyte” profile, comprising 
of genes that were more highly expressed in CD14+ blood monocytes than in B 
cells, T cells, or natural killer cells. It included genes related to macrophages such 
as colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte- 
macrophage) (CSF2RA), which is growth factor receptor important in macrophages. 
Furthermore positive correlation between the expression of collagen and monocyte 
genes was found (Lenz et al., 2008).  
Many tumour types are characterised by increased fibrosis commonly involving the 
deposition of collagens I and III (Kauppila et al., 1998) (Santala et al., 1999). 
Furthermore, there is a growing recognition of the importance of collagens, not 
simply as structural components of the extracellular matrix, but also as ligands which 
can influence signalling in both tumour and stromal cell compartments. At least 
thirteen different collagen receptors are encoded by the human genome, many of 
which are implicated in cancer-related processes; including cell proliferation, 
survival, migration and evasion of immune response (Multhaupt et al., 2016). 
In this study I have explored the expression of collagens and collagen receptors in 
DLBCL, focussing mainly on two collagen receptors: LAIR-1, DDR-1, and their 
respective ligands. 
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4.3 RESULTS 
4.2.1 Over-expression of collagens and collagen receptor genes in DLBCL 
 
As a first step to investigate the potential contribution of collagen signalling to the 
pathogenesis of DLBCL, the expression of known collagen and collagen receptor 
genes was initially analyzed in two published datasets, one of which used RNAseq 
to measure global gene expression in 86 cases of DLBCL by Morin et al (Morin et 
al., 2011), and the other, gene expression in normal GC B cells (centroblasts and 
centrocytes) from four donors by Béguelin et al  (Béguelin et al., 2013). I found that 
genes encoding collagen subunits and collagen receptors were significantly 
enriched (both p<0.0001) among genes up-regulated, but not among genes down-
regulated, in both GCB- and ABC-DLBCL compared to normal GC B cells (Figure 
4.1A).  
4.2.2 Over-expression of LAIR-1 in DLBCL 
I chose initially to focus on the collagen receptor, LAIR-1, which has been reported 
to have immune inhibitory functions (Meyaard et al., 1997, Meyaard, 1999). Figure 
4.1B and Figure 4.1C show that the mRNA expression of LAIR-1 and that of the 
genes that encode its known ligands, collagen I (COL1A1, COL1A2) and collagen 
III (COL3A1), respectively using re-analysis of Morin et al dataset (Morin et al., 
2011) was significantly higher in both subtypes of DLBCL compared with normal GC 
B cells. Figure 4.1D shows that the re-analysis of a separate gene expression 
dataset by Brune et al (GSE12453) (Brune et al., 2008) also revealed significantly 
higher expression of LAIR-1 in DLBCL compared with normal GC B cells.  
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Figure 4.1: Over-expression of collagens and collagen receptor genes in diffuse large B cell 
lymphoma A) Venn diagrams showing that genes encoding collagen subunits (left panel) and 
collagen receptors (right panel) were significantly enriched among genes up-regulated (p<0.0001), 
but not among genes down-regulated (not shown), in GC and ABC DLBCL compared to normal 
germinal centre (GC) B cells, B) The mRNA expression of LAIR-1 was significantly higher in both 
subtypes of DLBCL compared with normal GC B cells, C) The mRNA expression of the known LAIR-
1 ligands, collagen I (COL1A1, COL1A2) and collagen III (COL3A1), was also significantly higher in 
both subtypes of DLBCL compared with normal GC B cells, D) shows that the re-analysis of a 
separate gene expression dataset (Brune et al., 2008) also revealed significantly higher expression 
of LAIR-1 in diffuse large B cell lymphoma compared with normal GCB-cells.  
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4.2.3 The expression of LAIR-1 and its ligands are correlated in DLBCL 
 
Next, I studied the relationship between the expression of LAIR-1 and its collagen 
ligands in primary DLBCL. A meta-analysis of eleven different DLBCL datasets by 
Care et al, (Care et al., 2015), excluding the dataset used above (Morin et al., 
2011), revealed that genes positively correlated with LAIR-1 in primary DLBCL were 
significantly enriched (odds ratio= 2.09, p=0.044), and those negatively correlated 
with LAIR-1 in primary DLBCL, significantly depleted (odds ratio=0, p=0.016) for 
collagen genes (Figure 4.2A). Collagen genes positively correlated with LAIR-1 in 
DLBCL included COL1A1 and COL3A1.  
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Figure 4.2: The expression of LAIR-1 and its ligands are correlated in diffuse large B cell lymphoma 
Results of a meta-analysis of eleven different DLBCL datasets revealed that genes positively correlated with LAIR-1 in primary DLBCL 
were significantly enriched (odds ratio=2.09, p=0.044), and those negatively correlated with LAIR-1 in primary DLBCL, significantly 
depleted (odds ratio=0, p=0.016) for collagen genes.  
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4.2.4 Genes positively correlated with LAIR-1 expression in DLBCL are 
enriched for macrophage functions 
An ontology analysis of the genes that were positively correlated with LAIR-1 in the 
meta-analysis described above (Care et al., 2015), revealed, a significant 
enrichment of macrophage functions (Figure 4.3A). To confirm this observation, I 
compared the genes positively correlated with LAIR-1 with those comprising a 
published tumour macrophage gene signature generated from a DLBCL gene 
expression dataset and shown to be conserved across multiple un-related human 
cancer types (Doig et al., 2013) I found that genes positively correlated with LAIR-1 
in primary DLBCL were significantly enriched (odds ratio=93.64, p<0.0001), and 
those negatively correlated with LAIR-1 in primary DLBCL significantly depleted 
(odds ratio= 0, p<0.0001) for macrophage signature genes (Figure 4.3B).  
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Figure 4.3: Genes positively correlated with LAIR-1 expression in DLBCL are 
enriched for macrophage functions 
A) Gene ontology analysis reveals a significant enrichment of macrophage 
functions. Light grey bars show the observed percentage, and dark grey bars the 
expected percentage, of genes in each GO category. B) Genes positively correlated 
with LAIR-1 in primary DLBCL were significantly enriched (odds ratio=93.64, 
p<0.0001), and those negatively correlated with LAIR-1 in primary DLBCL 
significantly depleted (odds ratio= 0, p<0.0001) for macrophage signature genes, 
GO indicates gene ontology. 
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4.2.5 LAIR-1 is predominately expressed by M2 macrophages in the 
microenvironment of DLBCL  
To confirm these observations and to directly identify the cell types expressing LAIR-
1, I used immunohistochemistry. In normal lymphoid tissues I observed strong LAIR-
1 positivity mainly within CD68-positive macrophages, including those present 
within the GC (Figure 4.4A) which was confirmed by multiplex IF using CD68 (Figure 
4.4B). GCB-cells expressing either BCL6 (Figure 4.4C) or Ki67 (Figure 4.4D) were 
not stained with the LAIR-1 antibody confirming that GC B cells lack detectable 
LAIR-1 expression. 50 cases of DLBCL were also stained for LAIR-1. All cases 
showed positive staining for LAIR-1 in macrophages and not in tumour cells (Figure 
4.4E).  The absence of LAIR-1 in tumour cells but its abundant expression by 
macrophages in DLBCL was confirmed in 10 representative cases by dual IHC 
(Figure 4F-I).This was confirmed by the quantification of a representative DLBCL 
sample using Inform analysis which showed that most CD163 positive cells also 
expressed LAIR-1 (p<0.0001). With regard to the potential future analysis of in vivo 
models of DLBCL, it is noteworthy that I also observed the expression of LAIR-1 on 
mouse macrophages infiltrating A20 tumours in vivo (Figure 4.4J); A20 is a well-
established syngeneic mouse model of human DLBCL. I also showed that in most 
cases LAIR-1 was expressed in macrophages in the absence of LAIR-2, a negative 
regulator of LAIR-1 (Figure 4.4K). 
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Figure 4.4: LAIR-1 expression in normal lymphoid tissues and in DLBCL  
A) Low power photomicrograph showing IF for LAIR-1 (pink) located in GC cells 20X. B) Shows double labelling for LAIR-1 (pink) with 
CD68 (green) and confirm that LAIR-1-positive cells in the GC are macrophages (arrows) and in mantle zone lymphocytes, 40X C) IF 
shows that BCL6-expressing GC B cells (green) were LAIR-1 (red)-negative (arrows), 20X. D) IF shows that Ki67-expressing GC B 
cells (green) were also LAIR-1 (red)-negative (arrows),40X, E) IHC shows LAIR-1 expression in morphologically identifiable 
macrophages (brown), but not in tumour cells (blue nuclei) of DLBCL (arrows). F) IF confirms absence of LAIR-1 expression (green) 
in CD20-positive tumour cells (red) of DLBCL (arrows). G) IF confirms LAIR-1 expression (green) primarily located with tumour-
associated macrophages (CD68; red) of DLBCL. H) IF shows that LAIR-1 (red) is present mostly within M2 macrophages expressing 
CD163 (green), arrows, 40X, I) IF tonsil shows that LAIR-1 (red) is present within M2 macrophages expressing MRC1 (yellow) 
outside GC (arrows), 20X  J) IF shows that LAIR-1 (red) is present mostly within M2 macrophages expressing CD163 (green) and 
MRC1 (yellow) at the arrows, 20X, K) IHC shows recruitment of LAIR-1 positive cells with the morphology of macrophages in tumour 
microenvironment of A20 lymphoma mouse model, 40X L) IF of representative sample shows LAIR2 (blue) occasionally present in 
the microenvironment in contrast to abundance of LAIR-1 (red), 40X, IHC indicates immunohistochemistry, IF indicates 
immunofluorescence GC indicates germinal centre, MZ indicates mantle zone.  
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4.2.6 Low frequency of LAIR-1-expressing T cells in the microenvironment of 
DLBCL 
 
Given that LAIR-1 has been reported to be expressed on most normal immune cells, 
including T cells, I next wanted to quantify numbers of LAIR-1-expressing T cells in 
the microenvironment of DLBCL, compared to those present in normal lymphoid 
tissues. To do this I co-stained 10 representative cases of DLBCL and normal 
lymphoid tissues for CD3 and LAIR-1. I observed that in all cases DLBCL had 
proportionally significantly fewer LAIR-1-expressing CD3 T cells than did normal 
lymphoid tissues (Figure 4.5A-B). In DLBCL, LAIR-1/CD3 double positive 
cells=0.36%, while in tonsil LAIR-1/CD3 double positive cells=13.84%, p 
value=0.01. 
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Figure 4.5:  Lower frequency of T cells expressing LAIR-1 in DLBCL  
A) IF Co-staining of normal lymphoid tissues (tonsil) and B) a representative case of DLBCL IF for CD3 (red) and LAIR-1 (green).  
In all cases DLBCL had proportionally fewer LAIR-1-expressing CD3 T cells than did normal lymphoid tissue, 20X, IF indicates 
immunofluorescence. 
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4.2.7 Effect of collagen and LAIR-1 expression on in vitro monocyte 
differentiation 
Given that I had shown that LAIR-1 was highly expressed on M2 macrophages in 
DLBCL, I next explored the possibility that collagen might influence the 
differentiation of monocytes to macrophages. Before doing this I first wanted to 
measure the expression of LAIR-1 during the in vitro differentiation of peripheral 
blood derived monocytes using flow cytometry. These monocytes were 
differentiated with 5ng/ml of G-MCSF (for M1) 25ng/ml of MCSF for 10 days. In 
Figure 4.6, I show flow cytometry staining from monocytes polarized with GMCSF 
and MCSF on untreated or collagen coated plates for 10 days. There was no 
significant difference in LAIR-1 expression with or without collagen in M1, while in 
M2 it showed increase in levels of LAIR-1 while differentiating on collagen. Next, I 
used another method of collagen stimulation, post-differentiation of monocytes into 
macrophages (10 days) by adding soluble collagen. As seen in Figure 4.7, I show 
flow cytometry staining, there were no significant change in LAIR-1 expression 
following stimulation of differentiated M2 macrophages in collagen treated, acetic 
acid control and untreated cells. Next, I explored THP1 as a possible in vitro model 
for studying LAIR-1, using untreated and undifferentiated THP1 cells. In Figure 4.8, 
THP-1 showed baseline levels of expression of LAIR-1 (PE) and the monocyte 
marker CD14 (FITC) while there was expression of the M2 marker, CD163 (APC).  
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Figure 4.6 LAIR-1 increased in expression in M2 phenotype following differentiation 
on collagen coated plates 
Primary monocytes isolated from PBMCs were cultured with GMCSF and MCSF for 
polarisation to M1 and M2 respectively +/- collagen type 1 coated plates. CD163 was used 
as a marker for M2 polarisation. After 10 days the cells were harvested and LAIR-1 
expression was analysed by flow cytometry. I found LAIR-1 to be expressed on both 
stimulated and unstimulated M1 (panel A) and M2 macrophages (panel B), which showed 
to be increased on stimulated M2. 
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Figure 4.7 No significant difference in LAIR-1 expression in M1 and M2 
phenotype post-differentiation in untreated, treated with acid and collagen in 
macrophages on FACS level 
Primary monocytes isolated from PBMCs were cultured with GMCSF and MCSF for 
10 days. The cells were harvested and then stimulated with soluble collagen for 24 
hrs. Both M1 and M2 (the CD163+ population) was found to have no significant 
difference in level of expression of LAIR-1, PBMCs indicates peripheral blood 
mononuclear cell. 
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Figure 4.8 THP-1 was examined as a cell line model to study LAIR1. Determination of baseline levels of CD14, CD163 and 
LAIR-1 in THP-1. 
Graphical representation of THP-1 baseline levels of CD14, CD163 and LAIR-1. THP-1 has low expression of the monocyte marker, 
CD14, a low expression of LAIR-1, and a high expression of the M2 marker, CD163. 
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4.2.8 Expression of LAIR-1 ligands, Type I and Type III collagen, in DLBCL 
 
Next, I studied the protein expression of the two collagens, Type I and Type III, 
which are known ligands of LAIR-1. I selected these ligands because the re-analysis 
of the RNAseq data described above had shown the over-expression of collagen 
subunits, COL1A1, COL1A2, and COL3A1. Using IHC, I found that Type I collagen 
was present in the trabeculae/septa and vessels of the tonsil and absent from 
normal germinal centres (Figure 4.9A). Type III collagen was present in the 
capillaries and vessels in the mantle zone and the interfollicular regions, but was 
also absent from germinal centres (Figure 4.10A). Type I collagen was expressed 
in the stroma as fine fibres in 4/9 evaluable cases of DLBCL. In positive cases Type 
I collagen was not intimately associated with the tumour cell population but was 
rather located as a component of larger blood vessels and within surrounding 
connective tissues (Figure 4.9C-D). Type III Collagen was present in 4/8 evaluable 
cases of DLBCL (Figure 4.10B-D). Type III was observed in thick fibres around 
tumour cells, sometimes forming bands. Figure 4.10D shows the results of 
representative multiplex IHC confirming the close association between LAIR-1 
expressing cells and Collagen III in 3/3 positive cases. 
 221 
 
 
 
Figure 4.9: Expression of LAIR-1 ligand, Type I collagen in DLBCL Representative examples of IHC staining for Type I collagen (brown) 
showing it is absent in the GC A), 20x, In most cases Type I collagen was not intimately associated with the tumour cell population but was 
rather located as a component of larger blood vessels and within surrounding connective tissues as shown in these three examples, 40X, IHC 
indicates immunohistochemistry.  
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Figure 4.10: Expression of LAIR-1 ligand, Type III collagen in DLBCL. Representative examples of IHC and IF staining for Type III in DLBCL (brown and 
green, respectively). A) Collagen III is absent from germinal centres of tonsil but present in the vessels of the mantle zones, B-C) In most cases of DLBCL. 
Type III collagen was intimately associated with the tumour cell population as well as a component of blood vessels in the form of coarse intersecting bands in 
the tumour stroma (green and brown, respectively) D) shows the results of representative multiplex IHC showing a close association between LAIR-1 
expressing cells (pink) and Collagen III (green), 40X, IHC indicates immunohistochemistry, IF indicate immunofluorescence, BV indicates blood vessel, GC 
indicates germinal centre, MZ indicates mantle zone. 
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4.2.9 Expression of C1q, an additional functional ligand of LAIR-1 
 
I also studied the expression of C1q as a further known functional ligand of LAIR-1 
and which has already described to cause the phosphorylation of LAIR-1 in 
monocytes (Son et al., 2012). I used IHC in the TMA of DLBCL samples to show 
that C1q was expressed in the macrophages in 25/28 cases (Figure 4.11A-C). 
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Figure 4.11: Expression of LAIR-1 ligand, C1q in DLBCL. An IHC of DLBCL, with 
only vessels positive for C1q (A). (B) and C) Representative examples of staining 
for C1q in DLBCL (brown staining). In most cases C1q was expressed in 
macrophages within microenvironment at the arrows, 40X, IHC indicates 
immunohistochemistry. 
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4.2.10 Over-expression of the collagen receptor, DDR-1 in a subset of DLBCL 
 
Finally, I studied the expression of another collagen receptor, DDR-1, in DLBCL. 
Although the re-analysis of the datasets described in section 4.2.1 above did not 
reveal the over-expression of DDR-1 mRNA, this collagen receptor was of interest 
given that our group has already described its frequent over-expression in HL, a B 
cell malignancy related to DLBCL (Cader et al., 2013). I first used IF to show that 
DDR-1 was expressed in the tumour cells of 3/9 cases of DLBCL samples, which 
was confirmed by co-staining with CD20 (Figure 4.12). 
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Figure 4.12: Expression of DDR-1 in DLBCL  
Representative example of multiplex IF staining of DDR-1 and CD20 in DLBCL. DDR-1 was positive in the blood vessels (red 
arrow) and CD20-positive tumour cells (white arrows) 40X, IF indicate immunofluorescence.
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4.2.11 Expression of DDR-1 ligands, Type IV and Type VI collagen, in DLBCL 
 
Having shown that DDR-1 was over-expressed in primary DLBCL, I next studied the 
expression of two of its known ligands, collagens Type IV and Type VI. I selected 
these ligands because the re-analysis of the RNAseq data described above, had 
shown the over-expression of the collagen IV subunits, COL4A1, COL4A2, and 
COL4A5, as well as the collagen VI subunits COL6A1, COL6A2, COL6A3 and 
COL6A6. Using IHC, I found that Type IV collagen was absent in the normal 
germinal centres as highlighted by CD20 staining (Figure 4.14A). Type VI collagen 
was also largely absent from germinal centres, while present in the wall of blood 
vessels outside the germinal centre as highlighted by staining with B cell markers; 
CD19 and vessel marker; CD31. These collagen positive vessels were highlighted 
by staining of their endothelial cells with CD31 in normal tonsil (Figure 4.13 B and 
C respectively). Type VI collagen was observed in 24/25 evaluable cases of DLBCL. 
Type IV collagen was present in 4/6 evaluable cases of DLBCL (Figure 4.14B-D).  
In most cases Type IV collagen was deposited not only in the wall of the blood 
vessels, but also as fine branching fibres intimately associated with the tumour cell 
population and mainly emanating as a component of blood vessels, Type IV 
collagen was observed to be in close relation with LAIR-1 positive cells in an 
exploratory analysis of a small subset of DLBCL (Figure 4.14E). In contrast, Type 
VI was heterogeneously deposited as fine, or sometimes as coarse fibres intimately 
in contact with the tumour cells in addition to its presence in the wall of the blood 
vessels (Figure 4.13D-E). To confirm this, I used image J to measure the number of 
viable tumour cells in direct or close relation to Type VI collagen fibres. In all 6 cases 
studied (10 HPF (40x) per case), I found that >50% of tumour cells were intimately 
associated with Type VI collagen (Figure 4.13G).
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Figure 4.13: Expression of Type VI collagen in DLBCL 
Representative examples of staining for Type VI in DLBCL. A) IHC shows the absence of Type VI collagen in GC of tonsil, but its presence in 
the vessels of the mantle and inter-follicular zones, 20X. B) Double IF showed co-expression of CD31 (green) and collagen VI (red) in tonsil, 
at the arrows 40X. C) Double IHC shows the absence of Type VI collagen (pink) in the germinal centre which is highlighted with CD19, a B cell 
marker (brown), 40X. D-E) IHC shows that in most cases Type VI collagen was intimately associated with the tumour cell population as well 
as a component of blood vessels, 40X, IHC indicates immunohistochemistry, IF indicates immunofluorescence.
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F. Table 4.1 Results of quantification of COLVI DLBCL 
 
Case Number 
Viable tumour cells with contact or close contact 
collagen/10HPF 
Mean total Range of total % 
1 303.4 190-420 
59.65 
2 335.5 212-495 65.04 
3 355.4 129-551 58.86 
4 254.1 182-392 59.56 
5 347 249-484 53.67 
6 559.6 464-688 40.77 
7 254.1 198-337 62.98 
Total 2389.1 190-688 58.8 
 
Table 4.1: Results of quantification using Image J for contact index for Type VI 
collagen by IHC with tumour cells. Tumour cells showed frequent relation, either 
direct or close to collagen fibres in the tumour stroma. 
 230 
 
 
 
Figure 4.14: Expression of Type IV collagen in DLBCL 
Representative examples of staining for Type IV in DLBCL. A) IF shows CD20-positive B cells of a germinal centre in normal tonsil (red) 
showed absence of collagen, Collagen IV is absent from germinal centres, but present in the vessels of the mantle and interfollicular zones 
(green). B-D) Renal, nodal and skin DLBCL showed positivity for collagen IV as thin branching fibres at the white arrows. E) Dual IF shows 
Type IV collagen (green) was intimately associated with the LAIR-1 positive population (red) in DLBCL, at the white arrows, IF indicates 
immunofluorescence
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4.3 DISCUSSION 
In this chapter I have shown that DLBCL is characterized by the overexpression of 
number of collagens and collagen receptors. One of the collagen receptor that was 
overexpressed in DLBCL was LAIR-1. LAIR-1 is a type I transmembrane 
glycoprotein which is a member of the Ig superfamily. It is a unique collagen receptor 
which is involved in various immune reactions, being expressed on the majority of 
human PBMCs, including NK, T, B, monocytes, and dendritic cells, and the majority 
of thymocytes. Cross-linking of LAIR-1 on human NK cells induces a potent 
inhibitory signal that is capable of decreasing target cell lysis by both resting and 
activated NK cells in vitro. It also acts as an inhibitory receptor on effector T cells 
(Kridel et al., 2015). It is proposed that LAIR-1 signalling could be regulated via its 
expression because LAIR-1 levels are generally higher on less differentiated or 
naive cells, and lower on more activated or differentiated immune cells (Leitinger, 
2011). 
In a previous study using microarray analysis, DLBCL was classified into three 
clusters, cluster-1, 2 and 3 which are responsible for ‘’oxidative phosphorylation, 
mitochondrial function and electron transport chain’’, ‘’Cell-cycle regulatory 
genes/DNA repair gene’’ and the ‘host response cluster’; LAIR-1 was overexpressed 
in DLBCL in the NK/T cell subcategory in the ‘host response cluster’ (Monti et al., 
2005), but little is known about it in the microenvironment of DLBCL. A meta-
analysis performed in this chapter which included over 2000 DLBCL samples 
revealed that genes positively correlated with LAIR-1 were enriched for number of 
gene ontology terms which included regulation of nitric oxide (NO) biosynthetic 
process, regulation of macrophage activation during immune response and 
phagocytosis. Furthermore, genes positively correlated with LAIR-1 were 
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significantly enriched for genes present in a tumour macrophage signature (Doig et 
al., 2013). This observation suggested that LAIR-1 expression might be localized 
mainly to tumour associated macrophages in DLBCL. This was confirmed by IHC, 
which revealed the co-expression of LAIR-1 with CD68, a pan-macrophage marker, 
and with CD163 and MRC1 which are both markers of M2 macrophages. This meta-
analysis also revealed the significant enrichment of collagen genes among genes 
positively correlated with LAIR-1, including COL1A1 and COL3A1 which encode 
subunits of collagen type I and collagen type III, respectively. I used IHC to show 
that both collagen types are present in DLBCL. Significance of proteins expressed 
in vessel walls as in the vascular endothelium) may influence the tumour immune 
micro-environment, if such cells express collagens then these can potentially 
interact with tumour cells.  
Co-localisation studies using proteins expressed in vessel walls (e.g. smooth 
muscle actin or vimentin) might be helpful to characterise this further. In some cases 
these collagens were intimately associated with macrophages. Taken together 
these observations suggest that LAIR-1 could be activated by its collagen ligands 
potentially leading to important signalling events in the tumour associated 
macrophages of DLBCL. I also found that C1q was expressed by tumour associated 
macrophages, but not in tumour cells, in DLBCL, providing a further means to 
activate LAIR-1 in the macrophages of DLBCL.   
The expression of LAIR-1 was described before on monocytes and macrophages,  
but little is known about its function in these cells, except that LAIR-1 influenced the 
differentiation of monocytes to dendritic cells (Son et al., 2012) and that LAIR-1 
expressing macrophages of LAIR-1-/- KO mouse show reduced expression of 
macrophage activation markers such as CD86 (Tang et al., 2012).  
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During the course of these experiments I also observed that the expression of a 
naturally occurring functional antagonist of LAIR-1, LAIR-2, was expressed only at 
low levels on infiltrating macrophages.  
Although compared with normal lymphoid tissues, I observed fewer CD3 positive 
cells expressing LAIR-1 in the microenvironment of DLBCL, it could be that LAIR-1 
expression on tumour infiltrating T cells could have an immune checkpoint function 
mediated by collagen.  
It is interesting to speculate that collagen binding to LAIR-1 could have an inhibitory 
impact on phagocytic functions, this could be important in DLBCL because rituximab 
is known to kill CD20-positive cells, through opsonization and macrophage 
phagocytosis (Leidi et al., 2009). 
DDR-1 is a receptor tyrosine kinase which has been shown to be over-expressed in 
a number of cancer types and which activates potentially oncogenic signals 
following its over-expression (Valiathan et al., 2012). It has previously been shown 
that normal GC B cells express DDR-1 at very low levels, while in HL DDR-1 is more 
highly expressed. It has been shown that collagen type I can activate DDR-1 in HL 
cell lines. To compare these results, I have explored another EBV related B cell 
malignancy; DLBCL I explored the expression of DDR-1 in normal germinal centres 
and DLBCL tumours.  
I show here for the first time, that DDR-1 is over-expressed at the protein level in a 
subset of DLBCL tissue samples (3/9 cases). As it has been shown that collagen 
can activate DDR-1 leading to the increased survival of lymphoma cells (Cader et 
al., 2013). In this study, the expression of DDR ligands in DLBCL were examined. I 
found that collagens types III, IV and VI, are over-expressed in DLBCL, both at the 
RNA (re-analysis of published data) and also at the protein level. Biological functions 
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of DDRs can be targeted using small molecules inhibitors such as Bcr-Abl inhibitors 
(Day et al., 2008) and the B-Raf inhibitors, the VEGFR inhibitor and p38 MAPK 
inhibitor, which were found to inhibit both DDR-1 and DDR-2 (Borza and Pozzi, 
2014). Recently, few studies reported the identification of novel inhibitors, selected 
specifically for DDR-1 receptor, such as pyrozalopyrymidine, which has high affinity 
but not to others from 455 kinases tested, these can inhibit the proliferation of cancer 
cells highly expressing DDR-1 (Gao et al., 2013). These preliminary observations 
suggest that DDR-1 and its ligands are aberrantly expressed in DLBCL and could 
be a potineal targets in DLBCL.  
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CHAPTER FIVE 
 
S1PR1 DRIVES A FEED FORWARD SIGNALLING LOOP TO 
REGULATE THE OVER-EXPRESSION OF BATF3 IN HODGKIN 
LYMPHOMA CELLS 
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5.1 INTRODUCTION 
Sphingosine-1-phosphate (S1P) is a small oncogenic lipid implicated in cancer 
growth, survival and invasion (Moolenaar, 1999, Milstien and Spiegel, 2006).  S1P 
molecule can be generated by the enzyme, sphingosine kinase 1 (SPHK1), which 
is over-expressed in different cancer types, including some non-HL (Bayerl et al., 
2008). Conversely, sphingosine-1-phosphate phosphatase (SGPP1), an enzyme 
which degrades S1P, is down-regulated during tumour development and 
progression (Mandala et al., 2000, Le Stunff et al., 2007, Gao et al., 2015). 
Although the over-production of S1P is a characteristic of many cancers, the 
biological response to S1P is governed by the mix of different S1P receptors. There 
are five cell surface S1P receptors (S1PR1-5); each coupling to a different repertoire 
of G proteins. In B cells, S1PR1 mediates mitogenic/pro-survival and chemotactic 
S1P functions by coupling to Gi to activate Ras/ERK, PI3-K/Akt and Rac (Takuwa 
et al., 2001, Takuwa, 2002, Takuwa et al., 2002) whereas S1PR2 couples to 
G12/13 to inhibit PI3-K/Akt activity leading to reduced cell growth, survival and 
migration (Arikawa et al., 2003, Inoki et al., 2006, Sanchez et al., 2005, Du et al., 
2010). PI3-K is known to be aberrantly activated in many lymphomas where it 
provides one of the key survival signals (Westin, 2014). PI3-K is known to be 
aberrantly activated in many lymphomas where it provides one of the key survival 
signals (Westin, 2014). Multiple factors are such as loss of function of PTEN (Wang 
et al., 2015), PIK3CA gene mutations, mTOR (Westin, 2014) which are known to 
activate this pathway. S1PR1 has previously been reported to be over-expressed in 
HRS cells and to promote their migration in vitro (Kluk et al., 2013). In contrast, 
S1PR2 may be a tumour suppressor in B cell lymphomas; previous studies show 
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that S1PR2 is mutated in a subset of human DLBCL and that mice lacking S1PR2 
expression develop DLBCL (Cattoretti et al., 2009, Green and Cyster, 2012). 
Previous studies from our group have shown that HRS cells over-express SPHK1. 
Basic leucine zipper transcription factor ATF-like (BATF) family is composed of 
BATF, BATF2 and BATF3, which originate from a bigger family of basic leucine 
zipper transcription factors (Finn et al., 2009). BATF3 is normally expressed only in 
T helper type 1 cells and dendritic cells positive for CD8, while it is absent in T-reg 
and other hematopoietic cells (Lee et al., 2017b). BATF3 is important in the function 
and development of dendritic cells (Hildner et al., 2008, Murphy et al., 2013). 
BATF3 functions in the production of IL-12 in response to pathogens (Hildner et al., 
2008, Williams et al., 2001).  Studies show that T lymphocyte differentiation into T-
reg is inhibited by BATF3, as mediated by BATF3 inhibition of T-reg expression (Lee 
et al., 2017b). It was recently reported that BATF3 is one of the oncogenic targets 
of the JAK/STAT oncogenic pathway, which is characteristic of the majority of HL 
and PMLBCL. BATF3 was reported to be overexpressed in CD30 positive 
lymphomas; HL (70%), CD30 positive DLBCL (75%), PMLBCL (88.8%) (Lollies et 
al., 2018). BATF3 was shown to have an impact on the survival and growth of 
ALNHL and HL cell lines was associated with decreased cMYC expression in these 
cell lines, that BATF3 regulates cMYC functions mediated through binding to an AP1 
site in cMYC gene (Lollies et al., 2018). BATF3 has been reported to be expressed 
in the gene signature of ALNHL which is helpful in distinguishing this from another 
type of peripheral T cell NHL, with accuracy reaching 97% (Piva et al., 2010).  In 
this chapter I have used multiplex IF to study the expression of S1P receptors in HL, 
focusing mainly on S1PR1 and S1PR2, BATF3 as well as the expression and 
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activation of downstream signalling components. *Please note: Some data within this 
chapter is taken from our recent paper  (Vrzalikova et al., 2018). 
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5.2 RESULTS 
5.2.1 Expression of S1P receptors in normal lymphoid tissue  
 
I first studied the expression in HL, of S1PR1 and S1PR2; the major S1P 
receptors implicated in cancer pathogenesis. I first used conventional IHC and 
then multiplex IF with lymphoid markers, BCL6 and CD20, to show that normal GC 
B cells express S1PR2, but not S1PR1 (Figures 5.1 A and F) (Figures 5.1 B-E and 
G-L).  
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Figure 5.1: Expression of S1PR1 and S1PR2 in normal lymphoid tissues A-E) Normal tonsil IHC and multiplex IF: S1PR1 expression in MZ 
B cells and capillaries (white arrows) but not in normal GC B cells, confirmed by co-staining for CD20 (red) and S1PR1 (green). 
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F-J) Normal tonsil IHC and multiplex IF: S1PR2 was weakly expressed in normal GC B cells and in red blood cells (black arrows), confirmed by 
co-staining with CD20 in red (white arrows). 
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K-L) Co-staining with BCL6 (green) and S1PR2 (red) confirmed positivity for S1PR2 in GC B cells at the white arrows. A-K 40x 
magnification, L) zoomed. 
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5.2.2 Expression of S1P receptors in a cohort of HL  
I studied the expression of S1PR1 and S1PR2 in a cohort of 61 cases. In 36/61 
cases HRS cells expressed S1PR1 in the cytoplasm and/or membrane using a cut 
off whereby ≥25% of HRS cells had to be positive for the case to be scored positive. 
None of the 61 cases were positive for S1PR2. I confirmed these observations by 
multiplex staining with CD30 (Figure 5.2 A and B). I also found that HL cell lines 
including EBV positive (L591) and EBV negative (L428, L1236 and KMH2) lines 
showed expression of both receptors but in general levels of S1PR1 were higher 
(Figure 5.2 C). I concluded that in contrast to their normal counterparts, HRS cells 
in general express high levels of S1PR1 but lack expression of S1PR2. 
 244 
 
  
 
 
 
 245 
 
 
 
Figure 5.2: Expression of S1PR1 and S1PR2 in HRS cells in clinical samples and HL cell lines 
A) and B): HRS cells expressed S1PR1 (green) in cytoplasmic and membranous pattern but not S1PR2 (red) (white arrows) 
confirmed by CD30 co-staining. Endothelial cells and red blood cells were strongly positive for S1PR1 and S1PR2, respectively.  
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C) Expression of S1PR1 and S1PR2 in HL-derived cell lines: Immunohistochemical detection of S1PR1 (red) and S1PR2 (red) 
protein expression in HL cell lines, showing higher levels of S1PR1, 40x magnification.
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5.2.3 S1P-induced PI3-K signalling in HRS cells is mediated by the 
differential expression of S1P receptors  
I next studied the effects of S1P on PI3-K signalling in HRS cells using Akt 
phosphorylation as a read-out. L428 cells were treated with S1P and the 
phosphorylation of Akt in these cells studied using an antibody against the 
phosphorylated forms of Akt (Ser473). I found using IF followed by Vectra image 
analysis, that treatment of L428 cells with S1P increased the levels of pAkt in these 
cells compared to cells treated with BSA alone, used as a control. Time point was 
24 Incubation following 24 hour treatment with S1P or BSA (Figure 5.3 A and B). 
However, I did not observe any increase in pAkt in L1236 cells which is reported to 
have constitutively high Akt (Schwering et al., 2003a)  and which other members 
of our group have shown is resistant to the S1PR1 inhibitors, Siponimod and 
Ozanimod (Vrzalikova et al., 2018). To study the effects of the individual receptors 
on pAkt, I stained L428 cells following transfection with an S1PR1 expression vector 
carrying a V5 tag and treatment with S1P. Time point was 15 min incubation 
following 24 hour treatment with S1P or BSA. I co-stained these cells for V5 and 
pAkt and found that in V5-positive cells were significantly more likely to also express 
pAkt than were un-transfected cells in the same population. This effect was seen 
with (p<0.0001) and without (p<0.0001) the addition of exogenous S1P (Figure 5.4 
and table 5.1). To study the effect of S1PR2, which inhibits PI3-K/Akt activity, KMH2 
cells were transfected with an S1PR2-HA expression vector, S1PR2 transfection 
experiments were performed in KMH2 cells because this is one of the lines that 
reacts to S1P at the early time points. 
 
 248 
 
 IF used to detect pAkt and the HA tag. I found that cells ectopically expressing 
S1PR2 were significantly more likely to be phospho-Akt negative than HA-negative 
cells in the same transfected population, an effect we observed with (p<0.0001) and 
without (p<0.0001) the addition of exogenous S1P (Figure 5.5 and Table 5.2). I 
conclude that S1PR1 expression, in the absence of S1PR2, can activate PI3-K 
signalling in HRS cells.  
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Figure 5.3: Regulation of Akt by S1P in L428 HL cell line  A) SIP treatment correlated with the upregulation of the expression 
of Akt (yellow) in L428 cell line, 20x. B) Showed significant high levels of Akt in S1P treated L428, L591 and KMH2 but not L1236. 
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Figure 5.4: S1PR1 is correlated with overexpression of pAkt in S1P treated L428 cell line 
IF for phospho-Akt and V5tag of the S1PR1 expression vector. White arrow showed transfected V5tag cells, double labelled with Akt, 
40X.  
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Tables 5.1 showed the results of image analysis of phenotyping of V5 tag labelled 
L428 BSA and S1P treated cells.   
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Figure 5.5: S1P-induced PI3-K signalling in KMH2 cell line is mediated by differential expression of S1P receptors 
IF for phospho-Akt (green) and the HA tag of the S1PR2-HA expression vector (red), showing HA tag labelled cells ectopically expressing 
S1PR2, 40x.  
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Table 5.2: Results of image analysis of BSA and S1P treated KMH2 transfected with 
HA-tagged plasmid 
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5.2.4 Expression of the transcription factor, BATF3, is regulated by PI3-K 
signalling in HRS cells  
 
To identify the transcriptional targets of PI3-K signalling in HL cells, I took advantage 
of a microarray experiment that had been performed by a previous member of our 
group in which KMH2 cells were treated with the PI3-K inhibitor, LY294002 (Jücker 
et al., 2002). A re-analysis of these data showed that the addition of LY294002 for 
16 hours was followed by the up-regulation of 694 genes and the down-regulation 
of 330 genes. Re-analysis of Brune data set; GSE12453 (Brune et al., 2008) 
identified 743 genes up-regulated and 622 genes down-regulated in micro-
dissected HRS cells compared with normal centrocytes. Genes up-regulated in HRS 
cells (OR=2.15; p<0.0001), but not those down-regulated in HRS cells (OR=1.00; 
p=0.96), were significantly enriched in genes down-regulated following PI3-K 
inhibition. Likewise, genes down-regulated in HRS cells (OR=2.95; p<0.0001), but 
not those up-regulated in HRS cells (OR=1.28; p=0.056), were significantly enriched 
in genes up-regulated after PI3-K inhibition. These data indicate that the activation 
of PI3-K signalling contributes to the transcriptional programme of HRS cells. I next 
wanted to establish if this was also the case for both the EBV-positive and EBV-
negative forms of HL. To do this a third dataset was re-analysed from a  published 
microarray by Steidl et al  which compared gene expression in micro-dissected HRS 
cells with that in micro-dissected normal GCs and which had reported EBV status 
for a subset of cases (Steidl et al., 2012). This revealed that the transcriptional 
targets of PI3-K signalling identified above were significantly enriched in those 
genes differentially expressed in both EBV-positive and EBV-negative HRS cells 
(not shown).  
A gene ontology analysis revealed that genes regulated by PI3-K signalling in 
primary HRS cells were enriched for those with a function in ‘transcription initiation 
 256 
 
from RNA polymerase II promoter’, suggesting that PI3-K signalling might contribute 
to the aberrant expression of transcription factors observed in HRS cells (Figure 5.6 
A). To identify relevant transcription factors targets genes regulated by PI3-K 
signalling in primary HRS cells were compared with a comprehensive set of 
transcription factors described by Vaquerizas et al (Vaquerizas et al., 2009) .This 
revealed the up-regulation of 12, and the down-regulation of 47 transcription factors 
by PI3-K signalling in HRS cells (Figure 5.6 B). They included the dendritic cell 
transcription factor, BATF3, which was previously reported to be over-expressed at 
the mRNA level in HRS cells (Rosenwald, 2003, Schwering et al., 2003a) and 
which was also the PI3-K regulated gene most highly up-regulated in the re-analysis 
of global gene expression in primary HRS cells described above (Schwering et al., 
2003b, Brune et al., 2008, Steidl et al., 2012). 
To confirm that BATF3 was regulated by PI3-K signalling, I stained KMH2 cells 
transfected with a MYC-tagged plasmid containing either a constitutively active p110 
gene or a constitutively active Akt1 gene, titrating the MYC antibody to detect only 
exogenous MYC. I found that cells ectopically expressing either p110 or Akt (Figure 
5.7) were significantly more likely to be phospho-Akt-positive (both p<10-4) and 
BATF3-positive (both p<10-4) than were un-transfected cells (cells those that have 
not taken up the plasmid). These data show that PI3-K/Akt signalling leads to 
aberrant BATF3 expression in B cell lymphoma.  
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Figure 5.6: PI3-K signalling up-regulates BATF3 in HRS cells 
A) Gene ontology analysis of genes regulated by PI3-K signaling in primary HRS cells (in at least one comparison; total of 137 up-regulated 
and 443 down-regulated genes) revealed enrichment of several functions including ‘transcription initiation from RNA polymerase II promoter 
B) Comparison of genes regulated by PI3-K signalling in primary HRS cells with a comprehensive set of TF53 revealed the up-regulation of 12 
TF and the down-regulation of 47 TF by PI3-K signalling in HRS cells. 
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Figure 5.7: Regulation of BATF3 by Akt and p110 in KMH2 HL cell line. Multiplex IF following the transfection of KMH2 cells with a constitutively active 
p110 plasmid containing a MYC tag (top panel) and MYC tag activated Akt (bottom panel). Cells transfected with the plasmid were significantly more likely 
to stain with the phospho-Akt antibody (Chi square=80.46; p<0.00001) and to be BATF3-positive (Chi square=19.22; p<0.00001) (solid white arrows) 
compared with those cells in the same population that had not taken up the plasmid (broken white arrows), 40x.
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5.2.5 BATF3 expression in normal lymphoid tissues  
 
I next studied the expression of BATF3, a transcription factor that our group has 
shown in other preliminary experiments can be regulated by S1PR1 and which also 
regulates S1PR1, suggesting a feed-forward loop. A preliminary analysis performed 
in our group had also revealed that BATF3 mRNA was higher in HRS cells 
compared to all major B cell subsets. To verify this, I used IHC and IF for BATF3 
and various lymphoid and non-lymphoid markers to describe BATF3 expression in 
normal lymphoid tissues (Figure 5.8). I showed that BATF3 protein was not 
detectable in most normal GC B cells (as shown by co-staining for BCL6) and only 
rarely in CD20-positive B cells outside the GC (which were mostly of immunoblast 
morphology). These cells were also CD30-positive. BATF3 was not expressed in 
‘tingible body’ macrophages of the GC stained with CD68, or in CD123-positive 
plasmacytoid dendritic cells. BATF3 was only occasionally observed in CD3-positive 
cells in the interfollicular region and CD23-expressing follicular dendritic cells.  
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Figure 5.8: BATF3 expression in normal lymphoid tissues. Top  four panels: IHC and IF of normal lymphoid tissue, BATF3-positive cells were mainly 
located outside the GC, some of which expressed CD20 (red) and CD30 (red) with immunoblast morphology in the interfollicular area but not BCL6 (green) in 
the GC (arrowed), 60X, 40X, 40X and 20X respectively .Bottom four panels:  As expected BATF3 was not expressed in ‘tingible body’ macrophages of the 
GC stained with CD68 (red); arrowed and was only occasionally present in rare CD3-positive interfollicular T cells (red); arrowed but was not expressed in 
follicular T cells CD3-positive cells. BATF3 was occasionally detected in CD23 (green) while not present in CD123-positive follicular (green) plasmacytoid at 
the white arrows, dendritic cells, GC=germinal center, MZ=mantle zone, IF=interfollicular.  
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5.2.6 BATF3 overexpression in HL 
Next, I studied BATF3 expression in HL. I found by IHC that BATF3 protein was 
strongly expressed in HRS cells, an observation that was confirmed by co-
expression of BATF3 and CD30 in HRS cells shown by IF (Figure 5.9). BATF3 
protein was strongly expressed in both EBV-positive (7/10) and EBV-negative 
(29/42) HRS cells and this was confirmed by CD30 co-staining and in HL cell lines. 
As IHC studies revealed LMP-1 expression is consistently positive in EBV 
associated HL (Raab-Traub, 2002, Young and Rickinson, 2004, Deacon et al., 
1993), so EBV status was determined by LMP-1 staining. This finding was 
consistent with our group’s observation that EBV infection of peripheral blood and 
GC B cells was followed by the up-regulation of BATF3 mRNA expression and that 
ectopic expression of the EBV oncogene, LMP-1, increased BATF3 mRNA levels in 
primary human GC B cells. Therefore, there was no differences in BATF3 
expression amongst according to EBV status in HL. As, PI3-K is also regulated by 
other non-viral mechanisms e.g PTEN loss (Wang et al., 2015), therefore BATF3 
would also be expected to be upregulated also in EBV negative cases. This 
observation was further supported by my finding that LMP-1-expressing L591 and 
Farage cells were significantly more likely to express BATF3 than were LMP-1-
negative cells in the same culture (Chi square=552.5, p<0.00001 and Chi 
square=2621.11, p <0.00001, respectively). Furthermore, I also showed that LMP-
1 transfection increased BATF3 protein expression in SUDHL4, a GC type DLBCL 
cell line (Chi square= 10.02; p=0.0016), as shown in Figure 5.10 and Table 5.3.  
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Figure 5.9 BATF3 is overexpressed in HL. Top left and right panels, IHC BATF3 expression in the nuclei of HRS cells by IHC  (40X) and (60X) and bottom 
panels in same samples double stained for BATF3 (green) and CD30 (red) with low power (20X) and high power (40X) magnification. 
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Figure 5.10 Co-expression of BATF3 and LMP-1 in B cell derived lymphoma cell lines 
Double labelling showed that LMP-1-expressing L591, Farage and transfected SUDHL4 cells (red) were significantly more likely to express 
BATF3 (green) than were LMP-1-negative cells in the same culture, 40x. 
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Tables 5.3: Results of phenotyping of LMP-1 positive BATF3 cells in L591 HL cell line, 
transfected SUDHL4 and Farage DLBCL cell line  
 
 
Phenotypes 
L591 
Counts 
SUDHL4 cell line 
Counts 
Farage cell line 
Counts 
BATF3 LMP-1 double positive 2656 79 3672 
LMP-1 single positive 1312 0 121 
BATF3 single positive 288 489 643 
Negative 779 63 1181 
Total 5035 631 5617 
Chi square 552.5 10.02 2621.1107 
P-value <0.00001 0.0016 <0.00001 
 
Tables 5.3 show results of phenotyping of LMP-1 positive BATF3 in L591 HL cell line, 
SUDHL4 and Farage-EBV positive DLBCL cell line.  
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Expression of BATF3 and S1P receptors in primary DLBCL 
I also studied the expression of BATF3 and S1P receptors in the tissues of TMA 
composed of 28 DLBCL patients that I classified into GCB and non-GCB types using 
the Hans algorithm (Hans et al., 2004). Two cases showed drop out, so were 
excluded. 18/26 cases were positive for BATF3 (Figure 5.11 A-C) confirmed by 
double staining with CD20 (Figure 5.11 D). I also studied the relationship between 
BATF3, S1PR1 and S1PR2 expression in primary DLBCL. To do this, I used these 
same cases; 18 (69.23%) cases were positive for both BATF3 and S1PR1, 6 cases 
(23.07%) expressed only S1PR1, and 2 (7.69%) cases were negative for both and 
BATF3 single positive cases were absent. This represents a significant enrichment 
of S1PR1 positivity among BATF3-positive DLBCL (Chi-square=4.875, p=0.027). 
7/27 cases of DLBCL did not express S1PR2. Although I did not observe a 
statistically significant association between the expression S1PR1 and S1PR2 in 
this small series, a meta-analysis of ten different DLBCL gene expression datasets 
(Care et al., 2015) revealed that the expression of S1PR1 was not only positively 
correlated with that of BATF3 (r=0.17, p=0.013), but was also negatively correlated 
with that of S1PR2 (r=0.43, p<0.0001). 
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Figure 5.11 BATF3, S1PR1 and S1PR2 expression in DLBCL  
A-C) Representative examples of immunostaining of DLBCL showing expression of BATF3 in the nuclei of tumour cells, 60X, D) 
IF of DLBCL confirms co-expression of BATF3 (green) and CD20 (red) in the tumour cells,  E-H) IF of DLBCL confirms co-
expression of S1PR1 (green) and CD20 (red) in the tumour cells, 40X, I-M) IF of DLBCL confirms co-expression of S1PR2 (green) 
and CD20 (red) in the tumour cells, S1PR2 is positive also in red blood cells (red arrows), 40X. 
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5.2.7 BATF3 up-regulates S1PR1 expression in HL 
A microarray analysis following BATF3 knockdown in L428 cells performed by Dr 
Vrzalikova in our group had revealed that BATF3 increased S1PR1 mRNA (not 
shown). Next, I sought to show that BATF3 regulated S1PR1 at the protein level. To 
do this I stained HL cell lines (L1236, L428 and KMH2) treated with either BATF3 
siRNA or non-targeting siRNA as a control. L428 cell line was selected amongst 
other HL cell lines for BATF3 knockdown because it was the least difficult in 
transfection and shown to give the most efficient BATF3 knockdown. 
Multiplex IF revealed that compared to controls, the mean intensity per cell 
expression of BATF3 and S1PR1 protein was significantly lower in both L428 
(Figure 5.12 A) and L1236 cells (both p<0.0001; not shown). I did  find significantly 
decreased numbers of BATF3-positive and S1PR1-positive cells in siRNA-
transfected L428 with the mean intensity of BATF3 and S1PR1 positive cells  
3526/7479 [47.15%] of cells positive for BATF3 and S1PR1) compared with control 
cells (=2045/2401 [85.17%] and 1955/2401 (81.42%) of cells positive for BATF3 and 
S1PR1, respectively; not shown) (Chi square for the difference in proportions of 
BATF3 positive and S1PR1-positive cells=1077.82 and 864.64, respectively; 
p<0.0001 for both comparisons); (Figure 5.12 B). Finally, I co-stained untreated HL 
cell lines for both BATF3 and S1PR1. Furthermore I showed that, S1P treatment of 
HL cell lines, not only increase pAKT but also the protein expression of BATF3 and 
S1PR1, which is in keeping with the data in L428 cells. Time point was 24 hours 
incubation following 24 hour treatment with S1P or BSA, I found that S1P treatment 
increased the level of pAkt in both KMH2 and L591 cells, but while L1236 showed 
no change upon treatment. This analysis revealed that the expression of S1PR1 
and BATF3 were significantly positively correlated in all cell lines (Figure 5.13 A-B). 
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Co-expression of BATF3 and S1PR1 in normal lymphoid tissues 
Next, I performed a quantitative analysis of BATF3 in normal lymphoid tissue using 
multiplex IF. An illustration of the phenotyping of cells is shown in Figure 5.14. This 
analysis revealed the frequent co-expression of BATF3 and S1PR1 in cells of the 
extra-follicular regions of tonsil rather than in the GC (Figure 5.15 and Table 5.4). 
Co-expression of BATF3 and S1PR1 in primary HL samples 
Finally, I found that BATF3-positive primary HL were significantly more likely to be 
S1PR1-positive than BATF3-negative HL (p<0.0001; Figure 5.16 left panel). Next, I 
performed image analysis on representative cases of HL to ascertain the 
relationship between BATF3 and S1PR1 expression in HRS cells at the single cell 
level. In all the cases examined, using multiplex IF for BATF3-S1PR1-CD30, I found 
that BATF3-expressing CD30-positive HRS cells were significantly more likely to be 
S1PR1-positive than were BATF3-negative CD30-positive cells (Figure 5.16 right 
panel and Table 5.5). Taken together these data identify a feed forward S1P 
signalling loop that drives constitutive BATF3 expression in HRS cells.
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Figure 5.12 knock-down of BATF3 decreases S1PR1 protein expression in L428 cells 
A) Top right panels: Multiplex IF showed that the L428 cells transfected with BATF3 specific 
siRNA expressed lower levels of BATF3 and S1PR1 proteins than did control cells (left 
panels), 20X. B) This analysis revealed a significant reduction in the mean staining intensity 
in knockdown cells compared to controls for both BATF3 (L428 cells: control mean = 
22301.81; knock-down mean = 14496.72; t-test p-value <0.0001) and S1PR1 (L428 cells: 
control mean = 7033.26; knock-down mean =797.02; t test p-value <0.0001). Right panels: 
The levels of BATF3 and S1PR1 were significantly positively correlated at the single cell 
level in both siRNA-treated and control cell. 
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Figure 5.13 BATF3 expression correlates with S1PR1 expression in untreated, BSA and 
S1P treated HL cell lines 
A) Double staining shows that BATF3 positive cells (Top panels) were significantly more 
likely to also express S1PR1. Shown are representative images of the staining of the untreated 
L428 and KMH2 lines, 40X. Correlations between BATF3 and S1PR1 expression in all HL cell 
lines are shown in the lower panels with p<0.0001 (Bottom panels). 
B) Top panel: Representative images of S1P and BSA treated L428, showed BATF3 and 
S1PR1 co-localization in both conditions, 40X. C). Bottom panel showed Image analysis of 
single cells following the treatment of HL cell lines with S1P shows significantly increased 
levels of BATF3 and S1PR1 protein levels in L428, L591 and KMH2 cells measured by mean 
fluorescence intensity on IF.  
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Figure 5.14: BATF3 and S1PR1 co-expression and quantification in normal lymphoid tissue 
Top left panel shows the detection of S1PR1 (red) in a single BATF3-expressing lymphocyte (green) in the interfollicular region of 
a normal tonsil. Most of the S1PR1-positive cells in normal lymphoid tissues did not express BATF3, 40x. Top right panel is a 
phenotyping map showing that cells co-expressing BATF3 and S1PR1 are mainly located outside germinal centres.  
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Table 5.4: Phenotyping results of BATF3 expressing S1PR1 lymphoid cells in 
different anatomic localization in normal lymphoid tissue  
  
Anatomic distribution  
Phenotype 
BATF3 
single 
positive 
S1PR1 
single 
positive 
BATF3-
S1PR1 double 
positive 
Negative 
Follicular (Germinal 
centre+Mantle zone) 
112 6443 89 18148 
Non follicular 
(Interfollicular+Paracortical) 
260 477 62 3916 
Total  372 6920 151 22064 
 
Table 5.4 shows the results of single cell image analysis using Inform software 
indicating the proportions of cells co-expressing BATF3 and S1PR1 in different 
anatomic locations. 
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Figure 5.15: Correlation of BATF3 and S1PR1 HL, and single cell analysis of BATF3 and S1PR1 expression in CD30-
positive cells of HL. Left panel, photomicrograph of co-staining for BATF3, and S1PR1 in HL, with the majority of cases having 
co-expression of BATF3 and S1PR1 in HL, 40x. Right Panel, photomicrograph of co-staining for BATF3, S1PR1 and CD30 in HRS 
cells, 40x.  
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Table 5.5 single cell image analysis of BATF3 and S1PR1 in CD30 – positive 
cells of HL 
 
Phenotype Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 
BATF3 single 1 22 29 1 2 3 
S1PR1 single 0 0 0 0 0 0 
BATF3-S1PR1 
double positive 
51 131 89 448 215 217 
Negative 40 6 209 220 5 15 
Total 92 159 327 669 222 235 
Chi-square 84.105 23.569 212.790 659.990 126.340 179.470 
p-value <0.00001 <0.00001 <0.00001 <0.00001 <0.00001 <0.00001 
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Figure 5.16: Proposed model for the regulation of BATF3 by S1P signalling in HRS 
cells. S1P availability is regulated by SPHK1, which is upregulated in HRS cells and which 
catalyses S1P production, and SGPP1, which is down-regulated in HRS cells and which 
degrades S1P. S1P acts on the S1P receptor, S1PR1; in the absence of S1PR2 this drives 
PI3-K/Akt signalling leading to increased BATF3 expression. S1PR1 expression is 
increased by BATF3 leading to a feed-forward loop to sustain S1P signalling and 
constitutive BATF3 transcription. 
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5.3 DISCUSSION 
In this chapter I have shown that HRS cells express BATF3, a transcription factor 
that is important for the development of CD8α+ classical dendritic cells (Hildner et 
al., 2008) and related non-lymphoid CD103+CD11b- dendritic cells (Edelson et al., 
2010). Re-analysis of existing global expression datasets and IHC showed that 
BATF3 expression was significantly higher in primary HRS cells compared with 
normal B cells. My data also show that BATF3 is regulated by PI3-K/Akt signalling, 
a pathway that is known to be constitutively activated in HRS cells (Jücker et al., 
2002, Dutton et al., 2005, De and Brown, 2010). 
I showed that PI3-K/Akt signalling is regulated by S1P in HRS cells and that this is 
dependent upon the increased expression of S1PR1 together with the decreased 
expression of S1PR2. The up-regulation of S1PR1 in HRS cells has been reported 
before, albeit in only 7/57 cases, a considerable lower proportion than I have 
reported here (Kluk et al., 2013); despite the fact that I used the same cut-off 
employed by Kluk et al. The observation that BATF3 induces the expression of 
S1PR1 identifies a feed-forward loop which leads to constitutive S1P signalling, 
PI3-K/Akt activation and sustained BATF3 transcriptional activity (Figure 5.16). 
The major source of the S1P necessary to sustain this loop is likely to be the HRS 
cells, since they express SPHK1 in the absence of the S1P phosphatase, SGPP1 
(Vrzalikova et al., 2018). The feed-forward loop described here could be 
important for the pathogenesis of HL since it has been shown that the knockdown 
of BATF3 significantly reduces the survival of HL cell lines (Lollies et al., 2018) 
and that BATF3 can induce B cell lymphomas in a murine model (Weiser et al, 
personal communication)
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.Both EBV-positive and EBV-negative HRS cells displayed high levels of BATF3. 
This was consistent with our unpublished observation that BATF3 expression was 
increased following either EBV infection or LMP-1 expression in B cells. Given that 
EBV and LMP-1 are alone sufficient to induce PI3-K/Akt signalling in B cells 
(Dawson et al., 2003, Wlodarski et al., 2005) the regulation of BATF3 by EBV is 
likely to be mediated by PI3-K/Akt signalling. Because the EBV lytic cycle has been 
shown to be induced upon terminal B cell differentiation (Laichalk and Thorley-
Lawson, 2005) leading to viral replication and cell death, the increased BATF3 
expression observed in EBV-infected tumour cells could be important for 
suppression of the lytic cycle, in turn preventing replication-induced cell death.  
These data also suggest that the therapeutic blockade of S1P signalling could inhibit 
the oncogenic effects of BATF3. Studies using S1PR1 inhibitor and evaluation of 
BATF3 RNA and protein levels might be helpful to characterise downstream effect 
of S1PR1 on BATF3 in HL cell lines. 
The two functional antagonists of S1PR1, Ozanimod and Siponimod, which our 
group has shown can block the S1P-mediated activation of Akt, are already in phase 
II and III clinical trials of patients with inflammatory and autoimmune diseases. 
These and other S1PR1 modulators should be investigated for their therapeutic 
potential in HL.   
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6. General discussion 
I have shown for the first time that PD-L1 over-expression in NPC could be broadly 
separated into two types; marginal and diffuse with different pathogenic 
mechanisms; adaptive (induced) and constitutive (intrinsic) mechanisms 
respectively. These data suggest that NPC tumours can intrinsically up-regulate PD-
L1 in the tumour cells (Intrinsic type), while T cells infiltrating NPC can up-regulate 
PD-L1 in the marginal/cytokine induced type. These differences are important 
because they are associated with distinct effects on outcome (Heeren et al., 2016). 
This finding is of interest since it will help to develop immunotherapeutic strategies 
for PD-L1 positive NPC, although it will require information on larger patient cohort. 
I employed a new method of digital analysis of multiplexed stained tissue sections 
using Vectra and Inform software to study the differential expression of these 
markers in NPC as well as their relationship to T cells distribution in the same tumour 
in different tumour locations (tumour and tumour stroma). For the first time, I have 
shown that PD-L1 expressing tumour in the marginal type, were focally associated 
with T cell depleted/poor areas in the same tumour group expressing PD-L1 at the 
border. It will be of interest to determine if other immune cells in addition to T cells 
e.g. plasma cells, natural killer cells, myeloid-derived cell populations; dendritic cells 
and macrophages also expressing PD-L1 in the tumour microenvironment (Giuliani 
et al., 2017, Tang et al., 2018).  
I have shown that LMP-1 was not associated with up-regulation of PD-L1 using a 
re-analysis of published RNA-seq data. This suggests the possibility that non-viral 
molecular pathways are involved in up-regulating PD-L1. PD-L1 expression can be 
upregulated by other oncogenic signalling pathways such as NF-ĸb (Fang et al., 
2014). Recent genomic reports showed that LMP-1 expression and mutations 
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affecting negative regulators of NF-ĸB expression (found in 41% of cases) 
are  mutually exclusive in NPC, suggesting both viral (LMP-1) and non-viral 
(genetic) events can lead to PD-L1 expression in NPC (Li et al., 2017).  
I also discovered for the first time that multiple immune checkpoints can be co-
expressed in the same NPC tumours. These preliminary observations suggest that 
it is important to consider existence of these, in relation to their expression in 
patients, who do not respond to PD1/PD-L1 blockade, or in those who eventually 
develop resistance to these treatments. To determine if this is the case will 
necessitate further study and validation on larger patient cohorts. These possibilities 
are supported by the observation that PD1 inhibitors have shown modest response 
in NPC patients in clinical trial of advanced stage NPC (Hsu et al., 2017); however 
poor-response to single immunotherapy as PD1 blockade has been reported in 
subset of patients in one of those trials (Hsu et al., 2017). The rationale behind 
targeting multiple checkpoints is that some receptors can inhibit T cell function by 
regulating different immune mechanisms, such as CTLA-4 and PD1 where blocking 
both receptors has been to improve tumour responses in a murine model (Curran 
et al., 2010). In addition, targeting CTLA4 and PD1 using combined Nivolumab and 
Ipilimumab showed  a response rate of 60% compared to 11% using monotherapy 
(Ipilimumab) in melanoma patients (Li et al., 2016), although the high rate of 
immunosuppressive side effects were not encouraging (Callahan, 2016). Thus, I 
discovered other immune checkpoints apart from CTLA4 which were co-expressed 
in the re-analysis of NPC published data such as LAG3 which was co-expressed in 
same samples with PD-L1, which necessitates to be confirmed in NPC, but my 
finding was consistent with other reports which showed co-expression and positive 
correlation of PD1 and LAG3 in colorectal cancer (Lal et al., 2015). Current clinical 
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trial for melanoma patients showed good response for combined immunotherapy for 
LAG-3 and PD1. Furthermore other recent combination immune checkpoint therapy 
trials reported promising results including those that combine inhibitors of PD-1 with 
LAG-3, TIM3 or CTLA4 (O'Donnell et al., 2017).  
I have shown that T-regs positive for FOXP3 are frequent in NPC samples, which is 
consistent with previous reports (Lau et al., 2007, Yip et al., 2009). Clinical trials 
used anti-T-reg therapies such as the anti-CD25 antibody, daclizumab, reported 
successful depletion of T-regs (Rech and Vonderheide, 2009). In addition anti-
CD25 drug, denileukin diftitox resulted in the depletion of T-regs in NPC, which were 
supressing the CD8 specific immune response against EBNA-1 and LMP-2-
expressing positive tumour cells (Fogg et al., 2013).  
This study took the advantage of the benefits of multiplex IHC technologies. During 
the course of my studies, I optimized multiple panels which included collagen 
markers, immune cells of different types and specific LMP-1 target genes in three 
EBV related tumors. This approach was useful not only characterizing the 
microenvironment of DLBCL and NPC but also in studying LMP-1 related signalling 
pathways including PI3-K and another oncogenic pathways such as S1P signalling. 
In these studies, I characterized the expression of a novel transcription factor BATF3 
and was able to identify that it was not only over-expressed in HL, but also 
expressed by a subset of normal cells in normal lymphoid tissue including a subset 
of CD30 positive cells. In HL, I described its co-expression with S1PR1 in HRS cells, 
and studied its regulation by a constitutively active PI3-K mediated through 
signalling pathway pAKT. I also showed that the S1PR1 receptor is overexpressed 
in HRS cells in clinical samples which is consistent with previous reports (Kluk et 
al., 2013). I also showed that for the first time that S1PR1 but not S1PR2, is able to 
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activate AKT in HL, this was done using in vitro transfected EBV positive and 
negative HL cell lines and quantifying levels of downstream signalling proteins. This 
approach has the advantage over immunoblotting as it can quantify changes at the 
single cell level in vitro eliminating problems associated with poor efficiency of 
transient transfection. Furthermore, it enables assessment of relative levels of 
surrounding partners in primary tissue. Although the majority of HL patients respond 
to treatment, a subset (25%–30%) have refractory disease or will relapse following 
first-line therapy (Canellos et al., 2014), it is possible that targeting aberrant S1P 
signalling pathway could provide an alternative therapeutic approach for these 
patients which can block S1P signalling e.g. using Sphingomab antibody can benefit 
those patients. Sphingomab has showed clinical responses in resistant renal cell 
carcinoma with improved survival approaching 20 months (Pal et al., 2017). These 
data may suggest resistant HL patients may benefit from this drug.  
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7. Conclusions and future work 
In this thesis I have focused partly on the contribution of the microenvironment to 
the pathogens of DLBCL; by exploring both the expression of collagens and 
collagen receptors. My data revealed that LAIR-1 is highly expressed by tumour-
associated macrophages. Many studies have shown that the presence of M2 
macrophages is associated with poor outcomes in both DLBCL and HL. However, 
future work should include a study of the impact of tumour-associated macrophages 
expressing LAIR-1 on survival in DLBCL. KO LAIR-1-/- mice are available and 
provide an opportunity to study how LAIR-1 could influence macrophage function 
relevant to the pathogenesis of DLBCL. Moreover, recent studies have shown that 
M2 macrophages influence the therapeutic response to rituximab and so future 
studies could investigate how collagen ligation of LAIR-1 affects Rituximab-
mediated phagocytosis of tumour cells. LAIR-1 was also expressed on a minor 
subset of T cells in DLBCL and this warrants further study, as this could mediate an 
important immune checkpoint in DLBCL.  
I also explored the expression of immune checkpoints, including PD1/PD-L1 in NPC 
and I described that PD-L1 is present in the diffuse type in around 50% of patients 
which suggest the constitutive mechanism of resistance is present in some cases. I 
found also that the diffuse type of PD-L1 expression, unlike published data was 
present diffusely within some groups of tumour cells. The remaining half of patients 
displayed a marginal type expression. Further studies are required to determine the 
clinical impact of these different phenotypes after therapy using drugs including 
block PD1 effects. PD-L1 expression is significantly positively correlated with 
expression of PD-L2 and also with other immune checkpoints such as like BTLA, 
CTLA and IDO1. Further studies are required to establish which cell types express 
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these checkpoints molecules in NPC, and to explore simultaneous blockade of 
multiple immune checkpoints in animal models and eventually in NPC patients.   
As we have access to NPC samples with their clinic-pathological data with our 
collaborators in University of Malaysia, it will be interesting to explore the expression 
of other immune checkpoints protein and correlate them with outcome. 
Finally, I studied the S1P-S1PR1-AKT signalling pathway in HL and found that a 
signalling loop involving S1PR1 and BATF3 pathway. This pathway would seem to 
be important for the pathogenesis of HL, since it has previously been shown to be 
important for HRS cells survival. Further studies could explore if targeting S1P 
signalling, either using S1P neutralizing antibodies, such as sphingomab, or S1PR1 
inhibitor could be useful in blocking this pathway, both in vitro, and eventually in 
animal models.    
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APPENDICES 
Appendix 1: Clinical and pathological details of NPC samples 
Case 
number 
Gender Ethnicity 
Age at 
diagnosis 
(years) 
Histopathology 
1 Male White 34 
Non keratinizing 
Undifferentiated nasopharyngeal 
carcinoma 
2 Female Asian 40 
Undifferentiated nasopharyngeal 
carcinoma 
4 Male White 51 
Poorly 
differentiated/undifferentiated 
nasopharyngeal carcinoma 
6 Male White 78 
Poorly differentiated 
nasopharyngeal carcinoma 
7 Male White 60 
Keratinizing squamous cell 
carcinoma 
8 Male Chinese 79 Nasopharyngeal carcinoma ‘’NOS’’ 
9 Female Mixed 28 
Undifferentiated nasopharyngeal 
carcinoma 
‘’Non keratinizing 
type’’ 
10 Male White 21 
Undifferentiated nasopharyngeal 
carcinoma 
 
11 Male White 78 
Poorly differentiated 
nasopharyngeal carcinoma 
12 Male White 59 
Non keratinizing nasopharyngeal 
carcinoma 
14 Male White 19 
Undifferentiated nasopharyngeal 
carcinoma 
15 Male White 71 
Non keratinizing 
Undifferentiated nasopharyngeal 
carcinoma 
16 Female White 56 
Non keratinizing 
Undifferentiated nasopharyngeal 
carcinoma with spindle cell 
component 
17 
Female Other: 
Filipino/Latin 
37 Not available 
18 Male Chinese 47 
Non keratinizing 
Undifferentiated nasopharyngeal 
carcinoma with 
20 Male White 38 
Poorly differentiated 
nasopharyngeal carcinoma 
21 
Male White 45 Nasopharyngeal carcinoma 
‘’unclassified’’ 
 297 
 
22 Male White 61 
Poorly differentiated 
nasopharyngeal carcinoma 
 
Appendix 2: Immune related and immune checkpoint genes 
Gene list class Name of the gene 
Immune checkpoint receptors PDCD1 
CTLA4 
TIGIT 
BTLA 
HAVCR2 
LGALS9 
 
Immune checkpoint ligands CD274 
PDCD1LG2 
LAG3 
 
Costimulatory Receptors CD28 
CD40 
ICOS 
 
Costimulatory Ligands (B7 
family) 
CD80 
CD86 
CD40L 
VTCN1 
CD276 
 
TNF family 
 
TNFSF9 
TNFRSF4 
TNFSF4 
TNFRSF18 
TNFSF18 
TNFSF14 
TNFRSF14 
TNFSF11 
TNFRSF11A 
TNFRSF8 
LTBR 
CD27 
TNFRSF9 
 
Adhesion 
 
PVR 
CD226 
CEACAM1 
NECTIN2 
CD2 
 
Secreted enzymes 
 
IDO1 
GZMB 
ARG1 
IDO1 
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KIRs (NK Cell) 
 
KIR3DL1 
KIR2DL4 
KIR2DL3 
 
Interleukin 
 
IL2RB 
IL10 
IL1A 
IL6 
IL12B 
IL18 
 
Transcription factor TBX21 (T-bet) 
Leukocyte Ig-like family 
 
LILRB2 
LILRB1 
LILRA2 
LILRA3 
Unclassified CD160 
CD70 
CD47 
SIRPA 
ADORA2A 
SLAMF1 
LAIR1 
LAIR2 
NCR3 
TMIGD2 
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                       Appendix 3: Co-ordinate Immune Response Cluster (CIRC) 
signature genes 
Gene list class Name of the gene 
MHC class I-related HLA-A 
HLA-B 
HLA-C 
MICB 
ULBP1 
ULBP2 
ULBP3 
MHC class II-related HLA-DMA 
HLA-DMB 
HLA-DOA 
HLA-DOB 
HLA-DPA1 
HLA-DPB1 
HLA-DQA1 
HLA-DQA2 
HLA-DRA 
HLA-DRB5 
Chemokines/Receptors CCL11 
CCL2 
CCL5 
CX3CL1 
CXCL10 
CXCL9 
Cytokines/Receptors IFNγ 
IL12RB2 
IL17A 
IL18RAP 
IL7R 
 
Transcription Factors STAT1 
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STAT3 
TBX21 
IRF1 
 
TNF Family 
 
TNFRSF14 
TNFSF4 
B7 family CD80 
CD86 
CD276 
VTCN1 
 
Immune checkpoint 
ligands 
PDCD1LG2 
CD274 
LAG3 
 
Immune checkpoint 
receptors 
PDCD1 
CTLA4 
HAVCR2 
 
Scaffold ACTB 
CD3/TCR related CD247 
CD3D 
CD3E 
CD3G 
CD4 
CD8B 
 
Secreted Enzyme GNLY 
GZMB 
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